Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Chronic Heart Failure

Free Subscription Articles published in Eur J Heart Fail Retrieve available abstracts of 863 articles: HTML format

Single Articles

September 2025
1. ZHOU J, Jin X, Xu Y, Xie Z, et al
   Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China.
   Eur J Heart Fail. 2025 Sep 22. doi: 10.1002/ejhf.70035.
   PubMed     Abstract available
   
   
   
2. HARADA T, Reddy YNV, Sorimachi H, Obokata M, et al
   Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.
   Eur J Heart Fail. 2025 Sep 22. doi: 10.1002/ejhf.70050.
   PubMed     Abstract available
   
   
   
3. SIDDIQI TJ, Khan MS, Waqas SA, Van Spall HGC, et al
   Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity.
   Eur J Heart Fail. 2025 Sep 22. doi: 10.1002/ejhf.70048.
   PubMed     Abstract available
   
   
   
4. VERSNJAK J, Kuehne T, Fahjen P, Jovanovic N, et al
   Deep phenotyping of heart failure with preserved ejection fraction through multi-omics integration.
   Eur J Heart Fail. 2025 Sep 22. doi: 10.1002/ejhf.70041.
   PubMed     Abstract available
   
   
   
5. KNIERIM M, Hartmann N, Maurer W, Pabel S, et al
   Atrial fibrillation in end-stage heart failure: Cellular mechanisms behind CASTLE-HTx.
   Eur J Heart Fail. 2025 Sep 17. doi: 10.1002/ejhf.70051.
   PubMed    
   
   
   
6. BOHM M, Butler J, Abdin A, Filippatos G, et al
   Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced.
   Eur J Heart Fail. 2025 Sep 16. doi: 10.1002/ejhf.70021.
   PubMed     Abstract available
   
   
   
7. KOBAYASHI M, Duarte K, Ferreira JP, Baudry G, et al
   An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction.
   Eur J Heart Fail. 2025 Sep 16. doi: 10.1002/ejhf.70047.
   PubMed     Abstract available
   
   
   
8. ADAMO M, Pagnesi M, Chioncel O, Bayes-Genis A, et al
   Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC.
   Eur J Heart Fail. 2025 Sep 15. doi: 10.1002/ejhf.70023.
   PubMed     Abstract available
   
   
   
9. 
   Correction to "Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence".
   Eur J Heart Fail. 2025 Sep 15. doi: 10.1002/ejhf.70016.
   PubMed    
   
   
   
10. KERAMIDA K, Lopez-Fernandez T, Anker MS, Petrie MC, et al
    Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology.
    Eur J Heart Fail. 2025 Sep 12. doi: 10.1002/ejhf.70005.
    PubMed     Abstract available
    
    
    
11. BEER BN, Benson L, Basile C, Schrage B, et al
    Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes.
    Eur J Heart Fail. 2025 Sep 11. doi: 10.1002/ejhf.70046.
    PubMed     Abstract available
    
    
    
12. SHAH P, Bekfani T, Rubis P, Clark AL, et al
    Potential therapeutic effects of warming on patients with heart failure.
    Eur J Heart Fail. 2025 Sep 9. doi: 10.1002/ejhf.70011.
    PubMed    
    
    
    
13. CAMPAIN J, Wakeham DJ, Dias K, MacNamara JP, et al
    Distinct blood volume and left ventricular adaptation to severe obesity in middle-aged adults at risk for heart failure.
    Eur J Heart Fail. 2025 Sep 9. doi: 10.1002/ejhf.70037.
    PubMed     Abstract available
    
    
    
14. IVANOVSKI M, Mrak M, Meznar AZ, Jan M, et al
    The CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70013.
    PubMed     Abstract available
    
    
    
15. CHANG HC, Gau SY
    Letter regarding the article 'Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction'.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70045.
    PubMed    
    
    
    
16. ALMESNED MA, van Essen BJ, Voors AA, Lipsic E, et al
    Reply to the letter regarding the article 'Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction'.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70044.
    PubMed    
    
    
    
17. OSTROMINSKI JW, Claggett BL, Desai AS, Jhund PS, et al
    Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70034.
    PubMed     Abstract available
    
    
    
18. BARAKAT MF, Amaral N, Brayson D, Amin-Youssef G, et al
    Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC-HF II molecular substudy.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70028.
    PubMed     Abstract available
    
    
    
19. NASSIRI S, Voordes GHD, Handoko ML, Voors AA, et al
    Reply to the letter regarding the article 'Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial'.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70038.
    PubMed    
    
    
    
20. YANG Z, Kou L, Liao S
    Letter regarding the article 'Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial'.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70039.
    PubMed    
    
    
    
21. ECHEVERRIA LE, Bocchi E, Demacq C, de Barros E Silva PGM, et al
    Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70026.
    PubMed     Abstract available
    
    
    
22. KEMPF T, Fuge J, Bauersachs J
    Reply to the letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70029.
    PubMed    
    
    
    
23. SUN P
    Letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'.
    Eur J Heart Fail. 2025 Sep 8. doi: 10.1002/ejhf.70024.
    PubMed    
    
    
    
24. REIMER JENSEN AM, Ross JC, Arthur V, Hall ME, et al
    Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles.
    Eur J Heart Fail. 2025 Sep 2. doi: 10.1002/ejhf.70015.
    PubMed     Abstract available
    
    
    
25. BUNTING KV, Champsi A, Gill SK, Saadeh K, et al
    Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial.
    Eur J Heart Fail. 2025 Sep 2. doi: 10.1002/ejhf.70022.
    PubMed     Abstract available
    
    
    
26. AIMO A, Vergaro G, Pastore MC, Tomasoni D, et al
    High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study.
    Eur J Heart Fail. 2025 Sep 1. doi: 10.1002/ejhf.70030.
    PubMed    
    
    
    August 2025
27. FAUCHIER L, Lochon L, Lenormand T, Pierre B, et al
    Cardiovascular outcomes with tirzepatide in heart failure with preserved ejection fraction associated with obesity.
    Eur J Heart Fail. 2025 Aug 29. doi: 10.1002/ejhf.70012.
    PubMed    
    
    
    
28. BEGGS SAS, Petrie MC, Wright S, Connelly DT, et al
    Why do people with heart failure die? Rationale and design of the RHYTHM-HF study.
    Eur J Heart Fail. 2025 Aug 29. doi: 10.1002/ejhf.70014.
    PubMed     Abstract available
    
    
    
29. ANKER MS, Mahabadi AA, Totzeck M, Tewes M, et al
    Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial.
    Eur J Heart Fail. 2025 Aug 26. doi: 10.1002/ejhf.3799.
    PubMed     Abstract available
    
    
    
30. PANDEY A, Segar MW, Keshvani N, Llacer P, et al
    Diuretic resistance and the efficacy of hydrochlorothiazide in acute decompensated heart failure: A post-hoc analysis of the CLOROTIC trial.
    Eur J Heart Fail. 2025 Aug 26. doi: 10.1002/ejhf.70002.
    PubMed     Abstract available
    
    
    
31. HARM T, Keren A, Borst O
    Parvovirus B19 - more than a bystander in the prognosis of non-ischaemic heart failure.
    Eur J Heart Fail. 2025 Aug 26. doi: 10.1002/ejhf.70008.
    PubMed    
    
    
    
32. JEAN SS, Lai CC
    Letter regarding the article 'Incident heart failure is common and underrecognized in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease'.
    Eur J Heart Fail. 2025 Aug 26. doi: 10.1002/ejhf.3769.
    PubMed    
    
    
    
33. WEGERMANN K, Fudim M
    Reply to the letter regarding the article 'Incident heart failure is common and underrecognized in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease'.
    Eur J Heart Fail. 2025 Aug 26. doi: 10.1002/ejhf.3777.
    PubMed    
    
    
    
34. PETRIE MC, Cherney DZI, Desai AS, Testani JM, et al
    Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase.
    Eur J Heart Fail. 2025 Aug 20. doi: 10.1002/ejhf.3787.
    PubMed    
    
    
    
35. BAUDRY G, Crespo-Leiro MG, Delmas C, Guidetti F, et al
    Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC.
    Eur J Heart Fail. 2025 Aug 17. doi: 10.1002/ejhf.70003.
    PubMed     Abstract available
    
    
    
36. ZUIN M, Temporelli PL, Metra M, Savarese G, et al
    Heart failure-attributed mortality in Europe, 2012-2021.
    Eur J Heart Fail. 2025 Aug 17. doi: 10.1002/ejhf.70001.
    PubMed     Abstract available
    
    
    
37. ROSANO GMC, Bayes-Genis A, Kinugawa K, Teerlink JR, et al
    Healthcare system deficiencies should never be employed as justification for delivering sub-standard care to heart failure patients. Letter regarding the article 'Serial assessment of left ventricular ejection fraction for the management of heart fail
    Eur J Heart Fail. 2025 Aug 15. doi: 10.1002/ejhf.3772.
    PubMed    
    
    
    
38. PALAZZUOLI A, Pellicori P, Cleland JGF
    Reply to 'Healthcare system deficiencies should never be employed as justification for delivering sub-standard care to heart failure patients'.
    Eur J Heart Fail. 2025 Aug 15. doi: 10.1002/ejhf.3770.
    PubMed    
    
    
    
39. BUTT JH, McMurray JJV
    Reply to 'Impact of misclassification bias on interpretation of finerenone efficacy in chronic obstructive pulmonary disease and heart failure with mildly reduced/preserved ejection fraction: A critical appraisal of the FINEARTS-HF sub-analysis'.
    Eur J Heart Fail. 2025 Aug 15. doi: 10.1002/ejhf.3804.
    PubMed    
    
    
    
40. MALGIE J, Wilde MI, Koudstaal S, Denham R, et al
    Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF.
    Eur J Heart Fail. 2025 Aug 14. doi: 10.1002/ejhf.70006.
    PubMed     Abstract available
    
    
    
41. GREENE SJ, Sauer AJ, Bohm M, Bozkurt B, et al
    Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry.
    Eur J Heart Fail. 2025 Aug 11. doi: 10.1002/ejhf.3800.
    PubMed     Abstract available
    
    
    
42. UDELSON JE, Goldsmith SR, Burkhoff D, Colorado P, et al
    A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial.
    Eur J Heart Fail. 2025 Aug 11. doi: 10.1002/ejhf.3801.
    PubMed     Abstract available
    
    
    
43. STOCKER TJ, Geisler T, Rottbauer W, Lubos E, et al
    Rationale and design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) trial.
    Eur J Heart Fail. 2025 Aug 11. doi: 10.1002/ejhf.3795.
    PubMed     Abstract available
    
    
    
44. BURGOS LM, Baro Vila R, Goyeneche A, Costabel JP, et al
    Residual congestion defined by HFA-ESC multiparametric criteria and 90-day outcomes in worsening heart failure.
    Eur J Heart Fail. 2025 Aug 11. doi: 10.1002/ejhf.70004.
    PubMed    
    
    
    
45. ALMESNED MA, van Essen BJ, Emmens JE, Tromp J, et al
    Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction.
    Eur J Heart Fail. 2025 Aug 6. doi: 10.1002/ejhf.3788.
    PubMed    
    
    
    
46. WEERTS J, Tica O, Aranyo J, Basile C, et al
    Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2025 Aug 5. doi: 10.1002/ejhf.3782.
    PubMed     Abstract available
    
    
    
47. KESSLER T, Winkler M, Bayes-Genis A
    Embryonic transcripts in heart failure: Time for reprogrammed thinking?
    Eur J Heart Fail. 2025 Aug 4. doi: 10.1002/ejhf.3794.
    PubMed    
    
    
    July 2025
48. KARAKAS M, Friede T, Butler J, Talha KM, et al
    Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes.
    Eur J Heart Fail. 2025 Jul 31. doi: 10.1002/ejhf.3742.
    PubMed     Abstract available
    
    
    
49. SUN R, Kong D, Jiang T
    Expanding the horizon of medication adherence strategies in acutely decompensated heart failure. Letter regarding the article 'Medication adherence in patients with acutely decompensated heart failure: A cross-sectional study in the emergency departme
    Eur J Heart Fail. 2025 Jul 29. doi: 10.1002/ejhf.3805.
    PubMed    
    
    
    
50. KUNZ M, Schulz M, Mahfoud F
    Reply to 'Expanding the horizon of medication adherence strategies in acutely decompensated heart failure'.
    Eur J Heart Fail. 2025 Jul 29. doi: 10.1002/ejhf.3803.
    PubMed    
    
    
    
51. BAUMEIER C, Starlinger J, Aleshcheva G, Wiegleb G, et al
    Improved risk assessment in parvovirus B19-positive patients with heart failure by multiparametric analysis of endomyocardial biopsy using machine learning methods.
    Eur J Heart Fail. 2025 Jul 28. doi: 10.1002/ejhf.3798.
    PubMed     Abstract available
    
    
    
52. NASSIRI S, Voordes GHD, van Heerebeek L, van Raalte DH, et al
    Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial.
    Eur J Heart Fail. 2025 Jul 28. doi: 10.1002/ejhf.3711.
    PubMed     Abstract available
    
    
    
53. KAUFMANN CC, Ahmed A, Harbich PF, Auer L, et al
    Prognostic impact of frailty at admission and in-hospital changes of frailty status in elderly patients with acute heart failure.
    Eur J Heart Fail. 2025 Jul 25. doi: 10.1002/ejhf.3779.
    PubMed     Abstract available
    
    
    
54. CREMER S, von Scheidt M, Kirschbaum K, Tombor L, et al
    Prognostic significance of somatic mutations in myeloid cells of men with chronic heart failure - interaction between loss of Y chromosome and clonal haematopoiesis.
    Eur J Heart Fail. 2025 Jul 24. doi: 10.1002/ejhf.3778.
    PubMed     Abstract available
    
    
    
55. CAMPBELL RT, Petrie MC, Docherty KF, Brooksbank KJM, et al
    Artificial intelligence fully automated analysis of handheld echocardiography in real-world patients with suspected heart failure.
    Eur J Heart Fail. 2025 Jul 24. doi: 10.1002/ejhf.3783.
    PubMed     Abstract available
    
    
    
56. BIEGUS J, Ponikowski P
    Reply to the letter regarding the article 'Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study'.
    Eur J Heart Fail. 2025 Jul 23. doi: 10.1002/ejhf.3792.
    PubMed    
    
    
    
57. BAUDRY G, Pereira O, Roubille F, Girerd N, et al
    Reply to 'Beyond pharmacotherapy: Addressing system-level barriers in women's heart failure care'.
    Eur J Heart Fail. 2025 Jul 23. doi: 10.1002/ejhf.3793.
    PubMed    
    
    
    
58. ZHANG H, Gao W
    Beyond pharmacotherapy: Addressing system-level barriers in women's heart failure care. Letter regarding the article 'Sex-based differences in heart failure management and outcomes: Insights from the French-DataHF cohort'.
    Eur J Heart Fail. 2025 Jul 23. doi: 10.1002/ejhf.3791.
    PubMed    
    
    
    
59. PRAKASH ES
    Letter regarding the article 'Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study'.
    Eur J Heart Fail. 2025 Jul 23. doi: 10.1002/ejhf.3790.
    PubMed    
    
    
    
60. BIEGUS J, Zymlinski R, Ponikowski P
    Reply to 'Is sodium chloride supplementation ready for clinical practice in acute heart failure?'.
    Eur J Heart Fail. 2025 Jul 21. doi: 10.1002/ejhf.3773.
    PubMed    
    
    
    
61. KEMPF T, Geller W, Fuge J, Sandu MA, et al
    Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure.
    Eur J Heart Fail. 2025 Jul 21. doi: 10.1002/ejhf.3789.
    PubMed    
    
    
    
62. MASUDA Y, Yamamoto I
    Is sodium chloride supplementation ready for clinical practice in acute heart failure? Letter regarding the article 'Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-
    Eur J Heart Fail. 2025 Jul 21. doi: 10.1002/ejhf.3765.
    PubMed    
    
    
    
63. RAKISHEVA A, Farmakis D, Attanasio A, Genis AB, et al
    Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Cou
    Eur J Heart Fail. 2025 Jul 18. doi: 10.1002/ejhf.3753.
    PubMed     Abstract available
    
    
    
64. TOMASONI D, Adamo M, Hausleiter J, Pezzola E, et al
    Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair: Insights from EuroTR.
    Eur J Heart Fail. 2025 Jul 18. doi: 10.1002/ejhf.3757.
    PubMed     Abstract available
    
    
    
65. LEE S, Claggett BL, Fang JC, Mitchell GF, et al
    Changes in cardiac structure and function are associated with health-related quality of life in heart failure patients with reduced ejection fraction: Results from the EVALUATE-HF trial.
    Eur J Heart Fail. 2025 Jul 18. doi: 10.1002/ejhf.3760.
    PubMed     Abstract available
    
    
    
66. GIRERD N, Sandrin L, de Ledinghen V, Mebazaa A, et al
    Reply to the letter regarding the article 'Liver stiffness measurement for non-invasive assessment of central venous pressure in patients with heart failure: A multicentre pilot study'.
    Eur J Heart Fail. 2025 Jul 17. doi: 10.1002/ejhf.3785.
    PubMed    
    
    
    
67. WANG Y, Yang Z, Liao S
    Letter regarding the article 'Liver stiffness measurement for non-invasive assessment of central venous pressure in patients with heart failure: A multicentre pilot study'.
    Eur J Heart Fail. 2025 Jul 17. doi: 10.1002/ejhf.3784.
    PubMed    
    
    
    
68. AMERI P, Costa P, Benson L, Stolfo D, et al
    Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register.
    Eur J Heart Fail. 2025 Jul 17. doi: 10.1002/ejhf.3775.
    PubMed     Abstract available
    
    
    
69. BEYHOFF N, Braun VM, Kirchner M, Finnigan LEM, et al
    Computational modelling of myocardial metabolism in patients with advanced heart failure.
    Eur J Heart Fail. 2025 Jul 15. doi: 10.1002/ejhf.3746.
    PubMed     Abstract available
    
    
    
70. RAME JE, Schmitto JD, Kosevic DN, Kovacevic-Preradovic T, et al
    Cardio-microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C-MIC II open-label randomized controlled trial.
    Eur J Heart Fail. 2025 Jul 15. doi: 10.1002/ejhf.3763.
    PubMed     Abstract available
    
    
    
71. BIEGUS J, Iwanek G, Ponikowski P
    Reply to 'Sodium chloride supplementation in acute heart failure: A closer look at SOLVRED-AHF'.
    Eur J Heart Fail. 2025 Jul 15. doi: 10.1002/ejhf.3771.
    PubMed    
    
    
    
72. OKAZAKI T, Yaegashi Y
    Sodium chloride supplementation in acute heart failure: A closer look at SOLVRED-AHF. Letter regarding the article 'Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-A
    Eur J Heart Fail. 2025 Jul 15. doi: 10.1002/ejhf.3767.
    PubMed    
    
    
    
73. PACKER M, Butler J, Ferreira JP, Siddiqi TJ, et al
    Coordinated expression of BMP10/ALK1/endoglin-proteins that drive embryonic cardiac and vascular morphogenesis-in patients with heart failure: The EMPEROR Program.
    Eur J Heart Fail. 2025 Jul 14. doi: 10.1002/ejhf.3764.
    PubMed     Abstract available
    
    
    
74. BHATTI T
    Letter regarding the article 'Heart failure in patients with a systemic right ventricle: A multicentre study with long-term follow-up'.
    Eur J Heart Fail. 2025 Jul 14. doi: 10.1002/ejhf.3747.
    PubMed    
    
    
    
75. ANSARI RAMANDI MM, van Melle JP, Voors AA
    Reply to the letter regarding the article 'Heart failure in patients with a systemic right ventricle: A multicentre study with long-term follow-up'.
    Eur J Heart Fail. 2025 Jul 14. doi: 10.1002/ejhf.3750.
    PubMed    
    
    
    
76. KUNZ M, Schaar JM, Welker KR, Lauder L, et al
    Medication adherence in patients with acutely decompensated heart failure: A cross-sectional study in the emergency department (ADHF-ED).
    Eur J Heart Fail. 2025 Jul 10. doi: 10.1002/ejhf.3756.
    PubMed     Abstract available
    
    
    
77. SAKATA Y, Nochioka K, Yasuda S, Shimokawa H, et al
    Reply to the letter regarding the article 'Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure'.
    Eur J Heart Fail. 2025 Jul 10. doi: 10.1002/ejhf.3740.
    PubMed    
    
    
    
78. BOGOVIKU J, Nguyen TD, Westphal JG, Haertel F, et al
    Effects of empagliflozin on uric acid levels during acute heart failure recompensation: A sub-analysis of the EMPAG-HF trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure).
    Eur J Heart Fail. 2025 Jul 9. doi: 10.1002/ejhf.3723.
    PubMed     Abstract available
    
    
    
79. KOK TF, van Essen BJ, Yang Y, Gansevoort RT, et al
    Serially measured urinary albumin excretion is strongly associated with incident heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2025 Jul 7. doi: 10.1002/ejhf.3739.
    PubMed    
    
    
    
80. TANAKA TD, Shiraishi Y, Kang R, Kohno T, et al
    Residual pulmonary hypertension and clinical outcomes in acute decompensated heart failure patients stratified by left ventricular ejection fraction.
    Eur J Heart Fail. 2025 Jul 4. doi: 10.1002/ejhf.3755.
    PubMed     Abstract available
    
    
    
81. KALOGEROPOULOS AP, Hameed I, Anker SD, Bayes-Genis A, et al
    Changes in natriuretic peptide levels following patiromer-enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study.
    Eur J Heart Fail. 2025 Jul 3. doi: 10.1002/ejhf.3754.
    PubMed     Abstract available
    
    
    
82. GERAEDS CBG, Bruninx A, Dekker ALAJ, Barandiaran Aizpurua A, et al
    Exploring safety of down-titrating diuretics in heart failure management.
    Eur J Heart Fail. 2025 Jul 2. doi: 10.1002/ejhf.3714.
    PubMed     Abstract available
    
    
    
83. FERREIRA JP, Marques P, Brugts JJ
    Down-titrating diuretics in heart failure.
    Eur J Heart Fail. 2025 Jul 2. doi: 10.1002/ejhf.3726.
    PubMed    
    
    
    
84. 
    Abstracts of the Heart Failure 2025, 17-20 May 2025, Belgrade, Serbia.
    Eur J Heart Fail. 2025;27 Suppl 2:3-542.
    PubMed    
    
    
    
85. MARKWIRTH P, Hoevelmann J, Tokcan M, Haring B, et al
    What's new in heart failure? July 2025.
    Eur J Heart Fail. 2025;27:1155-1158.
    PubMed    
    
    
    
86. QUATAERT I, Blondeel M, Trenson S, Ingelaere S, et al
    Incidences and clinical outcomes of patients with a single or dual chamber implantable cardioverter-defibrillator developing an indication for cardiac resynchronization therapy.
    Eur J Heart Fail. 2025;27:1262-1269.
    PubMed     Abstract available
    
    
    
87. KAYE DM, Wang XS, Koay YC, Li M, et al
    Mechanical unloading is accompanied by reverse metabolic remodelling in the failing heart: Identification of a novel citraconate-mediated pathway.
    Eur J Heart Fail. 2025;27:1342-1352.
    PubMed     Abstract available
    
    
    
88. KRAMMER T, Baier MJ, Hegner P, Zschiedrich T, et al
    Cardioprotective effects of semaglutide on isolated human ventricular myocardium.
    Eur J Heart Fail. 2025;27:1315-1325.
    PubMed     Abstract available
    
    
    
89. LONGINOW J, Mirzai S, Chen PH, Hanna M, et al
    Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis.
    Eur J Heart Fail. 2025;27:1294-1303.
    PubMed     Abstract available
    
    
    June 2025
90. VAN VELDHUISEN DJ, Van der Meer P
    A second wind for digitalis glycosides in heart failure?
    Eur J Heart Fail. 2025 Jun 30. doi: 10.1002/ejhf.3743.
    PubMed    
    
    
    
91. BIMA P, Wussler D, Lopez-Ayala P, Belkin M, et al
    Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides.
    Eur J Heart Fail. 2025 Jun 30. doi: 10.1002/ejhf.3752.
    PubMed     Abstract available
    
    
    
92. IBE T, Demmer RT, Harada T, Doi S, et al
    Prognostic significance of unintentional weight loss in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2025 Jun 26. doi: 10.1002/ejhf.3745.
    PubMed     Abstract available
    
    
    
93. GOUDA P, Alemayehu W, Voors AA, Lam CSP, et al
    Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial.
    Eur J Heart Fail. 2025 Jun 20. doi: 10.1002/ejhf.3731.
    PubMed     Abstract available
    
    
    
94. BAUDRY G, Pereira O, Roubille F, Villaceque M, et al
    Sex-based differences in heart failure management and outcomes: Insights from the French-DataHF cohort.
    Eur J Heart Fail. 2025 Jun 20. doi: 10.1002/ejhf.3733.
    PubMed     Abstract available
    
    
    
95. CHENG Y, Peng H, Sun Y, Qin L, et al
    Letter regarding the article 'Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure'.
    Eur J Heart Fail. 2025 Jun 18. doi: 10.1002/ejhf.3734.
    PubMed    
    
    
    
96. DOI S, Tada A, Harada T, Naser JA, et al
    Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold.
    Eur J Heart Fail. 2025 Jun 18. doi: 10.1002/ejhf.3729.
    PubMed     Abstract available
    
    
    
97. HULOT JS, Ter Maaten JM, Bayes-Genis A, Halliday BP, et al
    Heart failure improvement, remission, and recovery: A European Journal of Heart Failure expert consensus document.
    Eur J Heart Fail. 2025 Jun 18. doi: 10.1002/ejhf.3732.
    PubMed     Abstract available
    
    
    
98. VAN DEN EYNDE J, Verbrugge FH
    Water and electrolyte homeostasis during decongestion in heart failure.
    Eur J Heart Fail. 2025 Jun 18. doi: 10.1002/ejhf.3727.
    PubMed     Abstract available
    
    
    
99. TOCCHETTI CG, Gonzalez A, Backs J, Pollesello P, et al
    How to facilitate seamless translation from basic concepts to new heart failure drugs. A scientific statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2025 Jun 18. doi: 10.1002/ejhf.3709.
    PubMed     Abstract available
    
    
    
100. SEFEROVIC PM, Polovina M, Savarese G, Milinkovic I, et al
     The European heart failure management resources, treatment reimbursement and activities of professional and patient organizations.
     Eur J Heart Fail. 2025 Jun 17. doi: 10.1002/ejhf.3691.
     PubMed     Abstract available
     
     
     
101. GIRERD N, Biegus J, Janas A, Buszman P, et al
     Liver stiffness measurement for non-invasive assessment of central venous pressure in patients with heart failure: A multicentre pilot study.
     Eur J Heart Fail. 2025 Jun 16. doi: 10.1002/ejhf.3722.
     PubMed     Abstract available
     
     
     
102. FRAGASSO G, Stolfo D, Anker MS, Bayes-Genis A, et al
     The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2025 Jun 16. doi: 10.1002/ejhf.3703.
     PubMed     Abstract available
     
     
     
103. BENGEL P, Sossalla S
     Letter regarding the article 'Guideline-directed medical therapy for heart failure in arrhythmia-induced cardiomyopathy with improved left ventricular ejection fraction'.
     Eur J Heart Fail. 2025 Jun 11. doi: 10.1002/ejhf.3712.
     PubMed    
     
     
     
104. LUO Y, Caliskan K
     Reply to the letter regarding the article 'Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review'.
     Eur J Heart Fail. 2025 Jun 11. doi: 10.1002/ejhf.3713.
     PubMed    
     
     
     
105. DING J, Li J, Li Y
     Letter regarding the article 'Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review'.
     Eur J Heart Fail. 2025 Jun 11. doi: 10.1002/ejhf.3717.
     PubMed    
     
     
     
106. INCIARDI RM, Vaduganathan M, Claggett B, AbouEzzeddine OF, et al
     Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction.
     Eur J Heart Fail. 2025 Jun 9. doi: 10.1002/ejhf.3698.
     PubMed     Abstract available
     
     
     
107. TOMASONI D, Benson L, Gatti P, Villaschi A, et al
     Cardiac resynchronization therapy for enabling guideline-directed medical therapy optimization in heart failure.
     Eur J Heart Fail. 2025 Jun 5. doi: 10.1002/ejhf.3719.
     PubMed     Abstract available
     
     
     
108. PALAZZUOLI A, Pellicori P, Cleland JGF
     Serial assessment of left ventricular ejection fraction for the management of heart failure: Unnecessary and unrealistic?
     Eur J Heart Fail. 2025 Jun 5. doi: 10.1002/ejhf.3716.
     PubMed    
     
     
     
109. BIEGUS J, Iwanek G, Testani J, Zymlinski R, et al
     Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study.
     Eur J Heart Fail. 2025 Jun 2. doi: 10.1002/ejhf.3708.
     PubMed     Abstract available
     
     
     
110. SOLOVEVA A, Fedorova D, Kuchinskaia S, Rakisheva A, et al
     Profiling hypotension in heart failure based on office, orthostatic and ambulatory blood pressure measurements.
     Eur J Heart Fail. 2025 Jun 2. doi: 10.1002/ejhf.3715.
     PubMed    
     
     
     
111. LEE MMY, Codina P, Tomasoni D, Aimo A, et al
     What's new in heart failure? June 2025.
     Eur J Heart Fail. 2025;27:935-939.
     PubMed    
     
     
     
112. BRAUN VM, Foryst-Ludwig A, Landmesser U, Baczko I, et al
     Cancer therapy-related cardiotoxicity is associated with distinct alterations of the myocardial lipidome.
     Eur J Heart Fail. 2025;27:1056-1066.
     PubMed     Abstract available
     
     
     
113. CHATUR S, Vaduganathan M, Fletcher RA, Perkovic V, et al
     Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials.
     Eur J Heart Fail. 2025;27:994-1002.
     PubMed     Abstract available
     
     
     May 2025
114. SEFEROVIC PM, Polovina M, Savarese G, Milinkovic I, et al
     Insights into the European heart failure epidemiology.
     Eur J Heart Fail. 2025 May 30. doi: 10.1002/ejhf.3710.
     PubMed     Abstract available
     
     
     
115. SUNDERMEYER J, Kellner C, Beer BN, Besch L, et al
     Kidney injury in patients with heart failure-related cardiogenic shock: Results from an international, multicentre cohort study.
     Eur J Heart Fail. 2025 May 28. doi: 10.1002/ejhf.3701.
     PubMed     Abstract available
     
     
     
116. BAUDRY G, Li G, Wang R, Newton RAV, et al
     Global heart failure epidemiology versus enrolment in pivotal trials: A formidable mismatch.
     Eur J Heart Fail. 2025 May 28. doi: 10.1002/ejhf.3707.
     PubMed     Abstract available
     
     
     
117. BOZKURT B, Rossignol P, Vassalotti JA
     Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease.
     Eur J Heart Fail. 2025 May 27. doi: 10.1002/ejhf.3683.
     PubMed     Abstract available
     
     
     
118. GREENE SJ, Kaltenbach LA, Fonarow GC, Chiswell K, et al
     Clinical and financial implications of inpatient and outpatient management of worsening heart failure.
     Eur J Heart Fail. 2025 May 26. doi: 10.1002/ejhf.3702.
     PubMed     Abstract available
     
     
     
119. LI JW, Wang J, Chen Y, Yang H, et al
     Longitudinal blood pressure and cardiovascular outcomes in heart failure: An individual patient data pooling analysis of clinical trials.
     Eur J Heart Fail. 2025 May 24. doi: 10.1002/ejhf.3706.
     PubMed     Abstract available
     
     
     
120. LEFER DJ, Sharp TE 3rd, Scarborough AL, Haydel AG, et al
     Renal denervation improves cardiac function and exercise duration in a miniswine model of heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2025 May 22. doi: 10.1002/ejhf.3700.
     PubMed     Abstract available
     
     
     
121. ANKER SD, Robertson M, McMurray JJV, Jhund PS, et al
     Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial.
     Eur J Heart Fail. 2025 May 20. doi: 10.1002/ejhf.3670.
     PubMed     Abstract available
     
     
     
122. WEGERMANN K, Chouairi F, Karachaliou GS, Ahlers C, et al
     Incident heart failure is common and underrecognized in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease.
     Eur J Heart Fail. 2025 May 19. doi: 10.1002/ejhf.3697.
     PubMed     Abstract available
     
     
     
123. BAVENDIEK U, Thomas NH, Berliner D, Liu X, et al
     DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials.
     Eur J Heart Fail. 2025 May 19. doi: 10.1002/ejhf.3679.
     PubMed     Abstract available
     
     
     
124. MEEKERS E, Martens P, Knevels R, Miseur M, et al
     Home-based urinary sodium monitoring via point-of-care testing for personalized diuretic titration in heart failure management: The EASY-STOP study.
     Eur J Heart Fail. 2025 May 19. doi: 10.1002/ejhf.3693.
     PubMed     Abstract available
     
     
     
125. WEERTS J, Barandiaran Aizpurua A, Patel RB, van de Bovenkamp AA, et al
     A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides.
     Eur J Heart Fail. 2025 May 19. doi: 10.1002/ejhf.3651.
     PubMed     Abstract available
     
     
     
126. GREENE SJ, Corda S, McMullan CJ, Palombo G, et al
     Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study.
     Eur J Heart Fail. 2025 May 19. doi: 10.1002/ejhf.3699.
     PubMed     Abstract available
     
     
     
127. CUNNINGHAM JW, Claggett BL, Vaduganathan M, Desai AS, et al
     Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.
     Eur J Heart Fail. 2025 May 16. doi: 10.1002/ejhf.3694.
     PubMed     Abstract available
     
     
     
128. CHIMURA M, Yang M, Henderson AD, Jhund PS, et al
     Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
     Eur J Heart Fail. 2025 May 16. doi: 10.1002/ejhf.3682.
     PubMed     Abstract available
     
     
     
129. KAPELIOS CJ, Liori S, Bonios M, Abraham WT, et al
     Effect of pulmonary artery pressure-guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta-analysis of real-world evidence with the CardioMEMS Heart Failure System.
     Eur J Heart Fail. 2025 May 13. doi: 10.1002/ejhf.3687.
     PubMed     Abstract available
     
     
     
130. PONIKOWSKA B, Biegus J
     Reply to the letter regarding the article 'Lower extremity lymphatic flow is associated with diuretic response in acute heart failure'.
     Eur J Heart Fail. 2025 May 12. doi: 10.1002/ejhf.3690.
     PubMed    
     
     
     
131. YANG C, Gao B, Huang J
     Letter regarding the article 'Lower extremity lymphatic flow is associated with diuretic response in acute heart failure'.
     Eur J Heart Fail. 2025 May 12. doi: 10.1002/ejhf.3686.
     PubMed    
     
     
     
132. STOLLBERGER C, Finsterer J, Schneider B
     Assessing heart failure after surgical occlusion of the left atrial appendage. Letter regarding the article 'Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial'.
     Eur J Heart Fail. 2025 May 8. doi: 10.1002/ejhf.3663.
     PubMed    
     
     
     
133. KRISAI P, Whitlock RP, Healey JS
     Reply to 'Assessing heart failure after surgical occlusion of the left atrial appendage'.
     Eur J Heart Fail. 2025 May 8. doi: 10.1002/ejhf.3666.
     PubMed    
     
     
     
134. LIM HS, Damman K, Baudry G, Cikes M, et al
     Donor heart allocation systems in Europe. A scientific statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2025 May 7. doi: 10.1002/ejhf.3681.
     PubMed     Abstract available
     
     
     
135. SAVARESE G, Schiattarella GG, Lindberg F, Anker MS, et al
     Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2025 May 6. doi: 10.1002/ejhf.3676.
     PubMed     Abstract available
     
     
     
136. CHIONCEL O, Mebazaa A, Farmakis D, Abdelhamid M, et al
     Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur J Heart Fail. 2025 May 4. doi: 10.1002/ejhf.3673.
     PubMed     Abstract available
     
     
     
137. PAILLARD M, Abdellatif M, Andreadou I, Bar C, et al
     Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial
     Eur J Heart Fail. 2025 May 4. doi: 10.1002/ejhf.3674.
     PubMed     Abstract available
     
     
     
138. RUBIS P, Piorkowski A, Winiarczyk M, Nurzynska K, et al
     Video thermography uncovers relationship between volume status and temperature in heart failure.
     Eur J Heart Fail. 2025 May 4. doi: 10.1002/ejhf.3680.
     PubMed     Abstract available
     
     
     
139. WEISS AJ, Maigrot JA, Tong MZY, Thuita L, et al
     Time-varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices.
     Eur J Heart Fail. 2025;27:822-829.
     PubMed     Abstract available
     
     
     
140. WANG X, Pabon MA, Cikes M, Jering K, et al
     Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiographic substudy.
     Eur J Heart Fail. 2025;27:788-799.
     PubMed     Abstract available
     
     
     April 2025
141. KONDO T, Jhund PS, Henderson AD, Claggett BL, et al
     The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF.
     Eur J Heart Fail. 2025 Apr 29. doi: 10.1002/ejhf.3669.
     PubMed     Abstract available
     
     
     
142. ANKER SD, Friede T, Butler J, Talha KM, et al
     Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials.
     Eur J Heart Fail. 2025 Apr 29. doi: 10.1002/ejhf.3658.
     PubMed     Abstract available
     
     
     
143. BAYES-GENIS A, Pagnesi M, Codina P, Abraham WT, et al
     Remote pulmonary artery pressure-guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC.
     Eur J Heart Fail. 2025 Apr 27. doi: 10.1002/ejhf.3619.
     PubMed     Abstract available
     
     
     
144. ANSARI RAMANDI MM, Budts W, Roos-Hesselink JW, Helbing WA, et al
     Heart failure in patients with a systemic right ventricle: A multicentre study with long-term follow-up.
     Eur J Heart Fail. 2025 Apr 25. doi: 10.1002/ejhf.3664.
     PubMed     Abstract available
     
     
     
145. ROSANO GMC, Teerlink JR, Kinugawa K, Bayes-Genis A, et al
     The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failu
     Eur J Heart Fail. 2025 Apr 22. doi: 10.1002/ejhf.3646.
     PubMed     Abstract available
     
     
     
146. BUTT JH, Solomon SD, Vaduganathan M, van Veldhuisen DJ, et al
     Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight.
     Eur J Heart Fail. 2025 Apr 21. doi: 10.1002/ejhf.3665.
     PubMed     Abstract available
     
     
     
147. LUO Y, Xiao W, Sener YZ, Meijers WC, et al
     Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review.
     Eur J Heart Fail. 2025 Apr 20. doi: 10.1002/ejhf.3652.
     PubMed     Abstract available
     
     
     
148. SAKATA Y, Nochioka K, Yasuda S, Ishida K, et al
     Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure.
     Eur J Heart Fail. 2025 Apr 15. doi: 10.1002/ejhf.3654.
     PubMed     Abstract available
     
     
     
149. BAYES-GENIS A, Anderson L, Harding E, Metra M, et al
     Late diagnosis in cancer sparks outrage-so why not heart failure?
     Eur J Heart Fail. 2025 Apr 15. doi: 10.1002/ejhf.3667.
     PubMed    
     
     
     
150. BUTT JH, Jhund PS, Henderson AD, Claggett BL, et al
     Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
     Eur J Heart Fail. 2025 Apr 13. doi: 10.1002/ejhf.3661.
     PubMed     Abstract available
     
     
     
151. BUTT JH, Jhund PS, Henderson AD, Claggett BL, et al
     Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
     Eur J Heart Fail. 2025 Apr 10. doi: 10.1002/ejhf.3649.
     PubMed     Abstract available
     
     
     
152. BOZKURT B, Mullens W, Leclercq C, Russo AM, et al
     Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document.
     Eur J Heart Fail. 2025 Apr 9. doi: 10.1002/ejhf.3641.
     PubMed     Abstract available
     
     
     
153. KARAKASIS P, Lefkou E, Pamporis K, Heymans S, et al
     Reply to the letter regarding the article 'Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis'.
     Eur J Heart Fail. 2025 Apr 9. doi: 10.1002/ejhf.3660.
     PubMed    
     
     
     
154. HUANG J
     Letter regarding the article 'Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis'.
     Eur J Heart Fail. 2025 Apr 9. doi: 10.1002/ejhf.3659.
     PubMed    
     
     
     
155. PONIKOWSKA B, Zymlinski R, Fudim M, Ponikowska B, et al
     Lower extremity lymphatic flow is associated with diuretic response in acute heart failure.
     Eur J Heart Fail. 2025 Apr 7. doi: 10.1002/ejhf.3655.
     PubMed     Abstract available
     
     
     
156. SUTHAHAR N, Mourmans SGJ, Achten A, Aboumsallem JP, et al
     Peroxiredoxin-4, a marker of systemic oxidative stress, is associated with incident heart failure.
     Eur J Heart Fail. 2025 Apr 6. doi: 10.1002/ejhf.3653.
     PubMed     Abstract available
     
     
     
157. AMIR O, Adamopoulos S, Burri H, Bayes-Genis A, et al
     Cardiac implantable electronic and other monitoring devices in continuous-flow left ventricular assist device patients. A clinical consensus statement of the Heart Failure Association and the European Heart Rhythm Association of the ESC.
     Eur J Heart Fail. 2025 Apr 1. doi: 10.1002/ejhf.3635.
     PubMed     Abstract available
     
     
     
158. CHEDID EL HELOU M, Nandar PP, Tereshchenko LG, Jacob M, et al
     Factors associated with the use of guideline-directed medical therapy in patients with left ventricular assist device.
     Eur J Heart Fail. 2025;27:650-655.
     PubMed     Abstract available
     
     
     
159. BOCCHINO PP, Frea S, Sacco A, Bertaina M, et al
     Organ perfusion pressure predicts outcomes in cardiogenic shock patients.
     Eur J Heart Fail. 2025;27:659-668.
     PubMed     Abstract available
     
     
     
160. LUSEBRINK E, Lanz H, Kellnar A, Karam N, et al
     Management of acute decompensated valvular heart disease.
     Eur J Heart Fail. 2025;27:630-649.
     PubMed     Abstract available
     
     
     March 2025
161. ABDIN A, Kulenthiran S, Komajda M, Borer JS, et al
     Ivabradine improves win ratios of heart failure outcomes in patients with reduced ejection fraction - insights from the SHIFT trial.
     Eur J Heart Fail. 2025 Mar 30. doi: 10.1002/ejhf.3648.
     PubMed    
     
     
     
162. LAUFS U, Greene SJ, Schulz M
     Time for a new perspective on polypharmacy in heart failure.
     Eur J Heart Fail. 2025 Mar 27. doi: 10.1002/ejhf.3650.
     PubMed    
     
     
     
163. GORENEK B, Wijnmaalen AP, Goette A, Mert GO, et al
     Ventricular arrhythmias in acute heart failure. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Heart Rhythm Association (EHRA) and the Heart Failure Association (HFA) of the ESC.
     Eur J Heart Fail. 2025 Mar 19. doi: 10.1002/ejhf.3645.
     PubMed     Abstract available
     
     
     
164. STOLFO D, Iacoviello M, Chioncel O, Anker MS, et al
     How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2025 Mar 17. doi: 10.1002/ejhf.3642.
     PubMed     Abstract available
     
     
     
165. VOLTERRANI M, Halasz G, Adamopoulos S, Agostoni PG, et al
     Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology.
     Eur J Heart Fail. 2025 Mar 12. doi: 10.1002/ejhf.3440.
     PubMed     Abstract available
     
     
     
166. VOORRIPS SN, Palm CL, Saucedo-Orozco H, Mahmoud B, et al
     Myocardial ketone body oxidation contributes to empagliflozin-induced improvements in cardiac contractility in murine heart failure.
     Eur J Heart Fail. 2025 Mar 11. doi: 10.1002/ejhf.3633.
     PubMed     Abstract available
     
     
     
167. INCIARDI RM, Steven D, Savarese G
     The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management.
     Eur J Heart Fail. 2025 Mar 11. doi: 10.1002/ejhf.3643.
     PubMed    
     
     
     
168. GHIGO A, Ameri P, Asnani A, Bertero E, et al
     Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellula
     Eur J Heart Fail. 2025 Mar 11. doi: 10.1002/ejhf.3636.
     PubMed     Abstract available
     
     
     
169. KARAKASIS P, Lefkou E, Pamporis K, Farmakis D, et al
     Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis.
     Eur J Heart Fail. 2025 Mar 10. doi: 10.1002/ejhf.3637.
     PubMed     Abstract available
     
     
     
170. SENNI M, Paruchuru P, Shi V, Bohm M, et al
     Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: Results from the open-label extension of the PARADIGM-HF study.
     Eur J Heart Fail. 2025 Mar 9. doi: 10.1002/ejhf.3634.
     PubMed    
     
     
     
171. O'CONNOR FK, Sabapathy S, Sharma P, Roberts L, et al
     Acute lower-limb heating improves exercise performance in individuals with heart failure with reduced ejection fraction.
     Eur J Heart Fail. 2025 Mar 5. doi: 10.1002/ejhf.3638.
     PubMed    
     
     
     
172. CLELAND JGF, Friday J, Iaconelli A, Kaur N, et al
     If a patient does not require treatment with loop diuretics, do they really have heart failure?
     Eur J Heart Fail. 2025 Mar 4. doi: 10.1002/ejhf.3628.
     PubMed    
     
     
     
173. ZAHIR ANJUM D, Garred CH, Carlson N, Fosbol E, et al
     Kidney status and events preceding death in heart failure: A real-world nationwide study.
     Eur J Heart Fail. 2025 Mar 2. doi: 10.1002/ejhf.3631.
     PubMed     Abstract available
     
     
     
174. 
     HFA Winter Research Meeting on Translational Heart Failure 2025 In collaboration with the ESC Working Group on Myocardial Function.
     Eur J Heart Fail. 2025;27 Suppl 1:3-29.
     PubMed    
     
     
     
175. HOEVELMANN J, Markwirth P, Tokcan M, Haring B, et al
     What's new in heart failure? March 2025.
     Eur J Heart Fail. 2025;27:409-411.
     PubMed    
     
     
     
176. PETRIE MC, Udell JA, Anker SD, Harrington J, et al
     Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial.
     Eur J Heart Fail. 2025;27:577-588.
     PubMed     Abstract available
     
     
     
177. AMIR O, Elbaz-Greener G, Carasso S, Claggett B, et al
     Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data.
     Eur J Heart Fail. 2025;27:558-565.
     PubMed     Abstract available
     
     
     
178. NEVES JS, Leite AR, Mentz RJ, Holman RR, et al
     Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
     Eur J Heart Fail. 2025;27:540-551.
     PubMed     Abstract available
     
     
     February 2025
179. MEEKERS E, Dauw J, Ter Maaten JM, Martens P, et al
     Urinary sodium analysis: The key to effective diuretic titration? European Journal of Heart Failure expert consensus document.
     Eur J Heart Fail. 2025 Feb 27. doi: 10.1002/ejhf.3632.
     PubMed     Abstract available
     
     
     
180. SKOURI H, Girerd N, Monzo L, Petrie MC, et al
     Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC.
     Eur J Heart Fail. 2025 Feb 26. doi: 10.1002/ejhf.3618.
     PubMed     Abstract available
     
     
     
181. FERREIRA JP, Vasques-Novoa F, Angermann CE, Biegus J, et al
     Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis.
     Eur J Heart Fail. 2025 Feb 20. doi: 10.1002/ejhf.3626.
     PubMed     Abstract available
     
     
     
182. BIEGUS J, Palazzuoli A, Greene SJ
     Effect of finerenone across the stages of heart failure: From prevention to treatment.
     Eur J Heart Fail. 2025 Feb 17. doi: 10.1002/ejhf.3606.
     PubMed    
     
     
     
183. PACKER M, Butler J
     The win ratio for trials for heart failure: academic desperation or investigator decadence?
     Eur J Heart Fail. 2025 Feb 16. doi: 10.1002/ejhf.3608.
     PubMed    
     
     
     
184. SALDARRIAGA CI, Zannad F, McMullan CJ, Xing A, et al
     Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.
     Eur J Heart Fail. 2025 Feb 16. doi: 10.1002/ejhf.3598.
     PubMed     Abstract available
     
     
     
185. ABDIN A, Izzat MB, Alsaadi AR, Katbeh A, et al
     Heart failure guideline implementation in developing countries: A testimony from Syria.
     Eur J Heart Fail. 2025 Feb 13. doi: 10.1002/ejhf.3625.
     PubMed    
     
     
     
186. MACGOWAN H, Brown OI, Drozd M, Walker AMN, et al
     Comorbidity trajectories before and after the diagnosis of heart failure: A UK Biobank cohort study.
     Eur J Heart Fail. 2025 Feb 11. doi: 10.1002/ejhf.3601.
     PubMed     Abstract available
     
     
     
187. HOEVELMANN J, Petrie MC, Haring B
     Alcohol and heart failure: A complex relationship!
     Eur J Heart Fail. 2025 Feb 11. doi: 10.1002/ejhf.3607.
     PubMed    
     
     
     
188. BACMEISTER L, Codina P, Westermann D
     Man versus machine in advanced heart failure: Can artificial intelligence beat clinicians?
     Eur J Heart Fail. 2025 Feb 11. doi: 10.1002/ejhf.3609.
     PubMed    
     
     
     
189. NUNEZ J, Minana G, de la Espriella R, Zegri-Reiriz I, et al
     Salt repletion and diuretic response: The role of serum chloride. A post-hoc analysis of the SALT-HF trial on furosemide and hypertonic saline solution administration in ambulatory patients with worsening heart failure.
     Eur J Heart Fail. 2025 Feb 11. doi: 10.1002/ejhf.3597.
     PubMed     Abstract available
     
     
     
190. INCIARDI RM, Bayes-Genis A
     Growth differentiation factor-15: A promising biomarker for early detection of pre-heart failure.
     Eur J Heart Fail. 2025 Feb 10. doi: 10.1002/ejhf.3613.
     PubMed    
     
     
     
191. ZHANG F, Li J
     Letter regarding the article 'Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis'.
     Eur J Heart Fail. 2025 Feb 10. doi: 10.1002/ejhf.3612.
     PubMed    
     
     
     
192. NGUYEN DV, Le TN, Nguyen HTT
     Reply to the letter regarding the article 'Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis'.
     Eur J Heart Fail. 2025 Feb 10. doi: 10.1002/ejhf.3610.
     PubMed    
     
     
     
193. ASSMUS B, Rakisheva A
     Unacceptably high mortality and readmission rates 5 years after heart failure hospitalization: The need to optimize long-term heart failure care by addressing diverse healthcare resources.
     Eur J Heart Fail. 2025 Feb 4. doi: 10.1002/ejhf.3600.
     PubMed    
     
     
     
194. TOMASONI D, Codina P, Lee MMY, Aimo A, et al
     What's new in heart failure? February 2025.
     Eur J Heart Fail. 2025;27:185-189.
     PubMed    
     
     
     January 2025
195. ANKER SD, Friede T, Butler J, Talha KM, et al
     Rationale and design of the FAIR-HF2-DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure.
     Eur J Heart Fail. 2025 Jan 28. doi: 10.1002/ejhf.3574.
     PubMed     Abstract available
     
     
     
196. GIRERD N, Jhund P
     Withdrawal of medical therapy for heart failure after rhythm control in arrhythmia-induced cardiomyopathy-a call for caution.
     Eur J Heart Fail. 2025 Jan 27. doi: 10.1002/ejhf.3594.
     PubMed    
     
     
     
197. BUTLER J, Kahwash R, Khan MS, Gerritse B, et al
     Continuous risk monitoring and management of heart failure: Rationale and design of the ALLEVIATE-HF trial.
     Eur J Heart Fail. 2025 Jan 27. doi: 10.1002/ejhf.3595.
     PubMed     Abstract available
     
     
     
198. CHOUAIRI F, Fudim M, Savarese G, Szabo B, et al
     Utility of loop diuretics as a marker of risk in clinical trials of heart failure with preserved ejection fraction: Analysis from the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2025 Jan 23. doi: 10.1002/ejhf.3578.
     PubMed     Abstract available
     
     
     
199. GONZALEZ-JUANATEY JR, Otero-Garcia O, Bohm M
     Beta-blockers and heart failure with mildly reduced and preserved ejection fraction. A personalized approach beyond the heart failure syndrome phenotypes is needed.
     Eur J Heart Fail. 2025 Jan 21. doi: 10.1002/ejhf.3588.
     PubMed    
     
     
     
200. QIN H, van Essen BJ, Ter Maaten JM, Voors AA, et al
     Alcohol consumption and incident heart failure in men and women.
     Eur J Heart Fail. 2025 Jan 20. doi: 10.1002/ejhf.3587.
     PubMed     Abstract available
     
     
     
201. DE LATHAUWER ILJ, Nieuwenhuys WW, Hafkamp F, Regis M, et al
     Remote patient monitoring in heart failure: A comprehensive meta-analysis of effective programme components for hospitalization and mortality reduction.
     Eur J Heart Fail. 2025 Jan 20. doi: 10.1002/ejhf.3568.
     PubMed     Abstract available
     
     
     
202. CHIARITO M, Stolfo D, Villaschi A, Sartori S, et al
     Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort.
     Eur J Heart Fail. 2025 Jan 20. doi: 10.1002/ejhf.3585.
     PubMed     Abstract available
     
     
     
203. STORK S, Hartner G, Lawson C
     The expanding role of heart failure nurses: A call for harmonized standards across Europe.
     Eur J Heart Fail. 2025 Jan 20. doi: 10.1002/ejhf.3572.
     PubMed    
     
     
     
204. GIRERD N, Barbet V, Seronde MF, Benchimol H, et al
     Association of a remote monitoring programme with all-cause mortality and hospitalizations in patients with heart failure: National-scale, real-world evidence from a 3-year propensity score analysis of the TELESAT-HF study.
     Eur J Heart Fail. 2025 Jan 14. doi: 10.1002/ejhf.3563.
     PubMed     Abstract available
     
     
     
205. PANDEY A, Kolkailah AA, McGuire DK, Frederich RC, et al
     Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
     Eur J Heart Fail. 2025 Jan 10. doi: 10.1002/ejhf.3511.
     PubMed     Abstract available
     
     
     
206. OSMANSKA J, Docherty KF, Berry C, Jhund PS, et al
     Cardiovascular magnetic resonance-estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction and dysglycaemia (SUGAR-DM-HF).
     Eur J Heart Fail. 2025 Jan 10. doi: 10.1002/ejhf.3570.
     PubMed     Abstract available
     
     
     
207. SHAHIM A, Linde C, Savarese G, Dahlstrom U, et al
     Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry.
     Eur J Heart Fail. 2025 Jan 9. doi: 10.1002/ejhf.3565.
     PubMed     Abstract available
     
     
     
208. SAVARESE G, Basile C, Adamo M, Anker SD, et al
     Registries on transcatheter edge-to-edge repair in heart failure: Current evidence and future perspectives.
     Eur J Heart Fail. 2025 Jan 8. doi: 10.1002/ejhf.3573.
     PubMed     Abstract available
     
     
     
209. CHANG KC, Su TH, Wu CK, Huang SC, et al
     Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure.
     Eur J Heart Fail. 2025 Jan 8. doi: 10.1002/ejhf.3567.
     PubMed     Abstract available
     
     
     
210. MARKWIRTH P, Hoevelmann J, Tokcan M, Haring B, et al
     What's new in heart failure? January 2025.
     Eur J Heart Fail. 2025;27:1-4.
     PubMed    
     
     
     December 2024
211. GIRERD N, Emrich I, Ferreira JP
     Applying the 'touch-and-go' concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management.
     Eur J Heart Fail. 2024 Dec 26. doi: 10.1002/ejhf.3564.
     PubMed    
     
     
     
212. GROTE BEVERBORG N, Alnuwaysir RIS, Markousis-Mavrogenis G, Hoes MF, et al
     The transcriptional profile of iron deficiency in patients with heart failure: Heme-sparing and reduced immune processes.
     Eur J Heart Fail. 2024 Dec 26. doi: 10.1002/ejhf.3562.
     PubMed     Abstract available
     
     
     
213. 
     Correction to "Cause-specific death in heart failure across the ejection fraction spectrum: a comprehensive assessment of over 100 000 patients in the Swedish heart failure registry".
     Eur J Heart Fail. 2024 Dec 26. doi: 10.1002/ejhf.3554.
     PubMed    
     
     
     
214. 
     Correction to "Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF".
     Eur J Heart Fail. 2024 Dec 19. doi: 10.1002/ejhf.3561.
     PubMed    
     
     
     
215. COTTER G, Davison B, Janiak P, Edwards C, et al
     Observational study for multiparametric assessment of cardiac congestion in outpatient worsening heart failure (EVOLUTION).
     Eur J Heart Fail. 2024 Dec 18. doi: 10.1002/ejhf.3555.
     PubMed     Abstract available
     
     
     
216. DOMINGUEZ-RODRIGUEZ LM, Dobarro D, Iglesias-Otero C, Crespo-Leiro MG, et al
     Guideline-directed medical therapy for heart failure in arrhythmia-induced cardiomyopathy with improved left ventricular ejection fraction.
     Eur J Heart Fail. 2024 Dec 18. doi: 10.1002/ejhf.3556.
     PubMed     Abstract available
     
     
     
217. WANG X, Vardeny O, Claggett B, Vaduganathan M, et al
     Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF.
     Eur J Heart Fail. 2024 Dec 15. doi: 10.1002/ejhf.3535.
     PubMed     Abstract available
     
     
     
218. LEONG DP, Joseph PG, Dokainish H, Stork S, et al
     The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study.
     Eur J Heart Fail. 2024 Dec 15. doi: 10.1002/ejhf.3550.
     PubMed     Abstract available
     
     
     
219. INCIARDI RM, Riccardi M, Savarese G, Metra M, et al
     Tailoring medical therapy for heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Dec 15. doi: 10.1002/ejhf.3558.
     PubMed    
     
     
     
220. VOORS AA, Metra M, Postmus D, Greenberg BH, et al
     End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2).
     Eur J Heart Fail. 2024 Dec 12. doi: 10.1002/ejhf.3551.
     PubMed     Abstract available
     
     
     
221. MONZO L, Bresso E, Dickstein K, Pitt B, et al
     Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction.
     Eur J Heart Fail. 2024 Dec 10. doi: 10.1002/ejhf.3547.
     PubMed     Abstract available
     
     
     
222. SUN G, Fosbol EL, Faurschou M, Schou M, et al
     Long-term rate of heart failure in patients with autoimmune disease: A nationwide cohort study.
     Eur J Heart Fail. 2024 Dec 9. doi: 10.1002/ejhf.3541.
     PubMed     Abstract available
     
     
     
223. ZELDIN L, Eichler JBS, Teruya SL, Weinsaft AY, et al
     Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy.
     Eur J Heart Fail. 2024 Dec 5. doi: 10.1002/ejhf.3540.
     PubMed     Abstract available
     
     
     
224. KESHVANI N, Rizvi S, Segar MW, Miller JW, et al
     Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial.
     Eur J Heart Fail. 2024 Dec 2. doi: 10.1002/ejhf.3537.
     PubMed     Abstract available
     
     
     
225. CODINA P, Lee MMY, Tomasoni D, Aimo A, et al
     What's new in heart failure? December 2024.
     Eur J Heart Fail. 2024;26:2477-2481.
     PubMed    
     
     
     
226. ECHEVERRIA LE, Serrano-Garcia AY, Rojas LZ, Berrios-Barcenas EA, et al
     Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster.
     Eur J Heart Fail. 2024;26:2502-2514.
     PubMed     Abstract available
     
     
     November 2024
227. TOKCAN M, Hoevelmann J, Markwirth P, Emrich I, et al
     What's new in heart failure? November 2024.
     Eur J Heart Fail. 2024 Nov 28. doi: 10.1002/ejhf.3538.
     PubMed    
     
     
     
228. DE BIASE N, Del Punta L, L'Hoyes W, Pellicori P, et al
     Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure.
     Eur J Heart Fail. 2024 Nov 28. doi: 10.1002/ejhf.3534.
     PubMed     Abstract available
     
     
     
229. PERIN EC, Borow KM, Henry TD, Jenkins M, et al
     Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM-HF.
     Eur J Heart Fail. 2024 Nov 26. doi: 10.1002/ejhf.3522.
     PubMed     Abstract available
     
     
     
230. WECKBACH LT, Stolz L, Doldi PM, Glaser H, et al
     Relevance of residual tricuspid regurgitation for right ventricular reverse remodelling after tricuspid valve intervention in patients with severe tricuspid regurgitation and right-sided heart failure.
     Eur J Heart Fail. 2024 Nov 26. doi: 10.1002/ejhf.3529.
     PubMed     Abstract available
     
     
     
231. LANDUCCI L, Faxen UL, Benson L, Dahlstrom U, et al
     Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction.
     Eur J Heart Fail. 2024 Nov 26. doi: 10.1002/ejhf.3523.
     PubMed     Abstract available
     
     
     
232. PAGNESI M, Metra M
     Reply to 'Malnutrition and severe heart failure in real-world study settings'.
     Eur J Heart Fail. 2024 Nov 26. doi: 10.1002/ejhf.3525.
     PubMed    
     
     
     
233. KRISAI P, Belley-Cote EP, McIntyre WF, Wong J, et al
     Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial.
     Eur J Heart Fail. 2024 Nov 25. doi: 10.1002/ejhf.3536.
     PubMed     Abstract available
     
     
     
234. VAN LINTHOUT S, Stellos K, Giacca M, Bertero E, et al
     State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases.
     Eur J Heart Fail. 2024 Nov 22. doi: 10.1002/ejhf.3516.
     PubMed     Abstract available
     
     
     
235. GHOSSEIN-DOHA C, Thilaganathan B, Vaught AJ, Briller JE, et al
     Hypertensive pregnancy disorder, an under-recognized women specific risk factor for heart failure?
     Eur J Heart Fail. 2024 Nov 19. doi: 10.1002/ejhf.3520.
     PubMed     Abstract available
     
     
     
236. BAUDRY G, Girerd N, Cikes M, Crespo-Leiro MG, et al
     Knowledge and application of ESC/HFA guidelines in the management of advanced heart failure.
     Eur J Heart Fail. 2024 Nov 19. doi: 10.1002/ejhf.3530.
     PubMed     Abstract available
     
     
     
237. SHARIF SM, Smith JR, Borlaug BA, Olson TP, et al
     Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Nov 19. doi: 10.1002/ejhf.3528.
     PubMed     Abstract available
     
     
     
238. GUPTA SD, Butt JH, McMurray EGM, Talebi A, et al
     Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF.
     Eur J Heart Fail. 2024 Nov 19. doi: 10.1002/ejhf.3515.
     PubMed     Abstract available
     
     
     
239. WU MC, Yang SC, Gau SY
     Malnutrition and severe heart failure in real-world study settings. Letter regarding the article 'Impact of malnutrition in patients with severe heart failure'.
     Eur J Heart Fail. 2024 Nov 19. doi: 10.1002/ejhf.3524.
     PubMed    
     
     
     
240. KARACAN MN, Yafasova A, Fosbol EL, Tas A, et al
     Long-term risk of heart failure in patients with postoperative atrial fibrillation following non-cardiac surgery: Insights from a nationwide cohort.
     Eur J Heart Fail. 2024 Nov 12. doi: 10.1002/ejhf.3518.
     PubMed     Abstract available
     
     
     
241. THYAGATURU H, Abugrin M, Awad M, Mensah SA, et al
     Psychological distress in heart failure patients: Implications for healthcare utilization and expenditure.
     Eur J Heart Fail. 2024 Nov 11. doi: 10.1002/ejhf.3517.
     PubMed     Abstract available
     
     
     
242. TANAKA A, Imai T, Kida K, Matsue Y, et al
     Angiotensin receptor-neprilysin inhibition and combination use of guideline-directed medical therapies in acute heart failure.
     Eur J Heart Fail. 2024 Nov 11. doi: 10.1002/ejhf.3526.
     PubMed    
     
     
     
243. SOHNS C, Fink T, Crijns HJGM, Costard-Jaeckle A, et al
     Preventive catheter ablation for ventricular arrhythmias in patients with end-stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE-VT trial.
     Eur J Heart Fail. 2024 Nov 11. doi: 10.1002/ejhf.3512.
     PubMed     Abstract available
     
     
     
244. HILL L, Girerd N, Castiello T, Jaarsma T, et al
     Examining the clinical role and educational preparation of heart failure nurses across Europe. A survey of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the Association of Cardiovascular Nursing and Allied Profess
     Eur J Heart Fail. 2024 Nov 8. doi: 10.1002/ejhf.3519.
     PubMed     Abstract available
     
     
     
245. OSTROMINSKI JW, Seferovic PM, Selvaraj S
     Metabolic dysfunction: An important driver of incident heart failure with preserved and reduced ejection fraction.
     Eur J Heart Fail. 2024 Nov 8. doi: 10.1002/ejhf.3507.
     PubMed    
     
     
     
246. LAUDER L, Pfister O, Mahfoud F
     Contextualizing heart rate: Visit-to-visit fluctuations and their impact on prognosis in heart failure.
     Eur J Heart Fail. 2024 Nov 8. doi: 10.1002/ejhf.3513.
     PubMed    
     
     
     
247. AVERBUCH T, Lee SF, Zagorski B, Pandey A, et al
     Long-term clinical outcomes and healthcare resource utilization in male and female patients following hospitalization for heart failure.
     Eur J Heart Fail. 2024 Nov 5. doi: 10.1002/ejhf.3499.
     PubMed     Abstract available
     
     
     
248. SUNDSTROM J, Lindholm D
     Reply to 'The patterns and changes of heart failure treatment in the last years of life still need further study'.
     Eur J Heart Fail. 2024 Nov 5. doi: 10.1002/ejhf.3514.
     PubMed    
     
     
     
249. CAO TH, Voors AA, Ng LL
     Reply to the letter regarding the article 'Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry'.
     Eur J Heart Fail. 2024 Nov 4. doi: 10.1002/ejhf.3482.
     PubMed    
     
     
     
250. BAUDRY G, Metra M, Delmas C
     Reply to the letter regarding the article 'Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?'.
     Eur J Heart Fail. 2024 Nov 3. doi: 10.1002/ejhf.3489.
     PubMed    
     
     
     
251. DORR M, Bohm M, Erdmann E, Gross S, et al
     Multicentre, randomized, double-blind, prospective study on the effects of ImmunoAdSorptiOn on cardiac function in patients with Dilated CardioMyopathy (IASO-DCM): Rationale and design.
     Eur J Heart Fail. 2024;26:2464-2473.
     PubMed     Abstract available
     
     
     
252. MIHALJ M, Reineke D, Just IA, Mulzer J, et al
     Association between caseload volume and outcomes in left ventricular assist device implantations - a EUROMACS analysis.
     Eur J Heart Fail. 2024;26:2400-2409.
     PubMed     Abstract available
     
     
     October 2024
253. ZHAO Y, Shen Z
     The patterns and changes of heart failure treatment in the last years of life still need further study. Letter regarding the article 'Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals'.
     Eur J Heart Fail. 2024 Oct 31. doi: 10.1002/ejhf.3508.
     PubMed    
     
     
     
254. REDDY YNV, Butler J, Anstrom KJ, Blaustein RO, et al
     Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.
     Eur J Heart Fail. 2024 Oct 30. doi: 10.1002/ejhf.3501.
     PubMed     Abstract available
     
     
     
255. DIEDEN A, Girerd N, Ottosson F, Molvin J, et al
     Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts.
     Eur J Heart Fail. 2024 Oct 28. doi: 10.1002/ejhf.3502.
     PubMed     Abstract available
     
     
     
256. LINDBERG F, Benson L, Dahlstrom U, Lund LH, et al
     Trends in heart failure mortality in Sweden between 1997 and 2022.
     Eur J Heart Fail. 2024 Oct 28. doi: 10.1002/ejhf.3506.
     PubMed     Abstract available
     
     
     
257. SAVAGE HO, McBeath K, Hogan J, MacKay-Thomas L, et al
     The 25in25 initiative: A novel transformative project to reduce mortality due to heart failure by 25% in the next 25 years.
     Eur J Heart Fail. 2024 Oct 25. doi: 10.1002/ejhf.3496.
     PubMed    
     
     
     
258. FOLEY PW, Kalra PR, Cleland JGF, Petrie MC, et al
     Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial.
     Eur J Heart Fail. 2024 Oct 25. doi: 10.1002/ejhf.3504.
     PubMed     Abstract available
     
     
     
259. ZIEROTH S, Giraldo CIS, Pinto F, Anker SD, et al
     Applicability of heart failure clinical practice guidelines in low- and middle-income countries.
     Eur J Heart Fail. 2024 Oct 25. doi: 10.1002/ejhf.3485.
     PubMed     Abstract available
     
     
     
260. ANKER MS, Porthun J, Bayes-Genis A, Van Linthout S, et al
     Time for differential weight management in heart failure.
     Eur J Heart Fail. 2024 Oct 25. doi: 10.1002/ejhf.3495.
     PubMed    
     
     
     
261. GIRERD N, Voors AA, Ter Maaten J
     Exploring the role of hypertonic saline in ambulatory heart failure management: One size does not fit all?
     Eur J Heart Fail. 2024 Oct 24. doi: 10.1002/ejhf.3500.
     PubMed    
     
     
     
262. SCIACCA V, Sohns C, Crijns HJGM, Marrouche NF, et al
     Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end-stage heart failure: Lessons from CASTLE-HTx.
     Eur J Heart Fail. 2024 Oct 24. doi: 10.1002/ejhf.3505.
     PubMed     Abstract available
     
     
     
263. SALVADOR-CASABON JM, Lacambra-Blasco I, Perez-Calvo JI
     Letter regarding the article 'Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry'.
     Eur J Heart Fail. 2024 Oct 24. doi: 10.1002/ejhf.3493.
     PubMed    
     
     
     
264. LU H, Claggett BL, Packer M, Pfeffer MA, et al
     Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials.
     Eur J Heart Fail. 2024 Oct 22. doi: 10.1002/ejhf.3487.
     PubMed     Abstract available
     
     
     
265. CUI F, Zheng L, Zhang J, Tang L, et al
     Long-term exposure to fine particulate matter constituents, genetic susceptibility, and incident heart failure among 411 807 adults.
     Eur J Heart Fail. 2024 Oct 22. doi: 10.1002/ejhf.3486.
     PubMed     Abstract available
     
     
     
266. COTTER G, Davison BA, Freund Y, Mebazaa A, et al
     Reply to 'Is it possible to establish a threshold to define the inflammatory risk of acute heart failure patients?' Letter regarding the article 'Burst steroid therapy for acute heart failure: The CORTAHF randomized, open-label, pilot trial'.
     Eur J Heart Fail. 2024 Oct 22. doi: 10.1002/ejhf.3491.
     PubMed    
     
     
     
267. CAMILLI M
     Is it possible to establish a threshold to define the inflammatory risk of acute heart failure patients? Letter regarding the article 'Burst steroid therapy for acute heart failure: the CORTAHF randomized, open-label, pilot trial'.
     Eur J Heart Fail. 2024 Oct 22. doi: 10.1002/ejhf.3494.
     PubMed    
     
     
     
268. MARTIN AC
     Letter regarding the article 'Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?'.
     Eur J Heart Fail. 2024 Oct 22. doi: 10.1002/ejhf.3484.
     PubMed    
     
     
     
269. ZHU L, Liu J, Zhao H
     A clinical classification method with outstanding advantages for quickly identifying hazardous types: Letter regarding the article 'Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-ter
     Eur J Heart Fail. 2024 Oct 18. doi: 10.1002/ejhf.3479.
     PubMed    
     
     
     
270. LEE MMY, Codina P, Tomasoni D, Aimo A, et al
     What's new in heart failure? October 2024.
     Eur J Heart Fail. 2024 Oct 14. doi: 10.1002/ejhf.3492.
     PubMed    
     
     
     
271. NOUHRAVESH N, Greene SJ, Clare R, Wojdyla D, et al
     Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.
     Eur J Heart Fail. 2024 Oct 4. doi: 10.1002/ejhf.3458.
     PubMed     Abstract available
     
     
     
272. IACONELLI A, Emrich I, Pellicori P, Cleland JGF, et al
     Managing congestive heart failure: It is mostly about water, not salt!
     Eur J Heart Fail. 2024 Oct 3. doi: 10.1002/ejhf.3457.
     PubMed    
     
     
     
273. MOLINER-ABOS C, Calvo-Barcelo M, Sole-Gonzalez E, Borrellas Martin A, et al
     Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission: The RevascHeart study.
     Eur J Heart Fail. 2024 Oct 2. doi: 10.1002/ejhf.3463.
     PubMed     Abstract available
     
     
     
274. SEGAR MW, Usman MS, Patel KV, Khan MS, et al
     Development and validation of a machine learning-based approach to identify high-risk diabetic cardiomyopathy phenotype.
     Eur J Heart Fail. 2024;26:2183-2192.
     PubMed     Abstract available
     
     
     
275. KEENE D, Kaza N, Srinivasan D, Ali N, et al
     Predictors of the efficacy of His bundle pacing in patients with a prolonged PR interval: A stratified analysis of the HOPE-HF randomized controlled trial.
     Eur J Heart Fail. 2024;26:2261-2268.
     PubMed     Abstract available
     
     
     September 2024
276. CHENG L, Hammersley D, Ragavan A, Javed S, et al
     Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.
     Eur J Heart Fail. 2024 Sep 30. doi: 10.1002/ejhf.3475.
     PubMed     Abstract available
     
     
     
277. BRANDT M, Cotter G, Wenzel P
     Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions.
     Eur J Heart Fail. 2024 Sep 27. doi: 10.1002/ejhf.3434.
     PubMed    
     
     
     
278. CHRISTODORESCU R, Geavlete O, Ferrini M, Kumler T, et al
     Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2024 Sep 24. doi: 10.1002/ejhf.3444.
     PubMed     Abstract available
     
     
     
279. HOEVELMANN J, Volterrani M, Emrich IE
     Barriers to the implementation of heart failure therapy in the elderly: Let's accept the challenge!
     Eur J Heart Fail. 2024 Sep 24. doi: 10.1002/ejhf.3449.
     PubMed    
     
     
     
280. ABDIN A, Abdin AD, Merone G, Aljundi W, et al
     Cardio-ocular syndrome: Retinal microvascular changes in acutely decompensated heart failure.
     Eur J Heart Fail. 2024 Sep 24. doi: 10.1002/ejhf.3474.
     PubMed     Abstract available
     
     
     
281. NG ACT, Dong X, Koepp KE, Obokata M, et al
     Sexual dimorphism in the relationships between intramyocardial fat, myocardial fibrosis, and exercise intolerance in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Sep 24. doi: 10.1002/ejhf.3473.
     PubMed    
     
     
     
282. HARING B, Abdin A, Bohm M
     Clonal haematopoiesis of indeterminate potential: A new biomarker for heart failure patients? Potential lessons to be learned from cardio-oncology.
     Eur J Heart Fail. 2024 Sep 24. doi: 10.1002/ejhf.3466.
     PubMed    
     
     
     
283. MIRO O, Ivars N, Espinosa B, Jacob J, et al
     Effect of seasonal influenza and COVID-19 vaccination on severity and long-term outcomes of patients with heart failure decompensations.
     Eur J Heart Fail. 2024 Sep 24. doi: 10.1002/ejhf.3469.
     PubMed     Abstract available
     
     
     
284. PABON MA, Vaduganathan M, Claggett BL, Chatur S, et al
     In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial.
     Eur J Heart Fail. 2024 Sep 19. doi: 10.1002/ejhf.3410.
     PubMed     Abstract available
     
     
     
285. WOOD N, Witte KK, Bowen TS
     Reply to the letter regarding the article 'Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction'.
     Eur J Heart Fail. 2024 Sep 18. doi: 10.1002/ejhf.3442.
     PubMed    
     
     
     
286. STOLLBERGER C, Finsterer J, Schneider B
     Letter regarding the article 'Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction'.
     Eur J Heart Fail. 2024 Sep 18. doi: 10.1002/ejhf.3441.
     PubMed    
     
     
     
287. KUSTER GM, Assmus B, Mahfoud F
     Myeloperoxidase: Reviving an old ally for immunomodulation in heart failure?
     Eur J Heart Fail. 2024 Sep 18. doi: 10.1002/ejhf.3468.
     PubMed    
     
     
     
288. LUND LH, James S, DeVore AD, Anstrom KJ, et al
     The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design.
     Eur J Heart Fail. 2024 Sep 16. doi: 10.1002/ejhf.3453.
     PubMed     Abstract available
     
     
     
289. WU CY, Shah BR, Sharma A, Sheng Y, et al
     Timing of sodium-glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: A population-based cohort study.
     Eur J Heart Fail. 2024 Sep 12. doi: 10.1002/ejhf.3464.
     PubMed     Abstract available
     
     
     
290. LUND LH, Crespo-Leiro MG, Laroche C, Zaliaduonyte D, et al
     Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry.
     Eur J Heart Fail. 2024 Sep 10. doi: 10.1002/ejhf.3445.
     PubMed     Abstract available
     
     
     
291. NGUYEN DV, Le TN, Truong BQ, Nguyen HTT, et al
     Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis.
     Eur J Heart Fail. 2024 Sep 9. doi: 10.1002/ejhf.3454.
     PubMed     Abstract available
     
     
     
292. ABDIN A, Aimo A, Hoevelmann J, Haring B, et al
     The month in heart failure! September 2024.
     Eur J Heart Fail. 2024 Sep 9. doi: 10.1002/ejhf.3465.
     PubMed    
     
     
     
293. INCIARDI RM, Staal L, Davison B, Lombardi CM, et al
     Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial.
     Eur J Heart Fail. 2024 Sep 6. doi: 10.1002/ejhf.3451.
     PubMed     Abstract available
     
     
     
294. DOHERTY DJ, Abdin A, Docherty KF
     Heart failure medical therapy in the last years of life: Prognosis and practicalities.
     Eur J Heart Fail. 2024 Sep 3. doi: 10.1002/ejhf.3450.
     PubMed    
     
     
     
295. KAZE AD, Bertoni AG, Fox ER, Hall ME, et al
     Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study.
     Eur J Heart Fail. 2024 Sep 3. doi: 10.1002/ejhf.3447.
     PubMed     Abstract available
     
     
     
296. MYHRE PL, Berge K, Orn S
     Reply to the letter regarding the article 'Changes in 6-min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction'.
     Eur J Heart Fail. 2024 Sep 2. doi: 10.1002/ejhf.3448.
     PubMed    
     
     
     
297. FIORI E, Magri D, Iacovoni A
     Letter regarding the article 'Changes in 6-min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction'.
     Eur J Heart Fail. 2024 Sep 2. doi: 10.1002/ejhf.3456.
     PubMed    
     
     
     
298. LU H, Claggett BL, Packer M, Pfeffer MA, et al
     Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trial.
     Eur J Heart Fail. 2024 Sep 1. doi: 10.1002/ejhf.3414.
     PubMed     Abstract available
     
     
     
299. MC CAUSLAND FR, McGrath MM, Claggett BL, Barkoudah E, et al
     Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI.
     Eur J Heart Fail. 2024;26:1984-1992.
     PubMed     Abstract available
     
     
     
300. ABDIN A, Kondo T, Bohm M, Jhund PS, et al
     Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.
     Eur J Heart Fail. 2024;26:1952-1963.
     PubMed     Abstract available
     
     
     August 2024
301. SUNDSTROM J, Gustafsson S, Cars T, Lindholm D, et al
     Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals.
     Eur J Heart Fail. 2024 Aug 31. doi: 10.1002/ejhf.3426.
     PubMed     Abstract available
     
     
     
302. MATSUMOTO S, Henderson AD, Shen L, Kondo T, et al
     Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.
     Eur J Heart Fail. 2024 Aug 31. doi: 10.1002/ejhf.3383.
     PubMed     Abstract available
     
     
     
303. VAN VELDHUISEN DJ, Rienstra M, Mosterd A, Alings AM, et al
     Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial.
     Eur J Heart Fail. 2024 Aug 30. doi: 10.1002/ejhf.3428.
     PubMed     Abstract available
     
     
     
304. COTTER G, Davison BA, Freund Y, Voors AA, et al
     Burst steroid therapy for acute heart failure: The CORTAHF randomized, open-label, pilot trial.
     Eur J Heart Fail. 2024 Aug 30. doi: 10.1002/ejhf.3452.
     PubMed     Abstract available
     
     
     
305. KERAMIDA K, Farmakis D, Rakisheva A, Tocchetti CG, et al
     The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.
     Eur J Heart Fail. 2024 Aug 28. doi: 10.1002/ejhf.3412.
     PubMed    
     
     
     
306. ZOCCA E, Cocianni D, Barbisan D, Perotto M, et al
     Dynamic evolution of tricuspid regurgitation during hospitalization in patients with acute decompensated heart failure.
     Eur J Heart Fail. 2024 Aug 27. doi: 10.1002/ejhf.3433.
     PubMed     Abstract available
     
     
     
307. LOPASCHUK GD, Sun Q, Ketema EB
     Glycolysis in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Aug 27. doi: 10.1002/ejhf.3432.
     PubMed    
     
     
     
308. HOLM H, Magnusson M, Jujic A, Lagrange J, et al
     Association of ventricular-arterial coupling with biomarkers involved in heart failure pathophysiology - the STANISLAS cohort.
     Eur J Heart Fail. 2024 Aug 27. doi: 10.1002/ejhf.3411.
     PubMed     Abstract available
     
     
     
309. FINK T, Sciacca V, Kirchhof P, Sommer P, et al
     Contemporary trends of atrial fibrillation management in heart failure patients: Do we practice what we preach?
     Eur J Heart Fail. 2024 Aug 27. doi: 10.1002/ejhf.3431.
     PubMed    
     
     
     
310. LAENENS D, Zegkos T, Kamperidis V, Wong RCC, et al
     Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H(2)FPEF score.
     Eur J Heart Fail. 2024 Aug 27. doi: 10.1002/ejhf.3413.
     PubMed     Abstract available
     
     
     
311. GIANNITSIS E, Frey N, Jhund PS
     Improving the rate of heart failure with improved ejection fraction.
     Eur J Heart Fail. 2024 Aug 22. doi: 10.1002/ejhf.3427.
     PubMed    
     
     
     
312. BIEGUS J, Cotter G, Metra M, Ponikowski P, et al
     Decongestion in acute heart failure: Is it time to change diuretic-centred paradigm?
     Eur J Heart Fail. 2024 Aug 21. doi: 10.1002/ejhf.3423.
     PubMed     Abstract available
     
     
     
313. GUIDETTI F, Giraldo CIS, Shchendrygina A, Kida K, et al
     Differences in heart failure with preserved ejection fraction management between care providers: an international survey.
     Eur J Heart Fail. 2024 Aug 21. doi: 10.1002/ejhf.3416.
     PubMed     Abstract available
     
     
     
314. YANG M, Kondo T, Anand IS, de Boer RA, et al
     Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment.
     Eur J Heart Fail. 2024 Aug 21. doi: 10.1002/ejhf.3417.
     PubMed     Abstract available
     
     
     
315. XIE S, Xu L, Zhang F, Xiao H, et al
     Letter regarding the article 'Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters'.
     Eur J Heart Fail. 2024 Aug 18. doi: 10.1002/ejhf.3436.
     PubMed    
     
     
     
316. DE LA ESPRIELLA R, Palau P, Guazzi M, Nunez J, et al
     Reply to the letter regarding the article 'Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters'.
     Eur J Heart Fail. 2024 Aug 18. doi: 10.1002/ejhf.3439.
     PubMed    
     
     
     
317. ABDIN A, Jhund PS
     Implementation of guideline-directed medical therapy for heart failure: Progress achieved, work ahead!
     Eur J Heart Fail. 2024 Aug 18. doi: 10.1002/ejhf.3438.
     PubMed    
     
     
     
318. BUTT JH, Thune JJ, Nielsen JC, Haarbo J, et al
     Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox.
     Eur J Heart Fail. 2024 Aug 18. doi: 10.1002/ejhf.3424.
     PubMed     Abstract available
     
     
     
319. HU Y, Li Z, Zhang Y
     Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure? Letter regarding the article 'Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE'.
     Eur J Heart Fail. 2024 Aug 18. doi: 10.1002/ejhf.3419.
     PubMed    
     
     
     
320. TRIMARCHI G, Panichella G, Aimo A
     Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat.
     Eur J Heart Fail. 2024 Aug 18. doi: 10.1002/ejhf.3420.
     PubMed    
     
     
     
321. BAUDRY G, Metra M, Delmas C
     Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?
     Eur J Heart Fail. 2024 Aug 15. doi: 10.1002/ejhf.3422.
     PubMed    
     
     
     
322. DOLDI PM, Stolz L, Hausleiter J
     Unravelling the complexity of heart failure with preserved ejection fraction and secondary mitral regurgitation.
     Eur J Heart Fail. 2024 Aug 15. doi: 10.1002/ejhf.3430.
     PubMed    
     
     
     
323. HAMMERSLEY DJ, Mukhopadhyay S, Chen X, Jones RE, et al
     Precision prediction of heart failure events in patients with dilated cardiomyopathy and mildly reduced ejection fraction using multi-parametric cardiovascular magnetic resonance.
     Eur J Heart Fail. 2024 Aug 15. doi: 10.1002/ejhf.3425.
     PubMed     Abstract available
     
     
     
324. FERREIRA JP, Voors AA
     Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'.
     Eur J Heart Fail. 2024 Aug 15. doi: 10.1002/ejhf.3415.
     PubMed    
     
     
     
325. MEEKERS E, Martens P, Dauw J, Gruwez H, et al
     Nurse-led diuretic titration via a point-of-care urinary sodium sensor in patients with acute decompensated heart failure (EASY-HF): A single-centre, randomized, open-label study.
     Eur J Heart Fail. 2024 Aug 14. doi: 10.1002/ejhf.3429.
     PubMed     Abstract available
     
     
     
326. KOLEINI N, Meddeb M, Zhao L, Keykhaei M, et al
     Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Aug 9. doi: 10.1002/ejhf.3389.
     PubMed     Abstract available
     
     
     
327. CAO TH, Tay WT, Jones DJL, Cleland JGF, et al
     Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry.
     Eur J Heart Fail. 2024 Aug 9. doi: 10.1002/ejhf.3378.
     PubMed     Abstract available
     
     
     
328. SLIWA K, Rakisheva A, Viljoen C, Pfeffer T, et al
     Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of Cardiology.
     Eur J Heart Fail. 2024 Aug 8. doi: 10.1002/ejhf.3377.
     PubMed     Abstract available
     
     
     
329. KAZMI S, Kambhampati C, Rigby AS, Cleland JGF, et al
     Disease progression in chronic heart failure is linear: Insights from multistate modelling.
     Eur J Heart Fail. 2024 Aug 6. doi: 10.1002/ejhf.3400.
     PubMed     Abstract available
     
     
     
330. ANDERSON KP
     The electrocardiogram in heart failure trials: Missing in action.
     Eur J Heart Fail. 2024 Aug 6. doi: 10.1002/ejhf.3392.
     PubMed    
     
     
     
331. TOCCHETTI CG, Farmakis D, Koop Y, Andres MS, et al
     Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.
     Eur J Heart Fail. 2024 Aug 1. doi: 10.1002/ejhf.3340.
     PubMed     Abstract available
     
     
     
332. VALENTE V, Ferrannini G, Benson L, Gatti P, et al
     Characterizing atrial fibrillation in patients with and without heart failure across the ejection fraction spectrum: Incidence, prevalence, and treatment strategies.
     Eur J Heart Fail. 2024 Aug 1. doi: 10.1002/ejhf.3402.
     PubMed     Abstract available
     
     
     
333. HOEVELMANN J, Markwirth P, Tokcan M, Haring B, et al
     What's new in heart failure? August-September 2024.
     Eur J Heart Fail. 2024;26:1665-1668.
     PubMed    
     
     
     July 2024
334. TROMP J, Lam CSP, Alemayehu W, de Filippi CR, et al
     Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial.
     Eur J Heart Fail. 2024 Jul 30. doi: 10.1002/ejhf.3397.
     PubMed     Abstract available
     
     
     
335. LEE MMY, Petrie MC, Cleland JGF, Donnelly P, et al
     Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic - insights from the IRONMAN trial.
     Eur J Heart Fail. 2024 Jul 30. doi: 10.1002/ejhf.3394.
     PubMed    
     
     
     
336. TENG TK, Yiu KH, Tromp J
     Global perspectives on heart failure with preserved ejection fraction: Unravelling regional variations in a complex syndrome.
     Eur J Heart Fail. 2024 Jul 30. doi: 10.1002/ejhf.3407.
     PubMed    
     
     
     
337. STOLFO D, Benson L, Lindberg F, Dahlstrom U, et al
     Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2024 Jul 30. doi: 10.1002/ejhf.3404.
     PubMed     Abstract available
     
     
     
338. HATTORI Y, Ihara M
     Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article 'Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRO
     Eur J Heart Fail. 2024 Jul 30. doi: 10.1002/ejhf.3406.
     PubMed    
     
     
     
339. DE LA ESPRIELLA R, Palau P, Losito M, Crisci G, et al
     Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters.
     Eur J Heart Fail. 2024 Jul 30. doi: 10.1002/ejhf.3401.
     PubMed     Abstract available
     
     
     
340. HOEVELMANN J, Markwirth P, Tokcan M, Haring B, et al
     What's new in heart failure? August-September 2024.
     Eur J Heart Fail. 2024 Jul 26. doi: 10.1002/ejhf.3399.
     PubMed    
     
     
     
341. MYHRE PL, Kleiven O, Berge K, Grundtvig M, et al
     Changes in 6-min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction.
     Eur J Heart Fail. 2024 Jul 26. doi: 10.1002/ejhf.3391.
     PubMed     Abstract available
     
     
     
342. COBO MARCOS M, de la Espriella R, Comin-Colet J, Zegri-Reiriz I, et al
     Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: The SALT-HF trial.
     Eur J Heart Fail. 2024 Jul 26. doi: 10.1002/ejhf.3390.
     PubMed     Abstract available
     
     
     
343. BELDHUIS IE, Heerspink HJL, Voors AA
     Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?
     Eur J Heart Fail. 2024 Jul 22. doi: 10.1002/ejhf.3387.
     PubMed    
     
     
     
344. CULIC V
     Sex hormones and heart failure. Letter regarding the article 'Pre-diagnostic free androgen and estradiol levels influence heart failure risk in both women and men: A prospective cohort study in the UK Biobank'.
     Eur J Heart Fail. 2024 Jul 18. doi: 10.1002/ejhf.3384.
     PubMed    
     
     
     
345. LIM J, Wong JYY
     Reply to 'Sex hormones and heart failure'.
     Eur J Heart Fail. 2024 Jul 18. doi: 10.1002/ejhf.3385.
     PubMed    
     
     
     
346. PARWANI AS, Kaab S, Friede T, Tilz RR, et al
     Catheter-based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA-HFPEF-DZHK27 trial.
     Eur J Heart Fail. 2024 Jul 18. doi: 10.1002/ejhf.3373.
     PubMed     Abstract available
     
     
     
347. ABOU KAMAR S, Bracun V, El-Qendouci M, Bomer N, et al
     Association of baseline and longitudinal changes in insulin-like growth factor-binding protein-7 with the risk of incident heart failure: Data from the PREVEND study.
     Eur J Heart Fail. 2024 Jul 17. doi: 10.1002/ejhf.3328.
     PubMed     Abstract available
     
     
     
348. REDDY YNV, Sundaram V
     Predicting worsening heart failure with preserved ejection fraction from non-invasive exercise testing.
     Eur J Heart Fail. 2024 Jul 17. doi: 10.1002/ejhf.3380.
     PubMed    
     
     
     
349. PELLICORI P, Cuthbert JJ, Clark AL, Cleland JGF, et al
     Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?
     Eur J Heart Fail. 2024 Jul 17. doi: 10.1002/ejhf.3374.
     PubMed    
     
     
     
350. BOCCHI EA, Biselli B, Guimaraes GV
     Dilemmas in recommending exercise for prevention of heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Jul 16. doi: 10.1002/ejhf.3364.
     PubMed    
     
     
     
351. EGBE AC, Reddy YNV, Ali AE, Younis A, et al
     Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta.
     Eur J Heart Fail. 2024 Jul 16. doi: 10.1002/ejhf.3379.
     PubMed     Abstract available
     
     
     
352. ABDIN A, Wilkinson C, Aktaa S, Bohm M, et al
     European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The Heart Failure Association of the ESC.
     Eur J Heart Fail. 2024 Jul 12. doi: 10.1002/ejhf.3376.
     PubMed     Abstract available
     
     
     
353. FERREIRA JP, Blatchford JP, Teerlink JR, Kosiborod MN, et al
     Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE.
     Eur J Heart Fail. 2024 Jul 9. doi: 10.1002/ejhf.3369.
     PubMed     Abstract available
     
     
     
354. PATERSON MA, Pilbrow AP, Frampton CM, Cameron VA, et al
     Plasma soluble fms-like tyrosine kinase-1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure.
     Eur J Heart Fail. 2024 Jul 9. doi: 10.1002/ejhf.3368.
     PubMed     Abstract available
     
     
     
355. CAMILLI M, Ballacci F, Rossi VA, Cannata A, et al
     Iron deficiency and supplementation in patients with heart failure: Results from the IRON-HF international survey.
     Eur J Heart Fail. 2024 Jul 4. doi: 10.1002/ejhf.3356.
     PubMed     Abstract available
     
     
     
356. BIANCUCCI M, Barbiero R, Pennella B, Cannata A, et al
     Hypoalbuminaemia and heart failure: A practical review of current evidence.
     Eur J Heart Fail. 2024 Jul 4. doi: 10.1002/ejhf.3363.
     PubMed     Abstract available
     
     
     
357. SUC G, Iung B
     Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions.
     Eur J Heart Fail. 2024 Jul 4. doi: 10.1002/ejhf.3360.
     PubMed    
     
     
     
358. BAUERSACHS J, Berliner D
     Navigating between Scylla and Charybdis: Diuretics during pregnancy - as much as needed, but the least possible.
     Eur J Heart Fail. 2024;26:1571-1573.
     PubMed    
     
     
     
359. BAYES-GENIS A, Greene SJ
     Bio-adrenomedullin: A weak biomarker for a STRONG patient.
     Eur J Heart Fail. 2024;26:1493-1494.
     PubMed    
     
     
     
360. HAEBEL L, Fuge J, Kuehn C, Hoeper MM, et al
     Survival and ability to return to work 1 year after extracorporeal membrane oxygenation for acute heart or lung failure.
     Eur J Heart Fail. 2024;26:1604-1605.
     PubMed    
     
     
     
361. VAN DER ZANDE JA, Greutmann M, Tobler D, Ramlakhan KP, et al
     Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC).
     Eur J Heart Fail. 2024;26:1561-1570.
     PubMed     Abstract available
     
     
     June 2024
362. PANICHELLA G, Tomasoni D, Aimo A
     Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow-up.
     Eur J Heart Fail. 2024 Jun 28. doi: 10.1002/ejhf.3357.
     PubMed    
     
     
     
363. AIMO A, Codina P, Lee MMY, Tomasoni D, et al
     What's new in heart failure? June-July 2024.
     Eur J Heart Fail. 2024 Jun 28. doi: 10.1002/ejhf.3371.
     PubMed    
     
     
     
364. TROMP J, Ouwerkerk W
     Left atrial enlargement and biomarker profiles: Time for integration of biomarkers and echocardiography in heart failure prevention.
     Eur J Heart Fail. 2024 Jun 27. doi: 10.1002/ejhf.3353.
     PubMed    
     
     
     
365. REDDY YNV, Sundaram V
     Towards more practical phenotyping in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Jun 26. doi: 10.1002/ejhf.3359.
     PubMed    
     
     
     
366. LASSEN MCH, Ostrominski JW, Claggett BL, Packer M, et al
     Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.
     Eur J Heart Fail. 2024 Jun 26. doi: 10.1002/ejhf.3304.
     PubMed     Abstract available
     
     
     
367. VADUGANATHAN M, Cannon CP, Jardine MJ, Heerspink HJL, et al
     Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial.
     Eur J Heart Fail. 2024 Jun 26. doi: 10.1002/ejhf.3292.
     PubMed     Abstract available
     
     
     
368. KITZMAN DW, Lewis GD, Pandey A, Borlaug BA, et al
     A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial.
     Eur J Heart Fail. 2024 Jun 26. doi: 10.1002/ejhf.3305.
     PubMed     Abstract available
     
     
     
369. 
     Correction to "Iron deficiency in heart failure: Screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine measurements collaborative project".
     Eur J Heart Fail. 2024 Jun 23. doi: 10.1002/ejhf.3344.
     PubMed    
     
     
     
370. WUSSLER D, Belkin M, Shrestha S, Wernicke H, et al
     Incremental value of C-reactive protein to the MEESSI acute heart failure risk score.
     Eur J Heart Fail. 2024 Jun 23. doi: 10.1002/ejhf.3349.
     PubMed     Abstract available
     
     
     
371. COTTER G, Pagnesi M, Davison B
     C-reactive protein, inflammation and short-term mortality in acute heart failure.
     Eur J Heart Fail. 2024 Jun 23. doi: 10.1002/ejhf.3361.
     PubMed    
     
     
     
372. INCIARDI RM, Vaduganathan M, Lombardi CM, Gussago C, et al
     OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry.
     Eur J Heart Fail. 2024 Jun 23. doi: 10.1002/ejhf.3260.
     PubMed     Abstract available
     
     
     
373. YANG M, Kondo T, Jhund PS, Alcocer-Gamba MA, et al
     Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction.
     Eur J Heart Fail. 2024 Jun 23. doi: 10.1002/ejhf.3352.
     PubMed     Abstract available
     
     
     
374. MEERKIN D, Perl L, Hasin T, Petriashvili S, et al
     Physician-directed patient self-management in heart failure using left atrial pressure: Interim insights from the VECTOR-HF I and IIa studies.
     Eur J Heart Fail. 2024 Jun 20. doi: 10.1002/ejhf.3338.
     PubMed     Abstract available
     
     
     
375. BRUGTS JJ
     Remote haemodynamic monitoring and the next step: Involving the patient in the self-management of heart failure.
     Eur J Heart Fail. 2024 Jun 20. doi: 10.1002/ejhf.3355.
     PubMed    
     
     
     
376. SCHUPP T, Abel N, Schmidberger M, Hopfner MK, et al
     Prevalence and prognosis of aortic valve diseases in patients hospitalized with heart failure with mildly reduced ejection fraction.
     Eur J Heart Fail. 2024 Jun 19. doi: 10.1002/ejhf.3337.
     PubMed     Abstract available
     
     
     
377. SEFEROVIC PM, Paulus WJ, Rosano G, Polovina M, et al
     Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases.
     Eur J Heart Fail. 2024 Jun 19. doi: 10.1002/ejhf.3347.
     PubMed     Abstract available
     
     
     
378. ANGERMANN CE
     Don't put too much weight on weight telemonitoring in high-risk heart failure patients!
     Eur J Heart Fail. 2024 Jun 19. doi: 10.1002/ejhf.3346.
     PubMed    
     
     
     
379. NOUHRAVESH N, Garg J, Rockhold FW, De Pasquale CG, et al
     Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.
     Eur J Heart Fail. 2024 Jun 19. doi: 10.1002/ejhf.3348.
     PubMed     Abstract available
     
     
     
380. LAUFS U, Wachter R
     Implementation of guideline-directed medical therapy for heart failure.
     Eur J Heart Fail. 2024 Jun 19. doi: 10.1002/ejhf.3343.
     PubMed    
     
     
     
381. SIMONENKO M, Hansen D, Niebauer J, Volterrani M, et al
     Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of
     Eur J Heart Fail. 2024 Jun 19. doi: 10.1002/ejhf.3185.
     PubMed     Abstract available
     
     
     
382. VOORDES G, Davison B, Biegus J, Edwards C, et al
     Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF.
     Eur J Heart Fail. 2024 Jun 14. doi: 10.1002/ejhf.3336.
     PubMed     Abstract available
     
     
     
383. CARRETE A, Codina P, Bayes-Genis A
     Influence of temperature on haemodynamic changes in heart failure: A CardioMEMS pulmonary artery monitoring analysis.
     Eur J Heart Fail. 2024 Jun 14. doi: 10.1002/ejhf.3331.
     PubMed    
     
     
     
384. PITT B, Rossignol P
     When chronic kidney disease (CKD) intersects with heart failure: Insights and implications of the identification of KDIGO-defined CKD in 1.4 million U.S. Veterans with heart failure.
     Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3298.
     PubMed    
     
     
     
385. CHOI KH, Kang D, Park H, Park TK, et al
     In-hospital and long-term outcomes of cardiogenic shock complicating myocardial infarction versus heart failure.
     Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3333.
     PubMed     Abstract available
     
     
     
386. ADAMOPOULOS S, Bonios M, Ben Gal T, Gustafsson F, et al
     Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC.
     Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3323.
     PubMed     Abstract available
     
     
     
387. MONZO L, Kovar J, Borlaug BA, Benes J, et al
     Circulating beta-hydroxybutyrate levels in advanced heart failure with reduced ejection fraction: Determinants and prognostic impact.
     Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3324.
     PubMed     Abstract available
     
     
     
388. ANKER SD, Friede T, von Bardeleben RS, Butler J, et al
     Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.
     Eur J Heart Fail. 2024 Jun 7. doi: 10.1002/ejhf.3286.
     PubMed     Abstract available
     
     
     
389. NAITO A, Kagami K, Yuasa N, Harada T, et al
     Prognostic utility of cardiopulmonary exercise testing with simultaneous exercise echocardiography in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Jun 6. doi: 10.1002/ejhf.3334.
     PubMed     Abstract available
     
     
     
390. HARADA T, Naser JA, Tada A, Doi S, et al
     Cardiac function, haemodynamics, and valve competence with exercise in patients with heart failure with preserved ejection fraction and mild to moderate secondary mitral regurgitation.
     Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3322.
     PubMed     Abstract available
     
     
     
391. VON STEIN P, Iliadis C
     EXPANDing horizons: Optimizing heart failure management following transcatheter edge-to-edge repair of mitral regurgitation.
     Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3327.
     PubMed    
     
     
     
392. PASCUAL-FIGAL D, Nunez Villota J, Perez-Martinez MT, Gonzalez-Juanatey JR, et al
     Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA).
     Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3300.
     PubMed     Abstract available
     
     
     
393. CANNATA A, Mizani MA, Bromage DI, Piper SE, et al
     A nationwide, population-based study on specialized care for acute heart failure throughout the COVID-19 pandemic.
     Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3306.
     PubMed     Abstract available
     
     
     
394. ALLACH Y, Barry-Loncq de Jong M, Clephas PRD, van Gent MWF, et al
     Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study.
     Eur J Heart Fail. 2024 Jun 2. doi: 10.1002/ejhf.3303.
     PubMed     Abstract available
     
     
     
395. AIMO A, Codina P, Lee MMY, Tomasoni D, et al
     What's new in heart failure? May-June 2024.
     Eur J Heart Fail. 2024;26:1273-1277.
     PubMed    
     
     
     
396. VELICKI L, Popovic D, Okwose NC, Preveden A, et al
     Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM).
     Eur J Heart Fail. 2024;26:1361-1368.
     PubMed     Abstract available
     
     
     
397. STRAW S, Flett A, Witte KK
     Which patients with non-ischaemic cardiomyopathy should receive a defibrillator?
     Eur J Heart Fail. 2024;26:1432-1434.
     PubMed    
     
     
     
398. DAMMAN K, Beldhuis IE, van der Meer P, Krikken JA, et al
     Renal function and natriuresis-guided diuretic therapy - a pre-specified analysis from the PUSH-AHF trial.
     Eur J Heart Fail. 2024;26:1347-1357.
     PubMed     Abstract available
     
     
     
399. GREENE SJ, Chambers R, Lerman JB, Harrington J, et al
     Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trial.
     Eur J Heart Fail. 2024;26:1393-1398.
     PubMed     Abstract available
     
     
     May 2024
400. CISNEROS-BARROSO E, Rossello X
     Sodium-glucose cotransporter 2 inhibitors in acute and chronic coronary syndrome with and without heart failure.
     Eur J Heart Fail. 2024 May 29. doi: 10.1002/ejhf.3321.
     PubMed    
     
     
     
401. PAGNESI M, Serafini L, Chiarito M, Stolfo D, et al
     Impact of malnutrition in patients with severe heart failure.
     Eur J Heart Fail. 2024 May 29. doi: 10.1002/ejhf.3285.
     PubMed     Abstract available
     
     
     
402. PABON MA, Vaduganathan M, Lam CSP
     Is the optimal dose of heart failure medical therapy different in women and men?
     Eur J Heart Fail. 2024 May 27. doi: 10.1002/ejhf.3320.
     PubMed    
     
     
     
403. LAM CSP, Kober L, Kuwahara K, Lund LH, et al
     Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.
     Eur J Heart Fail. 2024 May 23. doi: 10.1002/ejhf.3294.
     PubMed     Abstract available
     
     
     
404. ROSANO GMC, Stolfo D, Anderson L, Abdelhamid M, et al
     Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2024 May 23. doi: 10.1002/ejhf.3284.
     PubMed     Abstract available
     
     
     
405. SAVARESE G, Lindberg F, Cannata A, Chioncel O, et al
     How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2024 May 22. doi: 10.1002/ejhf.3295.
     PubMed     Abstract available
     
     
     
406. BUTLER J, Arshad MS, Khan MS
     Role of anti-obesity drugs in heart failure regardless of ejection fraction.
     Eur J Heart Fail. 2024 May 16. doi: 10.1002/ejhf.3224.
     PubMed    
     
     
     
407. PECK KH, Dulay MS, Hameed S, Rosano G, et al
     Intentional weight loss in overweight and obese patients with heart failure: A systematic review.
     Eur J Heart Fail. 2024 May 16. doi: 10.1002/ejhf.3270.
     PubMed     Abstract available
     
     
     
408. KITTIPIBUL V, Mentz RJ, Clare RM, Wojdyla DM, et al
     On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.
     Eur J Heart Fail. 2024 May 15. doi: 10.1002/ejhf.3293.
     PubMed     Abstract available
     
     
     
409. LASSEN MCH, Ostrominski JW, Inzucchi SE, Claggett BL, et al
     Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
     Eur J Heart Fail. 2024 May 15. doi: 10.1002/ejhf.3269.
     PubMed     Abstract available
     
     
     
410. VADUGANATHAN M, Claggett BL, Lam CSP, Pitt B, et al
     Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
     Eur J Heart Fail. 2024 May 14. doi: 10.1002/ejhf.3253.
     PubMed     Abstract available
     
     
     
411. VILLASCHI A, Chiarito M, Pagnesi M, Stolfo D, et al
     Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry.
     Eur J Heart Fail. 2024 May 14. doi: 10.1002/ejhf.3234.
     PubMed     Abstract available
     
     
     
412. CURTAIN JP, Talebi A, McIntosh A, McConnachie A, et al
     Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF.
     Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3290.
     PubMed     Abstract available
     
     
     
413. ESQUIVEL GAYTAN A, Bomer N, Grote Beverborg N, van der Meer P, et al
     404-error "Disease not found": Unleashing the translational potential of -omics approaches beyond traditional disease classification in heart failure research.
     Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3268.
     PubMed     Abstract available
     
     
     
414. PANICHELLA G, Tomasoni D, Aimo A
     Insulin-like growth factor binding protein-7 in heart failure: The challenge of moving from risk prediction to a biomarker-guided management.
     Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3287.
     PubMed    
     
     
     
415. RICCARDI M, Borlaug BA, Inciardi RM
     Mitral regurgitation and heart failure with preserved ejection fraction: Should we treat the muscle, the valve, or both?
     Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3288.
     PubMed    
     
     
     
416. VERBRUGGE FH
     Pushing the limits of natriuresis for poor kidneys in acute heart failure?
     Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3278.
     PubMed    
     
     
     
417. ASSMUS B, Sossalla S
     What we claim to do and what we really do - a discrepancy in heart failure treatment.
     Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3279.
     PubMed    
     
     
     
418. MALGIE J, Wilde MI, Clephas PRD, Emans ME, et al
     Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study.
     Eur J Heart Fail. 2024 May 12. doi: 10.1002/ejhf.3267.
     PubMed     Abstract available
     
     
     
419. KARACAN MN, Doi SN, Yafasova A, Thune JJ, et al
     New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
     Eur J Heart Fail. 2024 May 11. doi: 10.1002/ejhf.3239.
     PubMed     Abstract available
     
     
     
420. SOLOMON SD, Ostrominski JW, Vaduganathan M, Claggett B, et al
     Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.
     Eur J Heart Fail. 2024 May 11. doi: 10.1002/ejhf.3266.
     PubMed     Abstract available
     
     
     
421. PACKER M
     Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron-deficient heart failure.
     Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3238.
     PubMed     Abstract available
     
     
     
422. PACKER M, Anker SD, Butler J, Cleland JGF, et al
     Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure.
     Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3237.
     PubMed     Abstract available
     
     
     
423. ABDIN A, Kulenthiran S
     Improvements in quality of heart failure randomized controlled trials: Progress and persisting challenges!
     Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3289.
     PubMed    
     
     
     
424. KESSLER M, Rottbauer W, von Bardeleben RS, Grasso C, et al
     Impact of heart failure hospitalizations on clinical outcomes after mitral transcatheter edge-to-edge repair: Results from the EXPAND study.
     Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3250.
     PubMed     Abstract available
     
     
     
425. MEBAZAA A, Davison BA, Biegus J, Edwards C, et al
     Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study.
     Eur J Heart Fail. 2024 May 9. doi: 10.1002/ejhf.3265.
     PubMed     Abstract available
     
     
     
426. SALAH HM, Fudim M
     Guideline-directed medical therapy in patients with heart failure with preserved ejection fraction and polypharmacy: Do not be afraid.
     Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3283.
     PubMed    
     
     
     
427. WANG N, Rueter P, Ng M, Chandramohan S, et al
     Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3271.
     PubMed     Abstract available
     
     
     
428. PANICHELLA G, Tomasoni D, Aimo A
     Metabolomics to predict heart failure development: A new frontier?
     Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3281.
     PubMed    
     
     
     
429. 
     Correction to "Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction".
     Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3282.
     PubMed    
     
     
     
430. YANG M, Kondo T, Talebi A, Jhund PS, et al
     Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
     Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3263.
     PubMed     Abstract available
     
     
     
431. STOLZ L, Hausleiter J
     Under pressure: Advances in device-based heart failure therapy for patients with preserved or mildly reduced ejection fraction.
     Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3277.
     PubMed    
     
     
     
432. ZAHIR ANJUM D, Strange JE, Fosbol E, Garred CH, et al
     Use of medical therapy and risk of clinical events according to frailty in heart failure patients - A real-life cohort study.
     Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3249.
     PubMed     Abstract available
     
     
     
433. WOLSK E
     Is it worth tying the knot? The lifelong commitment between heart failure patients and pulmonary artery pressure monitoring.
     Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3275.
     PubMed    
     
     
     
434. PATEL SS, Raman VK, Zhang S, Deedwania P, et al
     Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure.
     Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3210.
     PubMed     Abstract available
     
     
     
435. FUJIMOTO Y, Matsue Y
     Seeking ways to address non-cardiovascular death in patients with heart failure.
     Eur J Heart Fail. 2024 May 2. doi: 10.1002/ejhf.3280.
     PubMed    
     
     
     
436. FERRARI A, Stolfo D, Uijl A, Orsini N, et al
     Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2024 May 2. doi: 10.1002/ejhf.3272.
     PubMed     Abstract available
     
     
     
437. CAFORIO ALP, Giordani AS, Baritussio A, Marcolongo D, et al
     Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: A propensity-weighted study.
     Eur J Heart Fail. 2024;26:1175-1185.
     PubMed     Abstract available
     
     
     
438. MATSUMOTO S, Yang M, Shen L, Henderson A, et al
     Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HF.
     Eur J Heart Fail. 2024;26:1125-1138.
     PubMed     Abstract available
     
     
     
439. KOBAYASHI M, Ferreira JP, Duarte K, Bresso E, et al
     Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
     Eur J Heart Fail. 2024;26:1231-1241.
     PubMed     Abstract available
     
     
     
440. DELMAS C, Ughetto A, Lebreton G, Roubille F, et al
     Venting strategies for extracorporeal membrane oxygenation patients: More questions than answers but a plea for more clinical trials on the topic!
     Eur J Heart Fail. 2024;26:1261-1264.
     PubMed    
     
     
     April 2024
441. LIN YC, Sung YH, Tsai CH
     Letter regarding the article 'Use of natriuretic peptides and echocardiography for diagnosing heart failure'.
     Eur J Heart Fail. 2024 Apr 30. doi: 10.1002/ejhf.3273.
     PubMed    
     
     
     
442. RAKISHEVA A, Sliwa K, Bauersachs J, Van Linthout S, et al
     Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3246.
     PubMed     Abstract available
     
     
     
443. ARMENTARO G, Cassano V, Condoleo V, Magurno M, et al
     Association of sodium-glucose cotransporter 2 inhibitors with changes in comprehensive geriatric assessment in elderly diabetic patients with heart failure: Data from MAGIC-HF.
     Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3262.
     PubMed    
     
     
     
444. RAO VN, Kozaily E, Tedford RJ
     Letting go of restraint: Tricuspid valve intervention in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3254.
     PubMed    
     
     
     
445. HALAVINA K, Bartko PE, Nitsche C
     Obese or lean: Whom to prescribe sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction?
     Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3261.
     PubMed    
     
     
     
446. NUNEZ E, Santas E, Merenciano H, Lorenzo-Hernandez M, et al
     Differential sex-related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudinal study.
     Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3252.
     PubMed     Abstract available
     
     
     
447. GORTER TM, Hoendermis ES, van Veldhuisen DJ
     Interatrial shunting as a treatment for heart failure: Where do we stand?
     Eur J Heart Fail. 2024 Apr 25. doi: 10.1002/ejhf.3251.
     PubMed    
     
     
     
448. GRASSI G, Dell'Oro R, Quarti-Trevano F
     Baroreceptors as a target of device-based neuromodulation in heart failure: Long-term outcomes.
     Eur J Heart Fail. 2024 Apr 25. doi: 10.1002/ejhf.3258.
     PubMed    
     
     
     
449. PAGNESI M, Adamo M, Metra M
     Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?
     Eur J Heart Fail. 2024 Apr 23. doi: 10.1002/ejhf.3257.
     PubMed    
     
     
     
450. LIEN T, Srikanth K, Ambrosy AP
     Follow the EMPULSE: In-hospital initiation of empagliflozin for heart failure across the spectrum of left ventricular ejection fraction.
     Eur J Heart Fail. 2024 Apr 23. doi: 10.1002/ejhf.3256.
     PubMed    
     
     
     
451. ANKER SD, Friede T, von Bardeleben RS, Butler J, et al
     Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design.
     Eur J Heart Fail. 2024 Apr 23. doi: 10.1002/ejhf.3247.
     PubMed     Abstract available
     
     
     
452. AMERI P, Mercurio V, Pollesello P, Anker MS, et al
     A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.
     Eur J Heart Fail. 2024 Apr 19. doi: 10.1002/ejhf.3236.
     PubMed     Abstract available
     
     
     
453. DHONT S, van den Acker G, van Loon T, Verbrugge FH, et al
     Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium.
     Eur J Heart Fail. 2024 Apr 17. doi: 10.1002/ejhf.3231.
     PubMed     Abstract available
     
     
     
454. JALLOH MB, Bot VA, Borjaille CZ, Thabane L, et al
     Reporting quality of heart failure randomized controlled trials 2000-2020: Temporal trends in adherence to CONSORT criteria.
     Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3229.
     PubMed     Abstract available
     
     
     
455. PORCARI A, Fontana M
     The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium-glucose cotransporter 2 inhibitors?
     Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3245.
     PubMed    
     
     
     
456. OEXNER RR, Ahn H, Theofilatos K, Shah RA, et al
     Serum metabolomics improves risk stratification for incident heart failure.
     Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3226.
     PubMed     Abstract available
     
     
     
457. MULLENS W, Damman K, Dhont S, Banerjee D, et al
     Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3244.
     PubMed     Abstract available
     
     
     
458. SETTERGREN C, Benson L, Shahim A, Dahlstrom U, et al
     Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3230.
     PubMed     Abstract available
     
     
     
459. HEIDECKER B, Pagnesi M, Luscher TF
     Heart failure and respiratory tract infection: Cause and consequence of acute decompensation?
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3209.
     PubMed    
     
     
     
460. LI J, Chen Y, Wang Y, Liu X, et al
     Impact of guideline-directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: A systematic review and meta-analysis.
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3208.
     PubMed     Abstract available
     
     
     
461. ZILE MR, Lindenfeld J, Weaver FA, Zannad F, et al
     Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3232.
     PubMed     Abstract available
     
     
     
462. PASCUAL-FIGAL DA, Hernandez-Vicente A, Pastor-Perez F, Martinez-Selles M, et al
     N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3222.
     PubMed     Abstract available
     
     
     
463. BEAVERS CJ, Bhatt DL, Gotter G
     Reply to 'The pharmacist ally in heart failure: Useful when involved'.
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3242.
     PubMed    
     
     
     
464. UREY MA, Hibbert B, Jorde U, Eckman P, et al
     Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results.
     Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3241.
     PubMed     Abstract available
     
     
     
465. FERREIRA JP, Packer M, Sattar N, Butler J, et al
     Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme.
     Eur J Heart Fail. 2024 Apr 8. doi: 10.1002/ejhf.3227.
     PubMed     Abstract available
     
     
     
466. BHATT AS, Vaduganathan M, Jena BP, Suminska S, et al
     Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction.
     Eur J Heart Fail. 2024 Apr 7. doi: 10.1002/ejhf.3233.
     PubMed    
     
     
     
467. LENSELINK C, Ricken KWLM, Groot HE, de Bruijne TJ, et al
     Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST-elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention.
     Eur J Heart Fail. 2024 Apr 4. doi: 10.1002/ejhf.3225.
     PubMed     Abstract available
     
     
     
468. TROMP J, Kosiborod MN, Angermann CE, Collins SP, et al
     Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
     Eur J Heart Fail. 2024 Apr 4. doi: 10.1002/ejhf.3218.
     PubMed     Abstract available
     
     
     
469. MORILLAS H, Nunez J, Moliner P
     Circulating levels of carbohydrate antigen 125 in chronic heart failure: Useful or futile?
     Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3212.
     PubMed    
     
     
     
470. RODES-CABAU J, Lindenfeld J, Abraham WT, Zile MR, et al
     Interatrial shunt therapy in advanced heart failure: Outcomes from the open-label cohort of the RELIEVE-HF trial.
     Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3215.
     PubMed     Abstract available
     
     
     
471. MOKRI H, Clephas PRD, de Boer RA, van Baal P, et al
     Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands.
     Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3213.
     PubMed     Abstract available
     
     
     
472. MARTENS P, Greene SJ, Mentz RJ, Li S, et al
     Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF.
     Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3207.
     PubMed     Abstract available
     
     
     
473. 
     HFA Winter Research Meeting on Translational Heart Failure 2024 In collaboration with the ESC Working Group on Myocardial Function, 11 - 14 May 2024, Lisbon & Online.
     Eur J Heart Fail. 2024;26 Suppl 1:3-16.
     PubMed    
     
     
     
474. PATEL N, Yeboah J
     Multimorbidity in the era of increasing life expectancy and aging population.
     Eur J Heart Fail. 2024;26:869-870.
     PubMed    
     
     
     
475. ROMMEL KP, Bonnet G, Fortmeier V, Stolz L, et al
     Congestion patterns in severe tricuspid regurgitation and transcatheter treatment: Insights from a multicentre registry.
     Eur J Heart Fail. 2024;26:1004-1014.
     PubMed     Abstract available
     
     
     
476. COATS AJS
     Sodium-glucose cotransporter 2 inhibitors and skeletal muscle.
     Eur J Heart Fail. 2024;26:936-937.
     PubMed    
     
     
     
477. D'AMARIO D, Laborante R, Santangeli P
     Comorbidities and cardiac resynchronization therapy: Do we talk the talk or should we walk the walk?
     Eur J Heart Fail. 2024;26:1047-1050.
     PubMed    
     
     
     
478. SATTAR N, Butler J, Lee MMY, Harrington J, et al
     Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.
     Eur J Heart Fail. 2024;26:900-909.
     PubMed     Abstract available
     
     
     
479. KERAMIDA K, Yang EH, Deswal A
     Moving theory and reality closer together in cardio-oncology training.
     Eur J Heart Fail. 2024;26:772-775.
     PubMed    
     
     
     
480. TANAKA T, Sugiura A, Kavsur R, Ozturk C, et al
     Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge-to-edge repair.
     Eur J Heart Fail. 2024;26:1015-1024.
     PubMed     Abstract available
     
     
     
481. RASTOGI T, Ferreira JP, Butler J, Kraus BJ, et al
     Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.
     Eur J Heart Fail. 2024;26:885-896.
     PubMed     Abstract available
     
     
     
482. FUDIM M, Dalgaard F, Friedman DJ, Abraham WT, et al
     Comorbidities and clinical response to cardiac resynchronization therapy: Patient-level meta-analysis from eight clinical trials.
     Eur J Heart Fail. 2024;26:1039-1046.
     PubMed     Abstract available
     
     
     March 2024
483. RAO VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, et al
     Serial direct sodium removal in patients with heart failure and diuretic resistance.
     Eur J Heart Fail. 2024 Mar 31. doi: 10.1002/ejhf.3196.
     PubMed     Abstract available
     
     
     
484. DONAL E, Gegout L, Lee KC
     More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure!
     Eur J Heart Fail. 2024 Mar 27. doi: 10.1002/ejhf.3201.
     PubMed    
     
     
     
485. LIM J, Hashemian M, Blechter B, Roger VL, et al
     Pre-diagnostic free androgen and estradiol levels influence heart failure risk in both women and men: A prospective cohort study in the UK Biobank.
     Eur J Heart Fail. 2024 Mar 25. doi: 10.1002/ejhf.3189.
     PubMed     Abstract available
     
     
     
486. DEHARO F, Grapsa J
     Global longitudinal strain as a predictor of risk in patients with heart failure with preserved ejection fraction: A deserved role?
     Eur J Heart Fail. 2024 Mar 25. doi: 10.1002/ejhf.3211.
     PubMed    
     
     
     
487. VAN DER LINDEN L, Karapinar-Carkit F, Forsyth P
     The pharmacist ally in heart failure: Useful when involved. Letter regarding the article 'Effective medications can work only in patients who take them: Implications for post-acute heart failure care'.
     Eur J Heart Fail. 2024 Mar 25. doi: 10.1002/ejhf.3217.
     PubMed    
     
     
     
488. SAVARESE G, Lindberg F, Christodorescu RM, Ferrini M, et al
     Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice.
     Eur J Heart Fail. 2024 Mar 22. doi: 10.1002/ejhf.3214.
     PubMed     Abstract available
     
     
     
489. DAVIS JA, Booth D, McEwan P, Solomon SD, et al
     Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
     Eur J Heart Fail. 2024 Mar 20. doi: 10.1002/ejhf.3197.
     PubMed     Abstract available
     
     
     
490. VANHENTENRIJK S, Tang WHW
     Renal perturbations with sodium-glucose cotransporter 2 inhibitor in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Mar 19. doi: 10.1002/ejhf.3205.
     PubMed    
     
     
     
491. PANICHELLA G, Tomasoni D, Aimo A
     Dissecting the heart failure phenotype through phenomics.
     Eur J Heart Fail. 2024 Mar 19. doi: 10.1002/ejhf.3204.
     PubMed    
     
     
     
492. PEIKERT A, Vaduganathan M, Claggett BL, Kulac IJ, et al
     Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.
     Eur J Heart Fail. 2024 Mar 15. doi: 10.1002/ejhf.3184.
     PubMed     Abstract available
     
     
     
493. WOOD N, Straw S, Cheng CW, Hirata Y, et al
     Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction.
     Eur J Heart Fail. 2024 Mar 11. doi: 10.1002/ejhf.3192.
     PubMed     Abstract available
     
     
     
494. COX ZL, Testani JM
     The salt paradox in heart failure.
     Eur J Heart Fail. 2024 Mar 11. doi: 10.1002/ejhf.3194.
     PubMed    
     
     
     
495. KRESOJA KP, Rosch S, Schober AR, Fengler K, et al
     Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Mar 11. doi: 10.1002/ejhf.3195.
     PubMed     Abstract available
     
     
     
496. EZEKOWITZ J, Alemayehu W, Edelmann F, Ponikowski P, et al
     Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
     Eur J Heart Fail. 2024 Mar 7. doi: 10.1002/ejhf.3179.
     PubMed     Abstract available
     
     
     
497. ROUBILLE F, Mercier G, Lancman G, Pasche H, et al
     Weight telemonitoring of heart failure versus standard of care in a real-world setting: Results on mortality and hospitalizations in a 6-month nationwide matched cohort study.
     Eur J Heart Fail. 2024 Mar 7. doi: 10.1002/ejhf.3191.
     PubMed     Abstract available
     
     
     
498. PAGNESI M, Vilamajo OAG, Meirino A, Dumont CA, et al
     Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial.
     Eur J Heart Fail. 2024 Mar 5. doi: 10.1002/ejhf.3174.
     PubMed     Abstract available
     
     
     
499. BUTLER J, Mentz RJ, Hernandez AF
     Iron replacement therapy in heart failure: Contextualizing the results of the HEART-FID trial.
     Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3193.
     PubMed    
     
     
     
500. TUBBEN A, Tingen HSA, Prakken NHJ, van Empel VPM, et al
     Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study.
     Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3186.
     PubMed    
     
     
     
501. FERREIRA JP, Zannad F, Packer M, Filippatos G, et al
     Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.
     Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3180.
     PubMed     Abstract available
     
     
     
502. FERREIRA JP, Packer M, Sattar N, Butler J, et al
     Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme.
     Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3166.
     PubMed     Abstract available
     
     
     
503. RICHARDS AM, Wang P, Wong LL
     'Micro'-managing heart failure: Restoring that which was lost in translation.
     Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3188.
     PubMed    
     
     
     
504. CHUNAWALA ZS, Keshvani N, Segar MW, Patel KV, et al
     Association of diabetes-specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study.
     Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3176.
     PubMed    
     
     
     
505. BAUERSACHS J, Solomon SD, Anker SD, Antorrena-Miranda I, et al
     Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial.
     Eur J Heart Fail. 2024;26:674-682.
     PubMed     Abstract available
     
     
     February 2024
506. SEGAR MW, Nair A, Pandey A
     An exercise enigma: Unravelling the complexity of exercise intolerance in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Feb 27. doi: 10.1002/ejhf.3170.
     PubMed    
     
     
     
507. D'ALTO M, Di Maio M, Argiento P, Romeo E, et al
     Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension.
     Eur J Heart Fail. 2024 Feb 26. doi: 10.1002/ejhf.3172.
     PubMed     Abstract available
     
     
     
508. PITT B, Iyer SPN, Humes HD
     New opportunity for targeting systemic inflammation in patients with heart failure through leucocyte immunomodulation.
     Eur J Heart Fail. 2024 Feb 23. doi: 10.1002/ejhf.3177.
     PubMed    
     
     
     
509. 
     Correction to 'Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology'.
     Eur J Heart Fail. 2024 Feb 20. doi: 10.1002/ejhf.3171.
     PubMed    
     
     
     
510. PELLICORI P, Felker GM, Cleland JGF
     Reply to 'Vasodilators in congestive heart failure: The perfect weapon aiming just off the target?'.
     Eur J Heart Fail. 2024 Feb 20. doi: 10.1002/ejhf.3159.
     PubMed    
     
     
     
511. TALHA KM, Januzzi JL Jr, Meng T, Greene SJ, et al
     Use of natriuretic peptides and echocardiography for diagnosing heart failure.
     Eur J Heart Fail. 2024 Feb 20. doi: 10.1002/ejhf.3165.
     PubMed     Abstract available
     
     
     
512. MINAMISAWA M, Inciardi RM, Claggett B, Cikes M, et al
     Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF study.
     Eur J Heart Fail. 2024 Feb 18. doi: 10.1002/ejhf.3167.
     PubMed     Abstract available
     
     
     
513. KOK WE
     Unravelling the gut hypothesis of heart failure with gut microbiota-derived metabolites.
     Eur J Heart Fail. 2024 Feb 15. doi: 10.1002/ejhf.3164.
     PubMed    
     
     
     
514. MIN KH, Jackson SA, Ambrosy AP
     A PACT for the future: Improving medication adherence in heart failure.
     Eur J Heart Fail. 2024 Feb 12. doi: 10.1002/ejhf.3169.
     PubMed    
     
     
     
515. ZHAO Y, Sun J, Xie C
     The gap between real-world and guidelines in the use of sodium-glucose cotransporter 2 inhibitors for heart failure patients with reduced ejection fraction: Is it underestimated or overestimated? Letter regarding the article 'Real-world use of sodium-
     Eur J Heart Fail. 2024 Feb 8. doi: 10.1002/ejhf.3163.
     PubMed    
     
     
     
516. BO W, Cheng X
     High blood pressure for heart failure patients: Where do the benefits come from? Letter regarding the article 'Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and meta-analysis'.
     Eur J Heart Fail. 2024 Feb 4. doi: 10.1002/ejhf.3161.
     PubMed    
     
     
     
517. VAN ESSEN BJ, Tharshana GN, Ouwerkerk W, Yeo PSD, et al
     Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach.
     Eur J Heart Fail. 2024 Feb 4. doi: 10.1002/ejhf.3156.
     PubMed     Abstract available
     
     
     
518. AVERBUCH T, Lee SF, Zagorski B, Mebazaa A, et al
     Effect of a transitional care model following hospitalization for heart failure: 3-year outcomes of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) randomized controlled trial.
     Eur J Heart Fail. 2024 Feb 1. doi: 10.1002/ejhf.3134.
     PubMed     Abstract available
     
     
     
519. RICCARDI M, Pagnesi M, Chioncel O, Mebazaa A, et al
     Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors.
     Eur J Heart Fail. 2024;26:411-431.
     PubMed     Abstract available
     
     
     
520. SUBRAMANIAN V, Keshvani N, Segar MW, Kondamudi NJ, et al
     Association of global longitudinal strain by feature tracking cardiac magnetic resonance imaging with adverse outcomes among community-dwelling adults without cardiovascular disease: The Dallas Heart Study.
     Eur J Heart Fail. 2024;26:208-215.
     PubMed     Abstract available
     
     
     
521. GARCIA-PAVIA P, Grogan M, Kale P, Berk JL, et al
     Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
     Eur J Heart Fail. 2024;26:397-410.
     PubMed     Abstract available
     
     
     
522. KRESOJA KP
     Exercise haemodynamics in post-Fontan patients: Diastolic dysfunction, again and again?
     Eur J Heart Fail. 2024;26:324-326.
     PubMed    
     
     
     
523. MAEDER MT
     Natriuretic peptides - Biomarker companions through thick and thin.
     Eur J Heart Fail. 2024;26:270-273.
     PubMed    
     
     
     
524. MONDA E, Limongelli G
     Expanding the knowledge on transthyretin p.V142I variant-related cardiomyopathy.
     Eur J Heart Fail. 2024;26:394-396.
     PubMed    
     
     
     
525. SCISCIOLA L, Paolisso P, Belmonte M, Gallinoro E, et al
     Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study.
     Eur J Heart Fail. 2024;26:471-482.
     PubMed     Abstract available
     
     
     
526. COUGHLAN JJ, Rossello X
     Anaemia in patients with cardiogenic shock complicating acute myocardial infarction: Surrogate marker of poor outcome or therapeutic target?
     Eur J Heart Fail. 2024;26:458-459.
     PubMed    
     
     
     
527. MERKELY B, Kosztin A
     De novo versus upgrade cardiac resynchronization therapy: A different patient population and outcome?
     Eur J Heart Fail. 2024;26:521-522.
     PubMed    
     
     
     
528. MEEKERS E, Petit T, Dauw J, Gruwez H, et al
     Analysing the accuracy of pressure measurements during exercise with pulmonary artery pressure sensors - Insights from the ACTION-MEMS study.
     Eur J Heart Fail. 2024;26:523-524.
     PubMed    
     
     
     
529. MIRANDA WR, Jain CC, Borlaug BA, Connolly HM, et al
     Exercise catheterization in adults post-Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology.
     Eur J Heart Fail. 2024;26:314-323.
     PubMed     Abstract available
     
     
     
530. OBRADOVIC D, Loncar G, Zeymer U, Poss J, et al
     Impact of anaemia and iron deficiency on outcomes in cardiogenic shock complicating acute myocardial infarction.
     Eur J Heart Fail. 2024;26:448-457.
     PubMed     Abstract available
     
     
     
531. RAZVI Y, Ioannou A, Patel RK, Chacko L, et al
     Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
     Eur J Heart Fail. 2024;26:383-393.
     PubMed     Abstract available
     
     
     
532. TRENSON S, Voros G, Martens P, Ingelaere S, et al
     Long-term outcome after upgrade to cardiac resynchronization therapy: A propensity score-matched analysis.
     Eur J Heart Fail. 2024;26:511-520.
     PubMed     Abstract available
     
     
     January 2024
533. SEGAR MW, Pandey A
     Understanding the language of the heart: The promise of natural language processing to diagnose heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Jan 31. doi: 10.1002/ejhf.3154.
     PubMed    
     
     
     
534. PARIKH PB, Mack M, Stone GW, Anker SD, et al
     Transcatheter aortic valve replacement in heart failure.
     Eur J Heart Fail. 2024 Jan 31. doi: 10.1002/ejhf.3151.
     PubMed     Abstract available
     
     
     
535. LIN GM, Lloyd-Jones DM, Colangelo LA, Lima JAC, et al
     Association between secondhand smoke exposure and incident heart failure: The Multi-Ethnic Study of Atherosclerosis (MESA).
     Eur J Heart Fail. 2024 Jan 30. doi: 10.1002/ejhf.3155.
     PubMed     Abstract available
     
     
     
536. KHAN MS, Fonarow GC, Greene SJ
     Guideline-directed medical therapy for heart failure: The key ingredient for successful in-hospital and post-discharge care.
     Eur J Heart Fail. 2024 Jan 30. doi: 10.1002/ejhf.3152.
     PubMed    
     
     
     
537. PELLICORI P, Cleland JGF
     Atrial myopathy and heart failure with preserved ejection fraction: When a label does more harm than good?
     Eur J Heart Fail. 2024 Jan 28. doi: 10.1002/ejhf.3148.
     PubMed    
     
     
     
538. HULLIN R
     Advantage of uptitration of foundational heart failure drugs in heart failure with reduced ejection fraction and low blood pressure.
     Eur J Heart Fail. 2024 Jan 25. doi: 10.1002/ejhf.3144.
     PubMed    
     
     
     
539. MULLENS W, Dauw J, Gustafsson F, Mebazaa A, et al
     Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
     Eur J Heart Fail. 2024 Jan 25. doi: 10.1002/ejhf.3150.
     PubMed     Abstract available
     
     
     
540. ABDIN A, Lauder L, Fudim M, Abraham WT, et al
     Neuromodulation interventions in the management of heart failure.
     Eur J Heart Fail. 2024 Jan 21. doi: 10.1002/ejhf.3147.
     PubMed     Abstract available
     
     
     
541. GONZALEZ-DEL-HOYO M, Rossello X
     Worsening heart failure comes into focus, chronic heart failure takes a backseat.
     Eur J Heart Fail. 2024 Jan 21. doi: 10.1002/ejhf.3143.
     PubMed    
     
     
     
542. DAUW J, Meekers E, Martens P, Deferm S, et al
     Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling.
     Eur J Heart Fail. 2024 Jan 21. doi: 10.1002/ejhf.3131.
     PubMed     Abstract available
     
     
     
543. DE LA ESPRIELLA R, Ortiz A, Nunez J
     The blood urea nitrogen to creatinine ratio in chronic heart failure: 'When the past is prologue'.
     Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3146.
     PubMed    
     
     
     
544. PITT B, Brown JM, Vaidya A, Diez J, et al
     Reassessing the management of hypertension: Time to prevent aldosterone-mediated heart failure.
     Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3141.
     PubMed    
     
     
     
545. GREENE SJ, Khan MS, Butler J
     Why do clinicians not prescribe quadruple medical therapy for heart failure with reduced ejection fraction?
     Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3133.
     PubMed    
     
     
     
546. USMAN MS, Januzzi JL, Anker SD, Salman A, et al
     The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
     Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3129.
     PubMed     Abstract available
     
     
     
547. BAYES-GENIS A, Aimo A
     Reply to the letter regarding the article 'Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines'.
     Eur J Heart Fail. 2024 Jan 16. doi: 10.1002/ejhf.3142.
     PubMed    
     
     
     
548. SEIDU S, Lawson CA, Kunutsor SK, Khunti K, et al
     Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and meta-analysis.
     Eur J Heart Fail. 2024 Jan 12. doi: 10.1002/ejhf.3108.
     PubMed     Abstract available
     
     
     
549. 
     Correction to 'Congestion in heart failure: A circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association' and articles listed below.
     Eur J Heart Fail. 2024 Jan 11. doi: 10.1002/ejhf.3123.
     PubMed    
     
     
     
550. DE BOER RA, Diez J
     Advancing the fight against fibrosis in patients with heart failure: The contribution of sodium-glucose cotransporter 2 inhibition.
     Eur J Heart Fail. 2024 Jan 9. doi: 10.1002/ejhf.3125.
     PubMed    
     
     
     
551. SAITO Y, Obokata M
     Diagnostic and therapeutic implications of obesity in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2024 Jan 8. doi: 10.1002/ejhf.3128.
     PubMed    
     
     
     
552. KALOGEROPOULOS AP, Jang KH, Hall ME
     Predicting heart failure: The promise of proteomics.
     Eur J Heart Fail. 2024 Jan 8. doi: 10.1002/ejhf.3126.
     PubMed    
     
     
     
553. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
     2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ES
     Eur J Heart Fail. 2024 Jan 3. doi: 10.1002/ejhf.3024.
     PubMed     Abstract available
     
     
     
554. KHAN MS, Sperry BW, Butler J
     Kidney involvement in transthyretin cardiac amyloidosis - Role of urinary albumin to creatinine ratio and need for further evidence generation.
     Eur J Heart Fail. 2024;26:74-76.
     PubMed    
     
     
     
555. BERTERO E, Chiti C, Schiavo MA, Tini G, et al
     Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
     Eur J Heart Fail. 2024;26:59-64.
     PubMed     Abstract available
     
     
     
556. SEOUDY H, Voran JC, Frank D
     Growth differentiation factor-15 in sodium-glucose cotransporter 2 inhibition: Mechanistic insights from the EMPEROR program.
     Eur J Heart Fail. 2024;26:165-166.
     PubMed    
     
     
     
557. RIVAS GARCIA S, Alvarez-Garcia J
     Sacubitril/valsartan: Where mechanism meets evidence-based medicine.
     Eur J Heart Fail. 2024;26:127-129.
     PubMed    
     
     
     
558. FERREIRA JP, Rossello X, Zannad F
     Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients.
     Eur J Heart Fail. 2024;26:140-141.
     PubMed    
     
     
     
559. ARDISSINO M, Halliday BP, de Marvao A
     The global landscape of peripartum cardiomyopathy: Morbidity, mortality, recovery and inequity.
     Eur J Heart Fail. 2024;26:43-45.
     PubMed    
     
     
     
560. IOANNOU A, Rauf MU, Patel RK, Razvi Y, et al
     Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance.
     Eur J Heart Fail. 2024;26:65-73.
     PubMed     Abstract available
     
     
     
561. MERLO M, Setti M, Sinagra G
     Coronary artery disease and dilated cardiomyopathy: Where parallel universes merge.
     Eur J Heart Fail. 2024;26:56-58.
     PubMed    
     
     
     
562. SCHOU M, Claggett B, Miao ZM, Fernandez A, et al
     Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
     Eur J Heart Fail. 2024;26:130-139.
     PubMed     Abstract available
     
     
     
563. MAEDA D, Matsue Y, Dotare T, Sunayama T, et al
     Clinical characteristics and prognosis of patients with isolated cardiac sarcoidosis: Insights from the ILLUMINATE-CS study.
     Eur J Heart Fail. 2024;26:77-86.
     PubMed     Abstract available
     
     
     
564. JACKSON AM, Bauersachs J, Petrie MC, van der Meer P, et al
     Outcomes at one year in women with peripartum cardiomyopathy: Findings from the ESC EORP PPCM Registry.
     Eur J Heart Fail. 2024;26:34-42.
     PubMed     Abstract available
     
     
     
565. JONES RE, Hammersley DJ, Zheng S, McGurk KA, et al
     Assessing the association between genetic and phenotypic features of dilated cardiomyopathy and outcome in patients with coronary artery disease.
     Eur J Heart Fail. 2024;26:46-55.
     PubMed     Abstract available
     
     
     December 2023
566. LARSON K, Omar M, Sorimachi H, Omote K, et al
     Impact of Clinical Phenogroup Diversity and Multiplicity: Impact on Mechanisms of Exercise Intolerance in Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Dec 29. doi: 10.1002/ejhf.3105.
     PubMed     Abstract available
     
     
     
567. WU J, Biswas D, Ryan M, Bernstein B, et al
     Artificial Intelligence methods for Improved Detection of undiagnosed Heart Failure with Preserved Ejection Fraction (HFpEF).
     Eur J Heart Fail. 2023 Dec 28. doi: 10.1002/ejhf.3115.
     PubMed     Abstract available
     
     
     
568. KOKKINOS P, Faselis C, Pittaras A, Samuel IBH, et al
     Cardiorespiratory Fitness and Risk of Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Dec 28. doi: 10.1002/ejhf.3117.
     PubMed     Abstract available
     
     
     
569. AMINI L, Kazmi S, Patel MJ
     Letter Regarding the Article, "Head-to-Head Comparison Between Recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines"(1).
     Eur J Heart Fail. 2023 Dec 28. doi: 10.1002/ejhf.3121.
     PubMed    
     
     
     
570. PATEL SM, Morrow DA, Bellavia A, Berg DD, et al
     Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.
     Eur J Heart Fail. 2023 Dec 22. doi: 10.1002/ejhf.3118.
     PubMed     Abstract available
     
     
     
571. TOMASONI D, Vitale C, Guidetti F, Benson L, et al
     The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2023 Dec 22. doi: 10.1002/ejhf.3112.
     PubMed     Abstract available
     
     
     
572. ADAMO M, Chioncel O, Pagnesi M, Bayes-Genis A, et al
     Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right-Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular
     Eur J Heart Fail. 2023 Dec 22. doi: 10.1002/ejhf.3106.
     PubMed     Abstract available
     
     
     
573. RANDHAWA VK, Baran DA
     Unraveling Heart Failure Cardiogenic Shock Profiles and Pathways.
     Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3113.
     PubMed    
     
     
     
574. COTTER G, Davison BA, Adams KF Jr, Ambrosy AP, et al
     Effective medications can work only in patients who take them: implications for post acute heart failure care.
     Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3109.
     PubMed    
     
     
     
575. TANG WHW, Nemet I, Li XS, Wu Y, et al
     Prognostic Value of Gut Microbe-Generated Metabolite Phenylacetylglutamine in Patients with Heart Failure.
     Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3111.
     PubMed     Abstract available
     
     
     
576. TOLOMEO P, Butt JH, Kondo T, Campo G, et al
     Independent prognostic importance of blood urea nitrogen (BUN) to creatinine ratio in heart failure.
     Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3114.
     PubMed     Abstract available
     
     
     
577. COLLINS NJ, Ngo DTM, Sverdlov AL
     New cimlanod trial provides insights into mechanistic effects of vasodilators in heart failure.
     Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3110.
     PubMed    
     
     
     
578. BOCCHINO PP, Gallone G, Frea S, De Ferrari GM, et al
     Vasodilators in congestive heart failure: The perfect weapon aiming just off the target?
     Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3122.
     PubMed    
     
     
     
579. DE LA ESPRIELLA R, Wahlberg KJ, Infeld M, Palau P, et al
     Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial.
     Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3107.
     PubMed     Abstract available
     
     
     
580. BAUDRY G, Pereira O, Duarte K, Ferreira JP, et al
     Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France.
     Eur J Heart Fail. 2023 Dec 7. doi: 10.1002/ejhf.3103.
     PubMed     Abstract available
     
     
     
581. OMOTE K, Sorimachi H, Obokata M, Verbrugge FH, et al
     Biatrial Myopathy in Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Dec 7. doi: 10.1002/ejhf.3104.
     PubMed     Abstract available
     
     
     
582. FERREIRA JP, Butler J, Anker SD, Januzzi JL, et al
     Effects of empaglifozin on collagen biomarkers in patients with Heart Failure. Findings from the EMPEROR trials.
     Eur J Heart Fail. 2023 Dec 1. doi: 10.1002/ejhf.3101.
     PubMed     Abstract available
     
     
     
583. TOMASONI D, Adamo M, Metra M
     December 2023 at a glance: Focus on medical therapy in chronic and acute heart failure.
     Eur J Heart Fail. 2023;25:2099-2101.
     PubMed    
     
     
     
584. D'AMARIO D, Borovac JA, Patti G
     A machine-learning-based prediction model in patients with takotsubo syndrome: 'You can't stop change any more than you can stop the suns from setting!'.
     Eur J Heart Fail. 2023;25:2312-2315.
     PubMed    
     
     
     
585. CANNATA A, Bromage DI, McDonagh TA
     When observation meets randomization: 'Don't let a crisis go to waste'.
     Eur J Heart Fail. 2023;25:2189-2190.
     PubMed    
     
     
     
586. DELMAS C, Vandenbriele C, Pappalardo F, Roubille F, et al
     What about current recommendations for extracorporeal life support in acute myocardial infarction-associated cardiogenic shock: Stay or go? or time to revise?
     Eur J Heart Fail. 2023;25:2102-2104.
     PubMed    
     
     
     
587. RUSSO G, Badano LP, Adamo M, Alessandrini H, et al
     Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry.
     Eur J Heart Fail. 2023;25:2243-2251.
     PubMed     Abstract available
     
     
     
588. POLOVINA M, Tschope C, Rosano G, Metra M, et al
     Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies.
     Eur J Heart Fail. 2023;25:2144-2163.
     PubMed     Abstract available
     
     
     
589. MARTYN T, Saef J, Khot UN, Martinez KA, et al
     The utilization and impact of cardiovascular specialists on guideline-directed medical scores: An analysis of a diverse, multi-state, electronic health record-based registry.
     Eur J Heart Fail. 2023;25:2333-2336.
     PubMed    
     
     
     
590. KOURANOS V, Khattar RS, Okafor J, Ahmed R, et al
     Predictors of outcome in a contemporary cardiac sarcoidosis population: Role of brain natriuretic peptide, left ventricular function and myocardial inflammation.
     Eur J Heart Fail. 2023;25:2287-2298.
     PubMed     Abstract available
     
     
     
591. DE FILIPPO O, Cammann VL, Pancotti C, Di Vece D, et al
     Machine learning-based prediction of in-hospital death for patients with takotsubo syndrome: The InterTAK-ML model.
     Eur J Heart Fail. 2023;25:2299-2311.
     PubMed     Abstract available
     
     
     November 2023
592. PELLICORI P, Cleland JGF, Borentain M, Taubel J, et al
     Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231).
     Eur J Heart Fail. 2023 Nov 21. doi: 10.1002/ejhf.3077.
     PubMed     Abstract available
     
     
     
593. LUND LH, Crespo-Leiro MG, Laroche C, Garcia-Pinilla JM, et al
     Rationale and Design of the ESC Heart Failure III Registry - Implementation and Discovery.
     Eur J Heart Fail. 2023 Nov 21. doi: 10.1002/ejhf.3087.
     PubMed     Abstract available
     
     
     
594. LITWIN SE, Komtebedde J, Seidler T, Borlaug BA, et al
     Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial.
     Eur J Heart Fail. 2023 Nov 21. doi: 10.1002/ejhf.3092.
     PubMed     Abstract available
     
     
     
595. FERREIRA JP, Packer M, Butler J, Filippatos G, et al
     GDF-15 and the Effect of Empagliflozin in Heart Failure: Findings from the EMPEROR Program.
     Eur J Heart Fail. 2023 Nov 14. doi: 10.1002/ejhf.3078.
     PubMed     Abstract available
     
     
     
596. RIDDELL CW, Chan C, McGrinder H, Earle NJ, et al
     College-level reading is required to understand ChatGPT's answers to lay questions relating to heart failure.
     Eur J Heart Fail. 2023 Nov 14. doi: 10.1002/ejhf.3083.
     PubMed    
     
     
     
597. BOBROWSKI D, Dorovenis A, Abdel-Qadir H, McNaughton CD, et al
     Association of Neighborhood-Level Material Deprivation with Adverse Outcomes and Processes of Care Among Patients with Heart Failure in a Single-Payer Healthcare System: A Population-Based Cohort Study.
     Eur J Heart Fail. 2023 Nov 13. doi: 10.1002/ejhf.3090.
     PubMed     Abstract available
     
     
     
598. PITT B, Zannad F
     The Use Of Mineralocorticoid Receptor Antagonists For Patients With Heart Failure With A Reduced Ejection Fraction: A Time For Reassessment.
     Eur J Heart Fail. 2023 Nov 13. doi: 10.1002/ejhf.3091.
     PubMed    
     
     
     
599. SUNDERMEYER J, Kellner C, Beer BN, Besch L, et al
     Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heart failure-related cardiogenic shock.
     Eur J Heart Fail. 2023 Nov 8. doi: 10.1002/ejhf.3082.
     PubMed     Abstract available
     
     
     
600. MCDOWELL K, Adamson C, Jackson C, Campbell R, et al
     Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes.
     Eur J Heart Fail. 2023 Nov 8. doi: 10.1002/ejhf.3085.
     PubMed     Abstract available
     
     
     
601. EMILSSON V, Jonsson BG, Austin TR, Gudmundsdottir V, et al
     Proteomic prediction of incident heart failure and its main subtypes.
     Eur J Heart Fail. 2023 Nov 8. doi: 10.1002/ejhf.3086.
     PubMed     Abstract available
     
     
     
602. TOMASONI D, Pagnesi M, Colombo G, Chiarito M, et al
     Guideline directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF Registry.
     Eur J Heart Fail. 2023 Nov 7. doi: 10.1002/ejhf.3081.
     PubMed     Abstract available
     
     
     
603. MILLER RJ, Howlett JG
     Un(b)locking Therapeutic Options: Potential for Calcium Channel Blockers in Heart Failure with non-Reduced LVEF.
     Eur J Heart Fail. 2023 Nov 6. doi: 10.1002/ejhf.3080.
     PubMed    
     
     
     
604. TOMASONI D, Adamo M, Metra M
     November 2023 at a glance: Focus on cardiogenic shock, post-discharge outcomes and cardiomyopathies.
     Eur J Heart Fail. 2023;25:1887-1890.
     PubMed    
     
     
     
605. LOBEEK M, Rienstra M, Gorter TM
     Epicardial adipose tissue and cardiac dysfunction: Progress in knowledge but questions remain.
     Eur J Heart Fail. 2023;25:1944-1946.
     PubMed    
     
     
     
606. DELMAS C, Vandenbriele C, Pappalardo F
     Persistent high mortality in acute myocardial infarction-associated cardiogenic shock despite early mechanical circulatory support: Need for stepwise and integrated approach of care.
     Eur J Heart Fail. 2023;25:2034-2036.
     PubMed    
     
     
     
607. MOLLER JE, Kjaergaard J, Hassager C
     Contemporary use of temporary mechanical circulatory support in infarct-related cardiogenic shock: Time to stop and reflect?
     Eur J Heart Fail. 2023;25:2032-2033.
     PubMed    
     
     
     
608. VISHRAM-NIELSEN JKK, Gustafsson F
     Watchful waiting for venting in venoarterial extracorporeal membrane oxygenation.
     Eur J Heart Fail. 2023;25:2047-2049.
     PubMed    
     
     
     
609. HAMMERSLEY DJ, Jones RE, Owen R, Mach L, et al
     Phenotype, outcomes and natural history of early-stage non-ischaemic cardiomyopathy.
     Eur J Heart Fail. 2023;25:2050-2059.
     PubMed     Abstract available
     
     
     
610. BOGERD M, Ten Berg S, Peters EJ, Vlaar APJ, et al
     Impella and venoarterial extracorporeal membrane oxygenation in cardiogenic shock complicating acute myocardial infarction.
     Eur J Heart Fail. 2023;25:2021-2031.
     PubMed     Abstract available
     
     
     
611. CHIN JF, Aga YS, Abou Kamar S, Kroon D, et al
     Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity.
     Eur J Heart Fail. 2023;25:1936-1943.
     PubMed     Abstract available
     
     
     
612. PARK H, Yang JH, Ahn JM, Kang DY, et al
     Early left atrial venting versus conventional treatment for left ventricular decompression during venoarterial extracorporeal membrane oxygenation support: The EVOLVE-ECMO randomized clinical trial.
     Eur J Heart Fail. 2023;25:2037-2046.
     PubMed     Abstract available
     
     
     
613. SEFEROVIC PM, Polovina M, Rosano G, Bozkurt B, et al
     State-of-the-art document on optimal contemporary management of cardiomyopathies.
     Eur J Heart Fail. 2023;25:1899-1922.
     PubMed     Abstract available
     
     
     October 2023
614. DOEHNER W, Bohm M, Boriani G, Christersson C, et al
     Interaction of Heart Failure and Stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis.
     Eur J Heart Fail. 2023 Oct 31. doi: 10.1002/ejhf.3071.
     PubMed     Abstract available
     
     
     
615. TER MAATEN JM, Mebazaa A, Davison B, Edwards C, et al
     Early changes in renal function during rapid uptitration of guideline directed medical therapy following an admission for acute heart failure.
     Eur J Heart Fail. 2023 Oct 31. doi: 10.1002/ejhf.3074.
     PubMed     Abstract available
     
     
     
616. NESTEROV SV, Raty J, Nammas W, Maaniitty T, et al
     The short-term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction. A randomized controlled study.
     Eur J Heart Fail. 2023 Oct 31. doi: 10.1002/ejhf.3072.
     PubMed     Abstract available
     
     
     
617. GIRERD N, Coiro S, Benson L, Savarese G, et al
     Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: Insights from the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2023 Oct 26. doi: 10.1002/ejhf.3066.
     PubMed     Abstract available
     
     
     
618. PACKER M
     Qiliqiangxin: a Multifaceted Holistic Treatment for Heart Failure or a Pharmacological Probe for the Identification of Cardioprotective Mechanisms?
     Eur J Heart Fail. 2023 Oct 25. doi: 10.1002/ejhf.3068.
     PubMed     Abstract available
     
     
     
619. WUSSLER D, Belkin M, Maeder MT, Walter J, et al
     Comprehensive Vasodilation in Women with Acute Heart Failure: Novel Insights from the GALACTIC randomized controlled trial.
     Eur J Heart Fail. 2023 Oct 23. doi: 10.1002/ejhf.3065.
     PubMed     Abstract available
     
     
     
620. MOLLOY CD, Long L, Mordi IR, Bridges C, et al
     Exercise-based cardiac rehabilitation for adults with heart failure - 2023 Cochrane systematic review and meta-analysis.
     Eur J Heart Fail. 2023 Oct 18. doi: 10.1002/ejhf.3046.
     PubMed     Abstract available
     
     
     
621. SAVARESE G, Butler J, Ponikowki P, Anker SD, et al
     SGLT2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: any incremental effect?
     Eur J Heart Fail. 2023 Oct 17. doi: 10.1002/ejhf.3064.
     PubMed    
     
     
     
622. SHAHIM A, Shahim B, Lund LH
     Reply by Shahim et al. to Letter "Aortic regurgitation for adverse cardiovascular events: really harmless or just hidden?" Regarding Article "Prevalence, Characteristics and Prognostic Impact of Aortic Valve Disease in Patients with Heart Failure and
     Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3062.
     PubMed    
     
     
     
623. PARK JJ, Jang SY, Adler E, Ahmad F, et al
     A Machine Learning Derived Risk Score Predicts Mortality in East Asian Patients with Acute Heart Failure.
     Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3059.
     PubMed    
     
     
     
624. MORICI N, Pappalardo F
     Heart Failure-Cardiogenic Shock: A Need for Time-Dependent Quality Indicators.
     Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3058.
     PubMed    
     
     
     
625. CASTAGNA F, Simitsis P, Mehra MR
     Overcoming Vulnerability in Heart Failure: Transitional Tactical Toughness.
     Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3054.
     PubMed    
     
     
     
626. SHAKOOR A, Abou Kamar S, Malgie J, Kardys I, et al
     The Different Risk of New-onset, Chronic, Worsening, and Advanced Heart Failure A Systematic Review and Meta-Regression Analysis.
     Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3048.
     PubMed     Abstract available
     
     
     
627. SCOTTI A, Slipczuk L, Latib A
     Aortic stenosis and heart failure with preserved ejection fraction: A shared phenotypic puzzle.
     Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3050.
     PubMed    
     
     
     
628. GUIDETTI F, Lund LH, Benson L, Hage C, et al
     Safety of Continuing Mineralocorticoid Receptor Antagonists Treatment in Patients with Heart Failure with Reduced Ejection Fraction and Severe Kidney Disease: Data from Swedish Heart Failure Registry.
     Eur J Heart Fail. 2023 Oct 5. doi: 10.1002/ejhf.3049.
     PubMed     Abstract available
     
     
     
629. TUBBEN A, Nienhuis HLA, van der Meer P
     Tafamidis in Patients with Severe Heart Failure Due to Transthyretin Amyloidosis Cardiomyopathy: Improved Long-term Survival.
     Eur J Heart Fail. 2023 Oct 4. doi: 10.1002/ejhf.3053.
     PubMed    
     
     
     
630. PASCUAL-FIGAL D, Fuster JJ, Bayes-Genis A
     Personalizing Anti-Inflammatory Therapy in Heart Failure: A New Way.
     Eur J Heart Fail. 2023 Oct 4. doi: 10.1002/ejhf.3052.
     PubMed    
     
     
     
631. BIEGUS J, Ponikowski P
     Striving for the "Perfect" Definition of Iron Deficiency in Heart Failure.
     Eur J Heart Fail. 2023 Oct 4. doi: 10.1002/ejhf.3051.
     PubMed    
     
     
     
632. TOMASONI D, Adamo M, Metra M
     October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities.
     Eur J Heart Fail. 2023;25:1719-1721.
     PubMed    
     
     
     
633. MARTENS P, Mullens W
     Using combinational diuretics across the spectrum of renal function.
     Eur J Heart Fail. 2023;25:1794-1796.
     PubMed    
     
     
     
634. BEER BN, Schrage B
     REMIniscence of aldosterone's role in myocardial remodelling.
     Eur J Heart Fail. 2023;25:1753-1754.
     PubMed    
     
     
     
635. REDDY YNV, Borlaug BA
     Provocative testing in the evaluation of heart failure with preserved ejection fraction: Not all stresses are created equal.
     Eur J Heart Fail. 2023;25:1781-1783.
     PubMed    
     
     
     
636. LEVI N, Hasin T
     Myocardial injury related to SARS-CoV-2 mRNA vaccination: The plot thickens.
     Eur J Heart Fail. 2023;25:1882-1883.
     PubMed    
     
     
     
637. VAN BERGEIJK KH, Voors AA, Wykrzykowska JJ
     Prevalence and predictive value of fluid overload in patients with severe symptomatic aortic valve stenosis.
     Eur J Heart Fail. 2023;25:1819-1821.
     PubMed    
     
     
     
638. ABBASI K, Ali P, Barbour V, Bibbins-Domingo K, et al
     Reducing the risks of nuclear war-the role of health professionals.
     Eur J Heart Fail. 2023;25:1722-1723.
     PubMed    
     
     
     
639. MONZO L, Huttin O, Ferreira JP, Lamiral Z, et al
     Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study.
     Eur J Heart Fail. 2023;25:1742-1752.
     PubMed     Abstract available
     
     
     
640. BUERGIN N, Lopez-Ayala P, Hirsiger JR, Mueller P, et al
     Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination.
     Eur J Heart Fail. 2023;25:1871-1881.
     PubMed     Abstract available
     
     
     
641. HALAVINA K, Koschutnik M, Dona C, Autherith M, et al
     Quantitative fluid overload in severe aortic stenosis refines cardiac damage and associates with worse outcomes.
     Eur J Heart Fail. 2023;25:1808-1818.
     PubMed     Abstract available
     
     
     September 2023
642. BHATT AS, Kosiborod MN, Claggett BL, Miao ZM, et al
     Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial.
     Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3043.
     PubMed     Abstract available
     
     
     
643. SAITO Y, Obokata M
     Reply to 'Phenotypic characterization of heart failure with preserved ejection fraction'.
     Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3040.
     PubMed    
     
     
     
644. HAGE C, Lund LH
     Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease - No heterogeneity.
     Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3041.
     PubMed    
     
     
     
645. MATSUMOTO S, Kondo T, Yang M, Campbell RT, et al
     Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.
     Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3044.
     PubMed     Abstract available
     
     
     
646. ELLIOTT P, Gundapaneni B, Garcia-Pavia P
     Reply to 'Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark.
     Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3042.
     PubMed    
     
     
     
647. CHIONCEL O, Davison B, Adamo M, Antohi LE, et al
     Noncardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: insights from the STRONG-HF trial.
     Eur J Heart Fail. 2023 Sep 20. doi: 10.1002/ejhf.3039.
     PubMed     Abstract available
     
     
     
648. BAYES-GENIS A, Doherty KF, Petrie MC, Januzzi JL, et al
     Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2023 Sep 15. doi: 10.1002/ejhf.3036.
     PubMed     Abstract available
     
     
     
649. FEUERSTEIN A, Schoenrath F, Belyavskiy E, Knierim J, et al
     Supervised exercise training in patients with advanced heart failure and left ventricular assist device: a multicenter randomized controlled trial (Ex-VAD trial).
     Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3032.
     PubMed     Abstract available
     
     
     
650. AGOSTONI P, Pluchinotta FR, Salvioni E, Mapelli M, et al
     Heart failure patients with improved ejection fraction: insights from the MECKI Score database.
     Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3031.
     PubMed     Abstract available
     
     
     
651. SEGAR MW, Keshvani N, Pandey A
     From Prediction to Prevention: The Role of Heart Failure Risk Models.
     Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3034.
     PubMed    
     
     
     
652. AMERI P, Vaduganathan M
     When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure.
     Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3035.
     PubMed    
     
     
     
653. BURGER PM, Savarese G, Tromp J, Adamson C, et al
     Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model.
     Eur J Heart Fail. 2023 Sep 10. doi: 10.1002/ejhf.3028.
     PubMed     Abstract available
     
     
     
654. SHERROD CF, Ikemura N, Spertus JA
     Knowledge is Power, Can It Be Leveraged to Improve Heart Failure Care?
     Eur J Heart Fail. 2023 Sep 6. doi: 10.1002/ejhf.3027.
     PubMed    
     
     
     
655. KALRA R
     SGLT2 Inhibitors in Hospitalized Heart Failure Patients: No Time Like Now.
     Eur J Heart Fail. 2023 Sep 4. doi: 10.1002/ejhf.3022.
     PubMed    
     
     
     
656. ABDIN A, Anker SD, Cowie MR, Filippatos GS, et al
     Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry.
     Eur J Heart Fail. 2023 Sep 4. doi: 10.1002/ejhf.3023.
     PubMed     Abstract available
     
     
     
657. YOGASUNDARAM H, Zheng Y, Ly E, Ezekowitz J, et al
     Relationship Between Baseline Electrocardiographic Measurements and Outcomes in Patients with High-Risk Heart Failure: Insights from the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
     Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3021.
     PubMed     Abstract available
     
     
     
658. HAGE C, Stahlberg M, Thorvaldsen T, Faxen UL, et al
     Acyl ghrelin infusion increases circulating growth hormone in patients with heart failure and reduced ejection fraction.
     Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3019.
     PubMed    
     
     
     
659. DE BIASE N, Mazzola M, Del Punta L, Di Fiore V, et al
     Haemodynamic and metabolic phenotyping of patients with aortic stenosis and preserved ejection fraction: a specific phenotype of heart failure with preserved ejection fraction?
     Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3018.
     PubMed     Abstract available
     
     
     
660. TOMASONI D, Adamo M, Metra M
     September 2023 at a glance: focus on acute heart failure and health status.
     Eur J Heart Fail. 2023;25:1473-1476.
     PubMed    
     
     
     
661. HARRINGTON J, Udell JA, Jones WS, Anker SD, et al
     Baseline characteristics of patients enrolled in the EMPACT-MI trial.
     Eur J Heart Fail. 2023;25:1708-1715.
     PubMed     Abstract available
     
     
     
662. YANG M, Kondo T, Adamson C, Butt JH, et al
     Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.
     Eur J Heart Fail. 2023;25:1606-1618.
     PubMed     Abstract available
     
     
     
663. ANKER MS, Potthoff SK, Lena A, Porthun J, et al
     Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
     Eur J Heart Fail. 2023;25:1635-1647.
     PubMed     Abstract available
     
     
     August 2023
664. PAPADOPOULOU C, Reinhold J, Gruner-Hegge N, Kydd A, et al
     Prognostic value of three iron deficiency definitions in patients with advanced heart failure.
     Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.2949.
     PubMed     Abstract available
     
     
     
665. ZHU Q, Wang S
     Aortic regurgitation for adverse cardiovascular events: Really harmless or just hidden? Letter regarding the article 'Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced,
     Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3016.
     PubMed    
     
     
     
666. SANDEEP B, Huang X, Xiao Z
     Artificial intelligence in heart failure improving the efficiency or dependency on it? Letter regarding the article 'Artificial intelligence and heart failure: A state-of-the-art review'.
     Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3017.
     PubMed    
     
     
     
667. DONAL E, Neveu A, Fontes-Carvalho R
     Global longitudinal strain: Ready for 'prime time' in heart failure characterization.
     Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3012.
     PubMed    
     
     
     
668. AIMO A, Vergaro G, Emdin M
     Effects of tafamidis on heart failure hospitalization: the tale of the dog that did not bark.
     Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3015.
     PubMed    
     
     
     
669. FAUVEL C, Giraldo CIS, Barassa A, Shchendrygina A, et al
     Differences between heart failure specialists and non-specialists regarding heart failure drug implementation and up-titration.
     Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3010.
     PubMed    
     
     
     
670. POLZL G, Altenberger J, Comin-Colet J, Delgado JF, et al
     Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial.
     Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3006.
     PubMed     Abstract available
     
     
     
671. BUTT JH, Lu H, Kondo T, Bachus E, et al
     Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.
     Eur J Heart Fail. 2023 Aug 26. doi: 10.1002/ejhf.3000.
     PubMed     Abstract available
     
     
     
672. PABON M, Claggett BL, Wang X, Miao ZM, et al
     Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.
     Eur J Heart Fail. 2023 Aug 26. doi: 10.1002/ejhf.3001.
     PubMed     Abstract available
     
     
     
673. KESHVANI N, Shah S, Ayodele I, Chiswell K, et al
     Sex differences in long-term outcomes following acute heart failure hospitalization: Findings from the Get With The Guidelines-Heart Failure registry.
     Eur J Heart Fail. 2023 Aug 26. doi: 10.1002/ejhf.3003.
     PubMed     Abstract available
     
     
     
674. NANAYAKKARA S, Kaye DM
     No Longer From Pillar to Post: The First Effective Step in Treating Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3007.
     PubMed    
     
     
     
675. BUCKLEY LF, Dorbala P, Claggett BL, Libby P, et al
     Circulating Neutrophil-Related Proteins Associate with Incident Heart Failure and Cardiac Dysfunction: The ARIC Study.
     Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3008.
     PubMed     Abstract available
     
     
     
676. FATIMA K, Butler J, Fonarow GC
     Residual Risk in Heart Failure and the Need for Simultaneous Implementation and Innovation.
     Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3005.
     PubMed    
     
     
     
677. RIPAMONTI CI, Chelazzi C
     Is Palliative care in Heart Failure Patients Coming Up?
     Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3002.
     PubMed    
     
     
     
678. MOURA B, Aimo A, Al-Mohammad A, Keramida K, et al
     Diagnosis and Management of Patients with Left Ventricular Hypertrophy: Role of Multimodality Cardiac Imaging. A Scientific Statement of the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2997.
     PubMed     Abstract available
     
     
     
679. CHIONCEL O, Tomasoni D, Metra M
     Addressing Comorbidities in Heart Failure: When Feeling Better and Living Longer Go in the Same Direction.
     Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2998.
     PubMed    
     
     
     
680. PIERCE JB, Butler J, Greene SJ
     Implementation of SGLT2 Inhibitors for Heart Failure with Reduced Ejection Fraction: Where We Are Versus Where We Need To Be.
     Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2999.
     PubMed    
     
     
     
681. BRENNAN AC, Campbell RT, Lee MMY
     Influenza vaccination: a simple, safe, and effective treatment for patients with ischaemic heart disease and heart failure.
     Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2993.
     PubMed    
     
     
     
682. KHAN MS, Arshad MS, Greene SJ, Van Spall HGC, et al
     Artificial Intelligence and Heart Failure: A State-of-the-Art Review.
     Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2994.
     PubMed     Abstract available
     
     
     
683. JHA AK
     Phenotypic characterization of heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2996.
     PubMed    
     
     
     
684. VAZIR A, Kapelios CJ, Agaoglu E, Metra M, et al
     Decongestion Strategies in patients presenting with acutely decompensated heart failure: a worldwide survey among physicians.
     Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2985.
     PubMed     Abstract available
     
     
     
685. WERNHART S, Goertz A, Hedderich J, Papathanasiou M, et al
     Diastolic Exercise Stress Testing in Heart Failure with Preserved Ejection Fraction - The DEST HF study.
     Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2995.
     PubMed     Abstract available
     
     
     
686. MARQUES P, Matias P, Packer M, Vieira JT, et al
     Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors.
     Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2992.
     PubMed     Abstract available
     
     
     
687. FERREIRA JP, Blatchford JP, Teerlink JR, Kosiborod MN, et al
     Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE.
     Eur J Heart Fail. 2023 Aug 4. doi: 10.1002/ejhf.2982.
     PubMed     Abstract available
     
     
     
688. TRULLAS JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, et al
     Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: a post-hoc analysis of the CLOROTIC trial.
     Eur J Heart Fail. 2023 Aug 4. doi: 10.1002/ejhf.2988.
     PubMed     Abstract available
     
     
     
689. NOUHRAVESH N, Strange JE, Holt A, Tonnesen J, et al
     Patient mortality following new-onset heart failure stratified by cancer type and status.
     Eur J Heart Fail. 2023 Aug 3. doi: 10.1002/ejhf.2984.
     PubMed     Abstract available
     
     
     
690. PAGNESI M, Serafini L, Adamo M
     Moving towards a comprehensive heart failure management beyond ejection fraction.
     Eur J Heart Fail. 2023 Aug 2. doi: 10.1002/ejhf.2987.
     PubMed    
     
     
     
691. COHEN-SOLAL A, Logeart D
     Exercise hypoxaemia in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2023 Aug 2. doi: 10.1002/ejhf.2989.
     PubMed    
     
     
     
692. PACKER M
     Foetal recapitulation of nutrient surplus signalling by O-GlcNAcylation and the failing heart.
     Eur J Heart Fail. 2023;25:1199-1212.
     PubMed     Abstract available
     
     
     
693. CHATUR S, Ezekowitz JA
     Give a nudge a shot: NUDGE-FLU bridging the cardiovascular quality chasm.
     Eur J Heart Fail. 2023;25:1459-1463.
     PubMed    
     
     
     
694. MYHRE PL, Liu Y, Kulac IJ, Claggett BL, et al
     Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
     Eur J Heart Fail. 2023;25:1396-1405.
     PubMed     Abstract available
     
     
     
695. MONDA E, Limongelli G
     Thromboembolic events in peripartum cardiomyopathy: Current dilemmas and future perspectives.
     Eur J Heart Fail. 2023;25:1467-1469.
     PubMed    
     
     
     
696. ROSSELLO X
     Globalization does not lead to homogenization in randomized controlled trials: Impact on sample size estimation.
     Eur J Heart Fail. 2023;25:1243-1245.
     PubMed    
     
     
     
697. MCDOWELL K, Campbell R, Simpson J, Cunningham JW, et al
     Incremental prognostic value of biomarkers in PARADIGM-HF.
     Eur J Heart Fail. 2023;25:1406-1414.
     PubMed     Abstract available
     
     
     
698. TROMP J, Jackson AM, Abdelhamid M, Fouad D, et al
     Thromboembolic events in peripartum cardiomyopathy: Results from the ESC EORP PPCM registry.
     Eur J Heart Fail. 2023;25:1464-1466.
     PubMed    
     
     
     
699. DHONT S, Martens P, Meekers E, Dauw J, et al
     Sodium and potassium changes during decongestion with acetazolamide - A pre-specified analysis from the ADVOR trial.
     Eur J Heart Fail. 2023;25:1310-1319.
     PubMed     Abstract available
     
     
     
700. BUTT JH, Claggett BL, Miao ZM, Jering KS, et al
     Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial.
     Eur J Heart Fail. 2023;25:1228-1242.
     PubMed     Abstract available
     
     
     July 2023
701. BLUM M, Goldstein NE, Jaarsma T, Allen LA, et al
     Palliative Care in Heart Failure Guidelines - A Comparison of the 2021 ESC and the 2022 AHA/ACC/HFSA Guidelines on Heart Failure.
     Eur J Heart Fail. 2023 Jul 26. doi: 10.1002/ejhf.2981.
     PubMed     Abstract available
     
     
     
702. BIEGUS J, Fudim M, Salah HM, Heerspink HJL, et al
     SGLT-2 inhibitors in heart failure: potential decongestive mechanisms and current clinical studies.
     Eur J Heart Fail. 2023 Jul 21. doi: 10.1002/ejhf.2967.
     PubMed    
     
     
     
703. HILL L, Baruah R, Beattie JM, Bistola V, et al
     Culture, ethnicity, and socio-economic status as determinants of the management of patients with advanced heart failure who need palliative care: A Clinical Consensus Statement from the Heart Failure Association (HFA) of the ESC, the ESC Patient Forum
     Eur J Heart Fail. 2023 Jul 21. doi: 10.1002/ejhf.2973.
     PubMed     Abstract available
     
     
     
704. WARNER B, Bruhn EJ, Olson TP, Bissen TG, et al
     Inspiratory Muscle Strength is Related to Exertional Dyspnea in Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Jul 21. doi: 10.1002/ejhf.2980.
     PubMed    
     
     
     
705. LUND LH, Lam CSP, Pizzato PE, Gabrielsen A, et al
     Rationale and design of ENDEAVOR: a sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
     Eur J Heart Fail. 2023 Jul 20. doi: 10.1002/ejhf.2977.
     PubMed     Abstract available
     
     
     
706. HARRINGTON J, Butler J
     Heart Failure after Myocardial Infarction: Glass Emptier Than Full.
     Eur J Heart Fail. 2023 Jul 18. doi: 10.1002/ejhf.2961.
     PubMed    
     
     
     
707. BELDHUIS IE, Damman K, Pang PS, Greenberg B, et al
     Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure.
     Eur J Heart Fail. 2023 Jul 18. doi: 10.1002/ejhf.2975.
     PubMed     Abstract available
     
     
     
708. ELLIOTT P, Gundapaneni B, Sultan MB, Ines M, et al
     Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
     Eur J Heart Fail. 2023 Jul 11. doi: 10.1002/ejhf.2974.
     PubMed     Abstract available
     
     
     
709. STOLFO D, Lund LH, Benson L, Lindberg F, et al
     Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2023 Jul 7. doi: 10.1002/ejhf.2971.
     PubMed     Abstract available
     
     
     
710. NADARAJAH R, Younsi T, Romer E, Raveendra K, et al
     Prediction models for heart failure in the community: a systematic review and meta-analysis.
     Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2970.
     PubMed     Abstract available
     
     
     
711. PACKER M, Butler J
     Similarities and Distinctions Between Acetazolamide and SGLT2 Inhibitors in Patients With Acute Heart Failure: Key Insights Into ADVOR and EMPULSE.
     Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2968.
     PubMed     Abstract available
     
     
     
712. PIESKE B, Armstrong PW
     Reply to 'Vericiguat in heart failure with reduced ejection fraction: the right choice above all else?'.
     Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2964.
     PubMed    
     
     
     
713. VOORDES G, Damman K
     Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: Treat the heart, cherish the kidney.
     Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2963.
     PubMed    
     
     
     
714. WU CK, Yang LT, Hung CL
     Exercise left atrial compliance: One more tool in the heart failure with preserved ejection fraction assistance toolbox?
     Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2966.
     PubMed    
     
     
     
715. CHANG AJ, Bhatt AS, Ambrosy AP
     Understanding Cardiohepatic Interactions in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2960.
     PubMed    
     
     
     
716. DOCHERTY KF, Jackson AM, Macartney M, Campbell RT, et al
     Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991-2016.
     Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2965.
     PubMed     Abstract available
     
     
     
717. GUSTAFSON SE, Ambrosy AP, Bhatt AS
     Special DELIVERy: Reducing High-Complexity Hospitalizations in Heart Failure.
     Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2958.
     PubMed    
     
     
     
718. OSKOUIE S, Michael F, Whitelaw S, Bozkurt B, et al
     A Scoping Review of Heart Failure Transitional Care Quality Indicators and Outcomes for Use in Clinical Care and Research.
     Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2955.
     PubMed     Abstract available
     
     
     
719. BAYES-GENIS A, Lupon J, Codina P
     Quality Over Quantity: Assessing the Need for Multiple Biomarkers in Predicting Heart Failure Outcomes.
     Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2956.
     PubMed    
     
     
     
720. 
     Abstracts of the Heart Failure 2023 and the World Congress on Acute Heart Failure, 20 - 23 May 2023, Prague, Czechia.
     Eur J Heart Fail. 2023;25 Suppl 2:3-457.
     PubMed    
     
     
     
721. TOMASONI D, Adamo M, Metra M
     July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities.
     Eur J Heart Fail. 2023;25:925-928.
     PubMed    
     
     
     
722. GREUTMANN M, Tobler D, Engel R, Heg D, et al
     Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.
     Eur J Heart Fail. 2023;25:1105-1114.
     PubMed     Abstract available
     
     
     
723. GOLDSMITH AJ, Jin M, Lucassen R, Duggan NM, et al
     Comparison of pulmonary congestion severity using artificial intelligence-assisted scoring versus clinical experts: A secondary analysis of BLUSHED-AHF.
     Eur J Heart Fail. 2023;25:1166-1169.
     PubMed     Abstract available
     
     
     
724. BHATT AS, Kosiborod MN, Vaduganathan M, Claggett BL, et al
     Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
     Eur J Heart Fail. 2023;25:981-988.
     PubMed     Abstract available
     
     
     
725. KHAN MS, Grayburn PA, Butler J
     Cardiac reverse remodelling with vericiguat: Victory or no victory?
     Eur J Heart Fail. 2023;25:1022-1024.
     PubMed    
     
     
     June 2023
726. MONZO L, Girerd N, Duarte K, Ferreira JP, et al
     Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2952.
     PubMed     Abstract available
     
     
     
727. MODIN D, Lassen MCH, Claggett B, Johansen ND, et al
     Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2945.
     PubMed     Abstract available
     
     
     
728. JOURY A
     Optimizing Heart Rate with Ivabradine in Heart Failure with Reduced Ejection Fraction: Insights from a Post-hoc Analysis of SHIFT Trial.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2953.
     PubMed    
     
     
     
729. BAYES-GENIS A, Rosano G
     Unlocking the Potential of Natriuretic Peptide Testing in Primary Care: A Roadmap for Early Heart Failure Diagnosis.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2950.
     PubMed    
     
     
     
730. YANG M, Kondo T, Adamson C, Butt JH, et al
     Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2944.
     PubMed     Abstract available
     
     
     
731. BRANN A, Miller J, Eshraghian E, Park JJ, et al
     Global Longitudinal Strain Predicts Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2947.
     PubMed     Abstract available
     
     
     
732. DOCHERTY KF, Lam CSP, Rakisheva A, Coats AJS, et al
     Heart Failure Diagnosis in the General Community - Who, How and When? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2946.
     PubMed     Abstract available
     
     
     
733. KERWAGEN F, Koehler K, Vettorazzi E, Stangl V, et al
     Remote patient management of heart failure across the ejection fraction spectrum: A prespecified analysis of the TIM-HF2 trial.
     Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2948.
     PubMed     Abstract available
     
     
     
734. ADAMO M, Chioncel O, Benson L, Shahim B, et al
     Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: insight from the ESC-HFA EORP Heart Failure Long-Term Registry.
     Eur J Heart Fail. 2023 Jun 26. doi: 10.1002/ejhf.2929.
     PubMed     Abstract available
     
     
     
735. STRACHINARU M, Roussoulieres A, Manintveld OC
     SGLT2i for Chronic Heart Failure: The Ultimate Solution?
     Eur J Heart Fail. 2023 Jun 22. doi: 10.1002/ejhf.2942.
     PubMed    
     
     
     
736. SINAGRA G, Gigli M, Dal Ferro M
     Heart failure with reduced ejection fraction and monogenic dilated cardiomyopathy: distinct diseases? Insights from randomized controlled trials.
     Eur J Heart Fail. 2023 Jun 22. doi: 10.1002/ejhf.2943.
     PubMed    
     
     
     
737. NAITO R, Kasai T
     One step towards tailor-made medicine for patients with heart failure.
     Eur J Heart Fail. 2023 Jun 21. doi: 10.1002/ejhf.2941.
     PubMed    
     
     
     
738. BOOTH D, Davis JA, McEwan P, Solomon SD, et al
     The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.
     Eur J Heart Fail. 2023 Jun 21. doi: 10.1002/ejhf.2940.
     PubMed     Abstract available
     
     
     
739. DONAL E, Cosyns B
     Moving forwards from clinical trials to a more individualized management of treatments in heart failure? Great value of echocardiography-Doppler data.
     Eur J Heart Fail. 2023 Jun 20. doi: 10.1002/ejhf.2938.
     PubMed    
     
     
     
740. GIRERD N
     Combating Therapeutic Inertia: Optimizing Iron Deficiency Treatment in Heart Failure.
     Eur J Heart Fail. 2023 Jun 20. doi: 10.1002/ejhf.2933.
     PubMed    
     
     
     
741. GIRERD N
     Beyond Loop Diuretics: Unlocking the Potential of Codiuretics in Heart Failure Management.
     Eur J Heart Fail. 2023 Jun 16. doi: 10.1002/ejhf.2936.
     PubMed    
     
     
     
742. BUTTE Z, Ambrosy AP
     Acetazolamide as a Decongestion Strategy in Acute Decompensated Heart Failure: Balancing Fluid Removal and Electrolyte Disturbances.
     Eur J Heart Fail. 2023 Jun 16. doi: 10.1002/ejhf.2935.
     PubMed    
     
     
     
743. NGUYEN NV, Lindberg F, Benson L, Ferrannini G, et al
     Eligibility for vericiguat in a real-world heart failure population according to trial, guidelines, and label criteria: Data from the Swedish Heart Failure Registry.
     Eur J Heart Fail. 2023 Jun 16. doi: 10.1002/ejhf.2939.
     PubMed     Abstract available
     
     
     
744. WANG S, Sun Q, Wang L
     Vericiguat in HFrEF: the right choice above all else? The answer may lie in time. Letter regarding the article 'Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA
     Eur J Heart Fail. 2023 Jun 15. doi: 10.1002/ejhf.2931.
     PubMed    
     
     
     
745. BAYES-GENIS A, Lupon J, Revuelta-Lopez E, Llibre C, et al
     Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO-HF trial.
     Eur J Heart Fail. 2023 Jun 15. doi: 10.1002/ejhf.2932.
     PubMed     Abstract available
     
     
     
746. OMAR M, Omote K, Sorimachi H, Popovic D, et al
     Hypoxemia in Patients with Heart Failure and Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Jun 14. doi: 10.1002/ejhf.2930.
     PubMed     Abstract available
     
     
     
747. SCHRAGE B, Lund LH, Benson L, Braunschweig F, et al
     Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments - An analysis from the Swedish heart failure registry.
     Eur J Heart Fail. 2023 Jun 14. doi: 10.1002/ejhf.2928.
     PubMed     Abstract available
     
     
     
748. SAKANIWA R, Tromp J, Streng KW, Suthahar N, et al
     Trajectories of renal biomarkers and new onset heart failure in the general population: Findings from the PREVEND study.
     Eur J Heart Fail. 2023 Jun 7. doi: 10.1002/ejhf.2925.
     PubMed     Abstract available
     
     
     
749. BOHM M, Butler J, Krawczyk M, Mahfoud F, et al
     Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial.
     Eur J Heart Fail. 2023 Jun 6. doi: 10.1002/ejhf.2922.
     PubMed     Abstract available
     
     
     
750. 
     Corrigendum to 'Weight change and clinical outcomes in heart failure with reduced ejection fraction: Insights from EMPEROR-Reduced' [Eur J Heart Fail 2023;25:117-127].
     Eur J Heart Fail. 2023 Jun 5. doi: 10.1002/ejhf.2910.
     PubMed    
     
     
     
751. ZIMERMAN A, da Silveira AD, Solomon SD, Rohde LE, et al
     NYHA Classification for Decision-Making in Heart Failure: Time to Reassess?
     Eur J Heart Fail. 2023 Jun 1. doi: 10.1002/ejhf.2923.
     PubMed    
     
     
     
752. TOMASONI D, Adamo M, Metra M
     June 2023 at a glance: focus on worsening heart failure, heart failure with preserved ejection fraction and valvular heart disease.
     Eur J Heart Fail. 2023;25:773-775.
     PubMed    
     
     
     
753. MULLER SA, Oerlemans MIFJ
     Implementing clinical pathways to enable early diagnosis and treatment of wild-type transthyretin amyloid cardiomyopathy.
     Eur J Heart Fail. 2023;25:854-856.
     PubMed    
     
     
     
754. KARAM N, Hausleiter J
     Hypoalbuminaemia and secondary mitral regurgitation mortality: an inevitable fate?
     Eur J Heart Fail. 2023;25:888-889.
     PubMed    
     
     
     
755. SCOTTI A, Jorde UP, Latib A
     Transcatheter edge-to-edge repair: fix the heart, heal the liver.
     Eur J Heart Fail. 2023;25:885-887.
     PubMed    
     
     
     
756. STOLZ L, Orban M, Karam N, Lubos E, et al
     Cardio-hepatic syndrome in patients undergoing mitral valve transcatheter edge-to-edge repair.
     Eur J Heart Fail. 2023;25:872-884.
     PubMed     Abstract available
     
     
     
757. TINI G, Milani P, Zampieri M, Caponetti AG, et al
     Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
     Eur J Heart Fail. 2023;25:845-853.
     PubMed     Abstract available
     
     
     May 2023
758. ARRIGO M, Biegus J, Asakage A, Mebazaa A, et al
     Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial.
     Eur J Heart Fail. 2023 May 29. doi: 10.1002/ejhf.2920.
     PubMed     Abstract available
     
     
     
759. HAVAKUK O, Topilsky Y
     Secondary Tricuspid Regurgitation in Heart Failure - Not Merely an Innocent Bystander?
     Eur J Heart Fail. 2023 May 25. doi: 10.1002/ejhf.2919.
     PubMed    
     
     
     
760. ALVAREZ-GARCIA J
     SGLT2 inhibitors for Heart Failure: time's up for indulging in wishful thinking.
     Eur J Heart Fail. 2023 May 23. doi: 10.1002/ejhf.2917.
     PubMed    
     
     
     
761. CHIONCEL O, Adamo M, Nikolaou M, Parissis J, et al
     Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of
     Eur J Heart Fail. 2023 May 23. doi: 10.1002/ejhf.2918.
     PubMed     Abstract available
     
     
     
762. COTTER G, Davison B
     Acute heart failure is a remitting-relapsing disorder and not a step towards advanced heart failure: Implications for decongestion therapy.
     Eur J Heart Fail. 2023 May 22. doi: 10.1002/ejhf.2916.
     PubMed    
     
     
     
763. CHATUR S, Cunningham JW, Vaduganathan M, Mc Causland FR, et al
     Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from the DELIVER Trial.
     Eur J Heart Fail. 2023 May 22. doi: 10.1002/ejhf.2915.
     PubMed     Abstract available
     
     
     
764. IACONELLI A, Pellicori P, Dolce P, Busti M, et al
     Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials.
     Eur J Heart Fail. 2023 May 22. doi: 10.1002/ejhf.2911.
     PubMed     Abstract available
     
     
     
765. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
     Electronic nudges to increase influenza vaccination uptake among patients with heart failure: a prespecified analysis of the NUDGE-FLU trial.
     Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2913.
     PubMed     Abstract available
     
     
     
766. PASCUAL-FIGAL DA, Zamorano JL, Domingo M, Morillas H, et al
     Impact of Dapagliflozin on cardiac remodeling in patients with chronic heart failure: DAPA-MODA study.
     Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2884.
     PubMed     Abstract available
     
     
     
767. SHAHIM B, Shahim A, Adamo M, Chioncel O, et al
     Prevalence, Characteristics and Prognostic Impact of Aortic Valve Disease in Patients with Heart Failure and Reduced, Mildly Reduced, and Preserved Ejection Fraction: An Analysis of the ESC Heart Failure Long-Term Registry.
     Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2908.
     PubMed     Abstract available
     
     
     
768. CHATUR S, Kondo T, Claggett BL, Docherty K, et al
     Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA-HF.
     Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2912.
     PubMed     Abstract available
     
     
     
769. MUSELLA F, Rosano GMC, Hage C, Benson L, et al
     Patient profiles in heart failure with reduced ejection fraction: prevalence, characteristics, treatments and outcomes in a real-world heart failure population.
     Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2892.
     PubMed     Abstract available
     
     
     
770. ANKER SD, Usman MS, Anker MS, Butler J, et al
     Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology
     Eur J Heart Fail. 2023 May 19. doi: 10.1002/ejhf.2894.
     PubMed     Abstract available
     
     
     
771. GUAZZI M
     The Biventricular Paths to Exercise Dyspnea in Heart Failure Preserved Ejection Fraction: The Future is Now.
     Eur J Heart Fail. 2023 May 18. doi: 10.1002/ejhf.2914.
     PubMed    
     
     
     
772. METRA M, Adamo M, Tomasoni D, Mebazaa A, et al
     Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2023 May 18. doi: 10.1002/ejhf.2888.
     PubMed     Abstract available
     
     
     
773. HORIUCHI Y, Asami M, Ide T, Yahagi K, et al
     Prevalence, Characteristics and Cardiovascular and Non-cardiovascular Outcomes in Patients with Heart Failure with Supra-normal Ejection Fraction; Insight from the JROADHF Study.
     Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2895.
     PubMed     Abstract available
     
     
     
774. CERLINSKAITE-BAJORE K, Lam CSP, Sliwa K, Adamo M, et al
     Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalisation for acute heart failure: insights from the STRONG-HF trial.
     Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2882.
     PubMed     Abstract available
     
     
     
775. HARRINGTON J, Mentz RJ
     Ironing out the Wrinkles: Unanswered Questions in Intravenous Iron Repletion in Heart Failure.
     Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2893.
     PubMed    
     
     
     
776. RICHARDS AM
     Plasma Markers to Risk Stratify for Heart Failure in Atrial Fibrillation.
     Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2885.
     PubMed    
     
     
     
777. BAUDRY G, Lescroart M, Kimmoun A
     Are LVEF phenotypes meaningful in acute heart failure?
     Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2889.
     PubMed    
     
     
     
778. BORIANI G, Mei DA, Imberti JF
     Therapeutic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: from outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progress
     Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2891.
     PubMed    
     
     
     
779. BARAT A, Chen CW, Patel-Murray N, McMurray JJV, et al
     Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trial.
     Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2886.
     PubMed     Abstract available
     
     
     
780. TOMASONI D, Adamo M, Metra M
     May 2023 at a glance: focus on pathophysiology, comorbidities and devices.
     Eur J Heart Fail. 2023;25:599-601.
     PubMed    
     
     
     
781. POETSCH MS, Palus S, Van Linthout S, von Haehling S, et al
     The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia.
     Eur J Heart Fail. 2023;25:673-686.
     PubMed     Abstract available
     
     
     
782. JAVED S, Halliday BP
     Implantable cardioverter-defibrillator implantation in non-ischaemic cardiomyopathy: towards individualized risk stratification.
     Eur J Heart Fail. 2023;25:751-753.
     PubMed    
     
     
     
783. ARRIGO M, Blet A, Morley-Smith A, Aissaoui N, et al
     Current and future trial design in refractory cardiogenic shock.
     Eur J Heart Fail. 2023;25:609-615.
     PubMed    
     
     
     
784. FONTANA M, Ioannou A, Bandera F
     Non-invasive left ventricle pressure-volume loops: a new tool to track treatment response in cardiac transthyretin amyloidosis?
     Eur J Heart Fail. 2023;25:737-739.
     PubMed    
     
     
     
785. GIANNONI A, Borrelli C, Gentile F, Sciarrone P, et al
     Autonomic and respiratory consequences of altered chemoreflex function: clinical and therapeutic implications in cardiovascular diseases.
     Eur J Heart Fail. 2023;25:642-656.
     PubMed     Abstract available
     
     
     
786. SHERIDAN WS, Wetterling F, Testani JM, Borlaug BA, et al
     Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation.
     Eur J Heart Fail. 2023;25:754-763.
     PubMed     Abstract available
     
     
     
787. DI MARCO A, Brown P, Mateus G, Faga V, et al
     Late gadolinium enhancement and the risk of ventricular arrhythmias and sudden death in NYHA class I patients with non-ischaemic cardiomyopathy.
     Eur J Heart Fail. 2023;25:740-750.
     PubMed     Abstract available
     
     
     
788. ROSENBLUM HR, Griffin JM, Minamisawa M, Prasad N, et al
     Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study.
     Eur J Heart Fail. 2023;25:727-736.
     PubMed     Abstract available
     
     
     April 2023
789. CAPPELLETTO C, Stolfo D, Savarese G
     Reply to Letter to the Editor "Why do obese patients with heart failure reduced ejection fraction have better outcomes from pharmacological treatments?".
     Eur J Heart Fail. 2023 Apr 28. doi: 10.1002/ejhf.2880.
     PubMed    
     
     
     
790. LINDBERG F, Lund LH, Benson L, Linde C, et al
     Iron deficiency in heart failure: screening, prevalence, incidence and outcome Data from the Swedish Heart Failure registry and the Stockholm CREAtinine Measurements collaborative project.
     Eur J Heart Fail. 2023 Apr 28. doi: 10.1002/ejhf.2879.
     PubMed     Abstract available
     
     
     
791. REDDY YNV, Borlaug BA
     Exercise Echocardiography to Diagnose Heart Failure with preserved Ejection Fraction - Are Two Measures Better than One?
     Eur J Heart Fail. 2023 Apr 27. doi: 10.1002/ejhf.2876.
     PubMed    
     
     
     
792. MYON F, Curtis E, L'official G, Donal E, et al
     Heart Failure with Preserved ejection Fraction: a haemodynamic explanation of exertional dyspnoea.
     Eur J Heart Fail. 2023 Apr 27. doi: 10.1002/ejhf.2877.
     PubMed    
     
     
     
793. KAPLON-CIESLICKA A, Benson L, Chioncel O, Crespo-Leiro MG, et al
     Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC HFA EORP Heart Failure Long-Term Registry.
     Eur J Heart Fail. 2023 Apr 27. doi: 10.1002/ejhf.2873.
     PubMed     Abstract available
     
     
     
794. SCHROEDER M, Lim YMF, Savarese G, Suzart-Woischnik K, et al
     Sex Differences in the Generalizability of Randomized Clinical Trials in Heart Failure with Reduced Ejection Fraction.
     Eur J Heart Fail. 2023 Apr 26. doi: 10.1002/ejhf.2868.
     PubMed     Abstract available
     
     
     
795. TSUTSUI H, Albert NM, Coats AJS, Anker SD, et al
     Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
     Eur J Heart Fail. 2023 Apr 26. doi: 10.1002/ejhf.2848.
     PubMed     Abstract available
     
     
     
796. METRA M, Tomasoni D, Adamo M, Bayes-Genis A, et al
     Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology.
     Eur J Heart Fail. 2023 Apr 26. doi: 10.1002/ejhf.2874.
     PubMed     Abstract available
     
     
     
797. BOHM M, Abdin A, Slawik J, Mahfoud F, et al
     Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
     Eur J Heart Fail. 2023 Apr 24. doi: 10.1002/ejhf.2870.
     PubMed     Abstract available
     
     
     
798. PEIGH G, Patel RB
     The Left Atrium: A Window into Cardiopulmonary Hemodynamics in Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Apr 24. doi: 10.1002/ejhf.2872.
     PubMed    
     
     
     
799. D'AMARIO D, Meerkin D, Restivo A, Ince H, et al
     Safety, usability, and performance of a wireless left atrial pressure monitoring system in patients with heart failure: the VECTOR-HF trial.
     Eur J Heart Fail. 2023 Apr 24. doi: 10.1002/ejhf.2869.
     PubMed     Abstract available
     
     
     
800. ALOGNA A, Omar M, Popovic D, Sorimachi H, et al
     Biventricular Cardiac Power Reserve in Heart Failure and Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Apr 17. doi: 10.1002/ejhf.2867.
     PubMed     Abstract available
     
     
     
801. KOBAYASHI M, Huttin O, Ferreira JP, Duarte K, et al
     A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2859.
     PubMed     Abstract available
     
     
     
802. HARADA T, Kagami K, Shina T, Sorimachi H, et al
     Diagnostic Value of Reduced Left Atrial Compliance during Ergometry Exercise in Heart Failure with Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2862.
     PubMed     Abstract available
     
     
     
803. ANKER SD, Shahzeb Khan M, Butler J, von Haehling S, et al
     Effect of Intravenous Iron Replacement on Recurrent Heart Failure Hospitalizations and Cardiovascular Mortality in Patients with Heart Failure and Iron Deficiency: A Bayesian Meta-Analysis.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2860.
     PubMed     Abstract available
     
     
     
804. FILIPPATOS G, Farmakis D, Butler J, Zannad F, et al
     Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2861.
     PubMed     Abstract available
     
     
     
805. TALHA KM, Butler J, Greene SJ, Aggarwal R, et al
     Potential Global Impact of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2864.
     PubMed     Abstract available
     
     
     
806. HEITZINGER G, Pavo N, Koschatko S, Jantsch C, et al
     Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2858.
     PubMed     Abstract available
     
     
     
807. BO W, Yanchun C, Cheng X
     Why do obese patients with heart failure reduced ejection fraction have better outcomes from pharmacological treatments?
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2865.
     PubMed    
     
     
     
808. SHARMA A, Ferreira JP, Zannad F, Pocock SJ, et al
     Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2857.
     PubMed     Abstract available
     
     
     
809. DEWAN P, Ferreira JP, Butt JH, Petrie MC, et al
     Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
     Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2856.
     PubMed     Abstract available
     
     
     
810. BIEGUS J, Zymlinski R, Testani J, Fudim M, et al
     The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery.
     Eur J Heart Fail. 2023 Apr 11. doi: 10.1002/ejhf.2852.
     PubMed     Abstract available
     
     
     
811. POCOCK SJ, Ferreira JP, Collier TJ, Angermann CE, et al
     The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse.
     Eur J Heart Fail. 2023 Apr 10. doi: 10.1002/ejhf.2853.
     PubMed     Abstract available
     
     
     
812. BUTLER J, Siddiqi TJ, Zannad F, Ferreira JP, et al
     Interaction of Natriuretic Peptide Levels and Ejection Fraction on Outcomes with Dapagliflozin and Empagliflozin in Heart Failure.
     Eur J Heart Fail. 2023 Apr 10. doi: 10.1002/ejhf.2854.
     PubMed    
     
     
     
813. HOGAN J
     9th March 2023, 25in25 Summit - reducing heart failure mortality by 25% in the next 25 years.
     Eur J Heart Fail. 2023 Apr 4. doi: 10.1002/ejhf.2835.
     PubMed    
     
     
     
814. GUALANDRO DM, Puelacher C, Mueller C
     Reply to the Letter regarding the article "Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes".
     Eur J Heart Fail. 2023 Apr 3. doi: 10.1002/ejhf.2850.
     PubMed    
     
     
     
815. ROSANO G, Bayes-Genis A, Metra M
     The Heart Failure Association endorses the 25in25 initiative.
     Eur J Heart Fail. 2023 Apr 3. doi: 10.1002/ejhf.2847.
     PubMed    
     
     
     
816. PACKER M
     A Reclassification of Heart Failure Based on Recognition of Heart Failure With Normal to Supranormal Ejection Fraction, a Clinically Common Form of Cardiac Contracture, With Distinctive Pathophysiological and Therapeutic Features.
     Eur J Heart Fail. 2023 Apr 3. doi: 10.1002/ejhf.2849.
     PubMed    
     
     
     
817. 
     HFA Winter Research Meeting on Translational Heart Failure 2023 In collaboration with the ESC Working Group on Myocardial Function, 20-23 May 2023.
     Eur J Heart Fail. 2023;25 Suppl 1:3-34.
     PubMed    
     
     
     
818. TOMASONI D, Adamo M, Metra M
     April 2023 at a glance: focus on diagnosis and comorbidities.
     Eur J Heart Fail. 2023;25:445-447.
     PubMed    
     
     
     
819. DELMAS C, Bonello L, Roubille F
     For the best management, please ask for assistance!
     Eur J Heart Fail. 2023;25:573-575.
     PubMed    
     
     
     
820. AIMO A, Tomasoni D, Porcari A, Vergaro G, et al
     Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis.
     Eur J Heart Fail. 2023;25:510-514.
     PubMed     Abstract available
     
     
     
821. DIEZ J, Rosano GMC, Butler J
     Time to reconsider the perception and management of hypertensive heart disease.
     Eur J Heart Fail. 2023;25:450-453.
     PubMed    
     
     
     
822. ITZHAKI BEN ZADOK O, Falk RH
     Variant and wild type transthyretin amyloidosis: two sides of the same coin or different currencies in different pockets?
     Eur J Heart Fail. 2023;25:525-527.
     PubMed    
     
     
     
823. SCHRAGE B, Sundermeyer J, Beer BN, Bertoldi L, et al
     Use of mechanical circulatory support in patients with non-ischaemic cardiogenic shock.
     Eur J Heart Fail. 2023;25:562-572.
     PubMed     Abstract available
     
     
     
824. PORCARI A, Razvi Y, Masi A, Patel R, et al
     Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
     Eur J Heart Fail. 2023;25:515-524.
     PubMed     Abstract available
     
     
     March 2023
825. POPOVIC D, Alogna A, Omar M, Sorimachi H, et al
     Ventricular Stiffening and Chamber Contracture in Heart Failure with Higher Ejection Fraction.
     Eur J Heart Fail. 2023 Mar 30. doi: 10.1002/ejhf.2843.
     PubMed     Abstract available
     
     
     
826. PIESKE B, Pieske-Kraigher E, Lam CSP, Melenovsky V, et al
     Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic Substudy.
     Eur J Heart Fail. 2023 Mar 30. doi: 10.1002/ejhf.2836.
     PubMed     Abstract available
     
     
     
827. PUGLIESE NR, De Biase N, Del Punta L, Balletti A, et al
     Deep phenotype characterization of hypertensive response to exercise: implications on functional capacity and prognosis across the heart failure spectrum.
     Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2827.
     PubMed     Abstract available
     
     
     
828. ROZENTRYT P, Niedziela JT, Gasior M
     Bones in heart failure - missing piece of the body wasting puzzle.
     Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2846.
     PubMed    
     
     
     
829. OYAMA K, Giugliano RP, Ruff CT, Berg DD, et al
     Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.
     Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2844.
     PubMed     Abstract available
     
     
     
830. D'AMARIO D, Rodolico D, Savarese G
     Reply to: Xie et al. What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?
     Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2837.
     PubMed    
     
     
     
831. PAGNESI M, Baldetti L, Adamo M
     Inferior vena cava monitoring in heart failure: don't wait until the last drop makes the cup run over.
     Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2839.
     PubMed    
     
     
     
832. FARMAKIS D, Tromp J, Marinaki S, Ouwerkerk W, et al
     Impact of left ventricular ejection fraction phenotypes on healthcare-resource utilization in hospitalized heart failure: A secondary analysis of REPORT-HF.
     Eur J Heart Fail. 2023 Mar 28. doi: 10.1002/ejhf.2833.
     PubMed     Abstract available
     
     
     
833. CARBONE S, Elagizi A, Lavie CJ
     Better Pharmacotherapy in Heart Failure with Reduced Ejection Fraction May Partly Explain the Obesity Paradox.
     Eur J Heart Fail. 2023 Mar 28. doi: 10.1002/ejhf.2832.
     PubMed    
     
     
     
834. SIDDIQI TJ, Anker SD, Filippatos G, Ferreira JP, et al
     Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction.
     Eur J Heart Fail. 2023 Mar 28. doi: 10.1002/ejhf.2831.
     PubMed     Abstract available
     
     
     
835. FUDIM M, Parikh K, Ganesh A, Molinger J, et al
     Splanchnic Nerve Block with Botulinum Toxin for Therapy of Chronic Heart Failure - Mechanism of Action (SPONGE-HF).
     Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2829.
     PubMed    
     
     
     
836. ZANNAD F, Alikhaani J, Alikhaani S, Butler J, et al
     PATIENT REPORTED OUTCOME MEASURES AND PATIENT ENGAGEMENT IN HEART FAILURE CLINICAL TRIALS: MULTI-STAKEHOLDER PERSPECTIVES.
     Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2828.
     PubMed     Abstract available
     
     
     
837. AKTAA S, Gale CP, Brida M, Giannakoulas G, et al
     European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology.
     Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2830.
     PubMed     Abstract available
     
     
     
838. DOBBIN SJH, Shen L, Petrie MC, Packer M, et al
     Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials.
     Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2818.
     PubMed     Abstract available
     
     
     
839. PANDEY AK, Dhingra NK, Pandey A, Puar P, et al
     Efficacy of sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors for heart failure in black patients: a systematic review and meta-analysis of randomized controlled trials.
     Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2825.
     PubMed    
     
     
     
840. SAITO Y, Obokata M, Harada T, Kagami K, et al
     Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non-invasive echocardiographic study.
     Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2821.
     PubMed     Abstract available
     
     
     
841. PAGNESI M, Adamo M, Ter Maaten JM, Beldhuis IE, et al
     Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial.
     Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2820.
     PubMed     Abstract available
     
     
     
842. LUDWIG S, Kalbacher D, Ali WB, Weimann J, et al
     Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis.
     Eur J Heart Fail. 2023;25:399-410.
     PubMed     Abstract available
     
     
     
843. SCOTTI A, Latib A
     MitraClip evolution: EXPANDed options for a bespoke treatment.
     Eur J Heart Fail. 2023;25:422-424.
     PubMed    
     
     
     
844. ROSSIGNOL P, Pitt B
     Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from 'real-world' evidence?
     Eur J Heart Fail. 2023;25:361-363.
     PubMed    
     
     
     
845. CODINA P, Zamora E, Bayes-Genis A
     Reply to 'The frail patient and the frailing heart'.
     Eur J Heart Fail. 2023;25:441-442.
     PubMed    
     
     
     
846. SCHRAGE B, Westermann D
     Cardiogenic shock is not a sprint, but a marathon.
     Eur J Heart Fail. 2023;25:436-437.
     PubMed    
     
     
     
847. PATOULIAS D, Fragakis N
     The frail patient and the frailing heart. Letter regarding the article 'Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment'.
     Eur J Heart Fail. 2023;25:441.
     PubMed    
     
     
     
848. SCHUSTER A, Schulz A, Lange T, Evertz R, et al
     Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2023;25:322-331.
     PubMed     Abstract available
     
     
     
849. VERGARO G, Castiglione V, Aimo A, Prontera C, et al
     N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
     Eur J Heart Fail. 2023;25:335-346.
     PubMed     Abstract available
     
     
     February 2023
850. BLUMER V, Truby LK, Zieroth S
     Sex Differences in Heart Failure: The Evolving Use of Biomarkers.
     Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2817.
     PubMed    
     
     
     
851. PACKER M
     Dosing of Iron Supplementation for Iron-Deficient Patients With Heart Failure: Should We Prefer More Intensive or Less Intensive Repletion Targets?
     Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2816.
     PubMed    
     
     
     
852. GUSTAFSSON F, Damman K, Nalbantgil S, Van Laake LW, et al
     Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the ESC.
     Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2814.
     PubMed     Abstract available
     
     
     
853. GARD EK, Beale AL, Telles F, Silvestry FE, et al
     Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction.
     Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2805.
     PubMed     Abstract available
     
     
     
854. ABBASI MA, Borlaug BA
     Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows.
     Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2800.
     PubMed    
     
     
     
855. PATEL L, Keshvani N, Pandey A
     Are post-influenza vaccine reactions truly 'adverse'?
     Eur J Heart Fail. 2023;25:311-312.
     PubMed    
     
     
     
856. DOMINGUEZ F, Cabrera E
     Mavacamten in obstructive hypertrophic cardiomyopathy - Are beta-blockers blocking part of its shine?
     Eur J Heart Fail. 2023;25:271-273.
     PubMed    
     
     
     
857. LIM HS, Yim IHW
     De novo aortic regurgitation related to left ventricular assist device therapy: the difficult questions in need of new perspectives.
     Eur J Heart Fail. 2023;25:295-298.
     PubMed    
     
     
     
858. OMOTE K, Verbrugge FH, Sorimachi H, Omar M, et al
     Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea.
     Eur J Heart Fail. 2023;25:185-196.
     PubMed     Abstract available
     
     
     
859. URIEL N, Milano C, Agarwal R, Lee S, et al
     Incidence and clinical correlates of de-novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis.
     Eur J Heart Fail. 2023;25:286-294.
     PubMed     Abstract available
     
     
     
860. WHEELER MT, Jacoby D, Elliott PM, Saberi S, et al
     Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
     Eur J Heart Fail. 2023;25:260-270.
     PubMed     Abstract available
     
     
     
861. PEIKERT A, Claggett BL, Kim K, Udell JA, et al
     Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial.
     Eur J Heart Fail. 2023;25:299-310.
     PubMed     Abstract available
     
     
     
862. LEVI N, Moravsky G, Weitsman T, Amsalem I, et al
     A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.
     Eur J Heart Fail. 2023;25:313-318.
     PubMed     Abstract available
     
     
     January 2023
863. MAEDER MT
     The beta3-adrenoreceptor agonist mirabegron for the treatment of combined pre- and post-capillary pulmonary hypertension: new pathway or dead end?
     Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2780.
     PubMed